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Abstract
Lenvatinib and sorafenib for differentiated thyroid cancer
after radioactive iodine: a systematic review and
economic evaluation
Nigel Fleeman,1* Rachel Houten,1 Adrian Bagust,1 Marty Richardson,1
Sophie Beale,1 Angela Boland,1 Yenal Dundar,1 Janette Greenhalgh,1
Juliet Hounsome,1 Rui Duarte1 and Aditya Shenoy2
1Liverpool Reviews and Implementation Group, University of Liverpool, Liverpool, UK
2The Clatterbridge Cancer Centre NHS Foundation Trust, Birkenhead, UK
*Corresponding author nigel.fleeman@liverpool.ac.uk
Background: Thyroid cancer is a rare cancer, accounting for only 1% of all malignancies in England and
Wales. Differentiated thyroid cancer (DTC) accounts for ≈94% of all thyroid cancers. Patients with DTC
often require treatment with radioactive iodine. Treatment for DTC that is refractory to radioactive iodine
[radioactive iodine-refractory DTC (RR-DTC)] is often limited to best supportive care (BSC).
Objectives: We aimed to assess the clinical effectiveness and cost-effectiveness of lenvatinib (Lenvima®;
Eisai Ltd, Hertfordshire, UK) and sorafenib (Nexar®; Bayer HealthCare, Leverkusen, Germany) for the
treatment of patients with RR-DTC.
Data sources: EMBASE, MEDLINE, PubMed, The Cochrane Library and EconLit were searched (date range
1999 to 10 January 2017; searched on 10 January 2017). The bibliographies of retrieved citations were
also examined.
Review methods: We searched for randomised controlled trials (RCTs), systematic reviews, prospective
observational studies and economic evaluations of lenvatinib or sorafenib. In the absence of relevant
economic evaluations, we constructed a de novo economic model to compare the cost-effectiveness of
lenvatinib and sorafenib with that of BSC.
Results: Two RCTs were identified: SELECT (Study of [E7080] LEnvatinib in 131I-refractory differentiated
Cancer of the Thyroid) and DECISION (StuDy of sorafEnib in loCally advanced or metastatIc patientS with
radioactive Iodine-refractory thyrOid caNcer). Lenvatinib and sorafenib were both reported to improve
median progression-free survival (PFS) compared with placebo: 18.3 months (lenvatinib) vs. 3.6 months
(placebo) and 10.8 months (sorafenib) vs. 5.8 months (placebo). Patient crossover was high (≥ 75%) in
both trials, confounding estimates of overall survival (OS). Using OS data adjusted for crossover, trial
authors reported a statistically significant improvement in OS for patients treated with lenvatinib compared
with those given placebo (SELECT) but not for patients treated with sorafenib compared with those given
placebo (DECISION). Both lenvatinib and sorafenib increased the incidence of adverse events (AEs), and
dose reductions were required (for > 60% of patients). The results from nine prospective observational
studies and 13 systematic reviews of lenvatinib or sorafenib were broadly comparable to those from the
RCTs. Health-related quality-of-life (HRQoL) data were collected only in DECISION. We considered the
feasibility of comparing lenvatinib with sorafenib via an indirect comparison but concluded that this would
not be appropriate because of differences in trial and participant characteristics, risk profiles of the
participants in the placebo arms and because the proportional hazard assumption was violated for five of
the six survival outcomes available from the trials. In the base-case economic analysis, using list prices only,
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the cost-effectiveness comparison of lenvatinib versus BSC yields an incremental cost-effectiveness ratio
(ICER) per quality-adjusted life-year (QALY) gained of £65,872, and the comparison of sorafenib versus
BSC yields an ICER of £85,644 per QALY gained. The deterministic sensitivity analyses show that none of
the variations lowered the base-case ICERs to < £50,000 per QALY gained.
Limitations: We consider that it is not possible to compare the clinical effectiveness or cost-effectiveness
of lenvatinib and sorafenib.
Conclusions: Compared with placebo/BSC, treatment with lenvatinib or sorafenib results in an improvement
in PFS, objective tumour response rate and possibly OS, but dose modifications were required to treat AEs.
Both treatments exhibit estimated ICERs of > £50,000 per QALY gained. Further research should include
examination of the effects of lenvatinib, sorafenib and BSC (including HRQoL) for both symptomatic and
asymptomatic patients, and the positioning of treatments in the treatment pathway.
Study registration: This study is registered as PROSPERO CRD42017055516.
Funding: The National Institute for Health Research Health Technology Assessment programme.
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factor receptor
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Plain English summary
What was the problem?
Differentiated thyroid cancer is a common type of thyroid cancer. For many patients, radioactive iodine is
an effective treatment; however, for some patients, the treatment stops working or becomes unsafe. Two
new drugs, lenvatinib (Lenvima®; Eisai Ltd, Hertfordshire, UK) and sorafenib (Nexar®; Bayer HealthCare,
Leverkusen, Germany), may be new treatment options.
What did we do?
We reviewed the clinical evidence of lenvatinib and sorafenib. We also estimated the costs and benefits
of treatment.
What did we find?
Compared with no treatment, treatment with lenvatinib or sorafenib may increase the time that people
live with thyroid cancer before their disease gets worse; however, both drugs are expensive and may have
unpleasant side effects.
What does this mean?
At their published (undiscounted) prices, lenvatinib or sorafenib may not be considered to provide good
value for money to the NHS.
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Thyroid cancer is a rare cancer, accounting for only 1% of malignancies in England and Wales. Differentiated
thyroid cancer (DTC) accounts for approximately 94% of thyroid cancers. For patients with DTC, the overall
10-year survival rate for middle-aged adults is 80–90%.
Treatment of DTC usually involves surgery. Following surgery, it is generally recommended that patients
undergo treatment with radioactive iodine. Treatment for DTC refractory to radioactive iodine [radioactive
iodine-refractory DTC (RR-DTC)] is often limited to best supportive care (BSC).
Two oral anti-cancer treatments for RR-DTC, used within their licensed indications, are the focus of this
review: lenvatinib (Lenvima®; Eisai Ltd, Hertfordshire, UK) and sorafenib (Nexar®; Bayer HealthCare,
Leverkusen, Germany). Both are types of tyrosine kinase inhibitors (TKIs) known as multikinase inhibitors.
Clinical advice to the Assessment Group (AG) is that in clinical practice there are concerns about the toxicity
of TKI therapy in patients and consequent effects on the quality of life of patients with asymptomatic
disease. This means that treatment tends to be given only to patients who are symptomatic or only when
clinically significant progressive disease develops.
Objectives
The remit of this research was to assess the clinical effectiveness and cost-effectiveness of lenvatinib and
sorafenib within their European Union marketing authorisations for the treatment of patients with RR-DTC.
Review methods
The research involved systematic reviews of clinical and cost-effectiveness evidence, including evidence
provided by the companies that manufacture lenvatinib (Eisai Ltd) and sorafenib (Bayer HealthCare).
The AG also carried out its own evidence review and developed a de novo economic model.
Five electronic databases were searched (on 10 January 2017) for randomised controlled trials (RCTs),
systematic reviews, prospective observational studies and economic evaluations. References in the
systematic reviews identified during the AG’s review and the professional stakeholder submissions,
received as part of the National Institute for Health and Care Excellence (NICE)’s multiple technology appraisal
process, were cross-checked to identify any relevant studies that the AG’s search may have missed. Only
studies of lenvatinib or sorafenib for treating RR-DTC were included. Clinical effectiveness outcomes
included overall survival (OS), progression-free survival (PFS), objective tumour response rate (ORR), adverse
events (AEs) and health-related quality of life (HRQoL). Cost-effectiveness outcomes included incremental
cost per life-year gained and incremental cost per quality-adjusted life-year (QALY) gained. Two reviewers
independently screened all titles and/or abstracts, applied inclusion criteria to relevant publications, and
quality assessed the included studies. The results of the data extraction and quality assessment were
summarised in structured tables and by narrative description. The AG constructed a de novo economic
model comparing the cost-effectiveness of lenvatinib and sorafenib with BSC.
DOI: 10.3310/hta24020 HEALTH TECHNOLOGY ASSESSMENT 2020 VOL. 24 NO. 2
© Queen’s Printer and Controller of HMSO 2020. This work was produced by Fleeman et al. under the terms of a commissioning contract issued by the Secretary of State for
Health and Social Care. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional
journals provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should
be addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
xxiii
Results from the systematic reviews
Evidence from randomised controlled trials
Two relevant Phase III, multicentre, double-blind RCTs were identified: SELECT (Study of [E7080] LEnvatinib
in 131I-refractory differentiated Cancer of the Thyroid) (lenvatinib vs. placebo) and DECISION (StuDy of
sorafEnib in loCally advanced or metastatIc patientS with radioactive Iodine-refractory thyrOid caNcer)
(sorafenib vs. placebo).
The proportions of patients in these trials who were asymptomatic at baseline are unknown; however,
the European Public Assessment Report for sorafenib reports that 20% of patients in DECISION were
retrospectively considered to be symptomatic.
The AG considered both trials to be well conducted and of good quality; however, there were some
differences in trial and patient characteristics, both within and across the two trials. Owing to event
hazards being proportional over time only for DECISION-unadjusted OS, all other hazard ratio results
from SELECT and DECISION should be interpreted with caution.
The primary outcome in both trials was PFS, assessed by blinded independent review, using data from
the first data cut-off point (after a median of 17 months’ follow-up in both trials). Results from SELECT
show that treatment with lenvatinib improved median PFS compared with placebo (18.3 vs. 3.6 months,
respectively). Results from DECISION show that treatment with sorafenib improved median PFS compared
with placebo (10.8 vs. 5.8 months, respectively). Results from the post hoc subgroup analyses of data
collected from symptomatic and asymptomatic participants show that median PFS for asymptomatic and
symptomatic participants treated with sorafenib is similar (10.8 vs. 10.7 months, respectively); however, for
participants treated with placebo, the median PFS of asymptomatic participants is twice that of symptomatic
participants (7.2 vs. 3.6 months, respectively).
The OS results from SELECT and DECISION at the third data cut-off point (after approximately 38 and
36 months’ follow-up, respectively) showed no statistically significant differences between trial arms;
however, patient crossover was high (≥ 75%) in both trials, confounding OS estimates. When OS results
from both trials were adjusted for treatment crossover, the only statistical difference between arms was in
SELECT, favouring lenvatinib over placebo.
The ORR in both trials was reported based on data from the first data cut-off point. ORR in SELECT was
64.8% in the lenvatinib arm and 1.5% in the placebo arm. ORR results for the sorafenib and placebo arms
of DECISION were 12.2% and 0.5%, respectively.
Analyses of safety data from SELECT and DECISION were reported from the first data cut-off point. Results
show that treatment with both lenvatinib and sorafenib led to an increase in the incidence of AEs versus
treatment with placebo (in particular, hypertension and hand–foot syndrome, respectively). The median
time to onset of AEs suggests that most AEs typically occur early, with a decrease in incidence, prevalence
and severity over time. Dose reductions were frequent (> 60%) in both trials.
Health-related quality-of-life data were collected only as part of DECISION. At baseline, HRQoL scores were
considered to be comparable to a normative adult cancer population; however, at the first assessment
(cycle 2, day 1), HRQoL scores worsened in the sorafenib arm whereas the scores for the placebo arm
remained very similar to the baseline score. Thereafter, the sorafenib arm scores remained similar to the
scores at first assessment, whereas the placebo arm scores remained similar to the baseline scores.
Prespecified subgroup analyses were conducted for OS, PFS and ORR in SELECT and for PFS in DECISION.
All findings favoured the intervention (lenvatinib or sorafenib) when compared with placebo.
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Both trials also included extended open-label phases including patients who had crossed over from
placebo to lenvatinib or sorafenib on disease progression. The extended open-label phase of DECISION
also involved patients who received additional sorafenib on disease progression. The efficacy findings
for PFS from the extended phase of SELECT and DECISION were similar to the findings reported in the
randomised phase of the trials. The incidence of AEs for patients treated with lenvatinib and sorafenib in
the open-label phases of the two trials tended to be slightly lower than the incidence of those reported
during the double-blind phase.
Indirect comparison
In the absence of direct clinical evidence comparing treatment with lenvatinib with treatment with
sorafenib, the AG considered whether or not it would be appropriate to undertake an indirect treatment
comparison. As SELECT and DECISION shared a common comparator (placebo), it is possible to construct
a network; however, differences in participant characteristics, both within and between the trials, raised
concerns about whether or not this approach was appropriate. The AG examined the PFS Kaplan–Meier
data and concluded that the risk profiles of the populations in the two placebo arms were not comparable.
In view of these issues, the AG concluded that it was not appropriate to undertake an indirect comparison,
and considered that the results generated by any indirect comparison that included data from SELECT
and DECISION should be interpreted with caution. Therefore, the AG could not conclude whether the
effectiveness of treatment with lenvatinib and effectiveness of treatment with sorafenib are similar
or different.
Evidence from other reviews and prospective observational studies
Thirteen studies were included in the AG’s review of systematic review evidence, including those reviews
conducted by Eisai Ltd and Bayer HealthCare, provided within their company submissions. Nine studies
were included in the AG’s review of prospective observational studies. Unadjusted median OS estimates
for patients treated with lenvatinib and sorafenib in SELECT and DECISION tended to be higher than those
reported in the reviewed prospective observational studies, whereas median PFS and ORR estimates tended
to be lower. Results from indirect comparisons conducted by the authors of systematic reviews showed
PFS (but not OS) to be statistically significantly improved with lenvatinib, when compared with sorafenib.
Overall, the safety findings from the RCTs were consistent with the findings from the prospective observational
studies and systematic reviews of lenvatinib and sorafenib. Results from indirect comparisons conducted by
the authors of two systematic reviews showed lenvatinib to result in statistically significantly fewer cases of
alopecia but statistically significantly more cases of hypertension, serious adverse events, treatment-related
serious adverse events and withdrawals owing to AEs, when compared with sorafenib.
Evidence from cost-effectiveness studies
The two submitting companies and the AG agreed that there are no published cost-effectiveness studies
relevant to the decision problem set out in the final scope issued by NICE.
Company submissions (economics)
Both companies submitted economic evidence generated by de novo economic models. Using list prices,
the Eisai Ltd base-case incremental cost-effectiveness ratio (ICER) for the comparison of treatment with
lenvatinib and treatment with sorafenib is £22,491 per QALY gained; for the comparison of treatment
with lenvatinib and BSC, it is £48,569 per QALY gained. The analyses carried out by Bayer HealthCare
used the Commercial Medicines Unit price for sorafenib and the list price for lenvatinib. The Bayer
HealthCare ICERs per QALY gained for the comparison of treatment with sorafenib and treatment with
lenvatinib, and treatment with sorafenib and BSC, are commercial in confidence and cannot be reported.
Using the list price for sorafenib, the AG found that Bayer HealthCare’s model generates an ICER per
QALY gained of £56,417 for the comparison of treatment with sorafenib versus BSC.
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Summary of the Assessment Group’s cost-effectiveness results
The AG considered that it was inappropriate to compare data from SELECT and DECISION in the same
evidence network, and concluded that it was not possible to carry out a cost-effectiveness analysis of
lenvatinib versus sorafenib for patients with RR-DTC. Instead, the AG used a standard partitioned survival
model structure, applied to the patient population specified in the final scope issued by NICE, to consider
the cost-effectiveness of lenvatinib and sorafenib separately in comparison with BSC (as represented by
the placebo arms of SELECT and DECISION, respectively). The design of the AG’s model allowed each
intervention to be represented in its natural time metric: 30-day cycles for lenvatinib and 28-day cycles for
sorafenib. This involved creating two parallel models using the same assumptions and model parameters,
but each with its own placebo arm calibrated from its respective clinical trial data.
The AG’s base-case analysis, using list prices only, for the comparison of the cost-effectiveness of
treatment with lenvatinib and BSC yields an ICER per QALY gained of £65,872, and for the comparison of
sorafenib and BSC it yields an ICER per QALY gained of £85,644. The AG’s deterministic sensitivity analysis
involved varying 18 parameters, and the results of these analyses show that none of the variations lowers
the AG’s base-case ICERs below £50,000 per QALY gained. The AG’s probabilistic sensitivity analysis
results show that, compared with BSC, the probability of sorafenib being cost-effective at a threshold of
£50,000 per QALY gained is < 0.05%, and the probability of lenvatinib being cost-effective is 5.4%.
When the AG compared the cost-effectiveness of lenvatinib and BSC using placebo data from DECISION,
and the cost-effectiveness of sorafenib and BSC using placebo data from SELECT, the ICERs per QALY
gained approximately doubled (to £130,592) and halved (to £41,716), respectively. These results highlight
that the choice of BSC comparator is very influential in this appraisal.
Discussion
Strengths
A key strength of this review is that it has brought together all the available relevant evidence (RCTs,
observational studies, systematic reviews, indirect comparisons and cost-effectiveness studies) for assessing
the clinical effectiveness and cost-effectiveness of treatment with lenvatinib versus sorafenib in patients
with RR-DTC. The AG considered that SELECT and DECISION are good-quality, well-conducted trials.
Weaknesses and areas of uncertainty
Owing to a lack of confidence in any results generated by an indirect comparison, the AG considered that
it is not possible to compare the relative effectiveness of treatment with lenvatinib with the relative
effectiveness of treatment with sorafenib.
The generalisability of the findings of SELECT and DECISION to NHS clinical practice is questionable, as,
in clinical practice, concerns about the toxicity of TKI therapy in patients, and consequent effects on the
quality of life of patients with asymptomatic disease, means that treatment is generally only given to
patients who are symptomatic or when clinically significant progressive disease develops. However, results
from a post hoc analysis of DECISION data showed no difference in median PFS between symptomatic
and asymptomatic patients (retrospectively categorised) treated with sorafenib.
Owing to a lack of HRQoL studies, there is considerable uncertainty around the HRQoL of patients with
RR-DTC in general.
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Conclusions
Compared with placebo, treatment with lenvatinib and sorafenib results in an improvement in PFS, ORR
and possibly OS; however, compared with placebo, treatment with both drugs increases the incidence of
AEs. Dose reductions with both drugs are, therefore, frequently required.
The AG considered that it is not possible to compare the clinical effectiveness or cost-effectiveness of
lenvatinib with the clinical effectiveness or cost-effectiveness of sorafenib. This is primarily because the risk
profiles of the participants in the placebo arms of SELECT and DECISION do not appear to be comparable.
Using list prices, compared with BSC, both treatments exhibit estimated ICERs of > £50,000 per QALY
gained. Compared with BSC, the probability of sorafenib and lenvatinib being cost-effective at a threshold
of £50,000 per QALY gained is < 0.05% and 5.4%, respectively.
Recommendations for research
These recommendations are ranked in order of priority.
1. Future clinical effectiveness research should focus on a head-to-head RCT that includes lenvatinib,
sorafenib and BSC, and addresses the following questions:
i. Should both symptomatic and asymptomatic patients be treated with lenvatinib and/or sorafenib?
ii. How does treatment with lenvatinib and sorafenib affect the HRQoL of patients (progressed and
non-progressed, and symptomatic and asymptomatic)?
iii. What is the clinical effectiveness of lenvatinib and sorafenib compared with BSC and compared with
each other?
iv. How should lenvatinib, sorafenib and BSC be positioned in the treatment pathway?
2. The AG considered that it is important to explore more than just standard differences in participant and
trial characteristics when considering the heterogeneity of studies that may be included in an indirect
comparison. The AG suggests that, before undertaking an indirect comparison, the risk profiles of
patient populations for the relevant outcome should be checked to confirm that they are proportional
both within and across all trials that are being considered for inclusion in the network. This assessment
would avoid generating indirect comparison results that are of unknown reliability.
Study registration
This study is registered as PROSPERO CRD42017055516.
Funding
Funding for this study was provided by the Health Technology Assessment programme of the National
Institute for Health Research.
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Thyroid cancer is a rare cancer, representing only 1% of all malignancies in England and Wales.1 It is
caused by the growth of abnormal cells in the thyroid gland. This is a small gland at the base of the neck
that secretes three hormones: triiodothyronine (T3), thyroxine (T4) and calcitonin. T3 and T4 control the
rate of metabolism in the body, and calcitonin works with the parathyroid hormone to control the amount
of calcium in the blood.2 Thyroid cancer is usually asymptomatic and is often discovered incidentally via
imaging studies [e.g. sonograms, computerised tomography (CT) scans and magnetic resonance imaging
(MRI)] that are carried out for another reason, or when patients present with a large palpable nodule in
the neck.3 The actual diagnosis of thyroid cancer is usually made using ultrasonography and biopsy
(typically, a fine-needle aspiration).4
The incidence of thyroid cancer is increasing worldwide.4–10 In the UK, between the period 2003–5 and
the period 2012–14, thyroid cancer incidence rates increased by 74% (Figure 1).1 In 2014, there were
3404 patients diagnosed with thyroid cancer in the UK, 2941 in England and 123 in Wales.1 The reasons
for the increase in incidence are unknown, but are thought to be, at least in part, attributable to improved
diagnostic and detection techniques.11
The incidence of thyroid cancer is 2.5 times greater in women than in men.1 The reasons for this disparity
are unclear.12 Thyroid cancer incidence is strongly related to age, with the highest incidence rates being in
older males, and the highest incidence rates among females being in younger and middle-aged women
(Figure 2).
In the UK, thyroid cancer accounts for < 1% of male cancer deaths and < 1% of female cancer deaths.13
The mortality rate in the UK is reported to be < 1 death per 100,000 people.13 In 2014, there were 376
thyroid cancer deaths in the UK, 154 (41%) in males and 222 (59%) in females, giving a male-to-female



































































FIGURE 1 Average number of new cases per year per 100,000 people in the UK. Based on a graphic created by
Cancer Research UK.1
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1
Although the incidence of thyroid cancer in the UK increased between the period 2003–5 and the period
2012–14, overall mortality rates remained stable during this time (Figure 3);13 however, between 1970 and
2014, thyroid cancer mortality rates decreased by 46% in the UK, the decrease being more marked in
females (54%) than in males (24%).13 Mortality rates for thyroid cancer are projected to rise in the future:
in the UK, it is expected that between 2014 and 2035 mortality will increase by 7%; however, the overall
rate is expected to remain relatively low at 1 death per 100,000 people.13
Differentiated thyroid cancer
The most common form of thyroid cancer is differentiated thyroid cancer (DTC); DTC is reported to
account for approximately 94% of thyroid carcinomas.14,15 Less common types of thyroid cancer include
medullary carcinoma and anaplastic carcinoma; these have been reported to account for approximately





















































































































































































































FIGURE 3 European age-standardised thyroid cancer mortality rates in the UK: 1971–2014. Based on a graphic
created by Cancer Research UK.13
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Differentiated thyroid cancer is a specific type of thyroid cancer made up of different subtypes including
papillary carcinoma (PTC), follicular carcinoma (FTC) and Hürthle cell carcinoma. PTC is the most common
type of DTC, accounting for approximately 83%15 to 86%16 of all cases; FTC accounts for approximately
10%16 to 13%,15 and Hürthle cell carcinoma accounts for approximately 3%15 to 4%.16 Hürthle cell
carcinomas are usually grouped with FTCs because they present and behave similarly.17
The median age for all patients with DTC is reported to be 45 years;18 however, estimates of the median
age at onset for the subtypes of DTC have been reported to vary:
l Papillary carcinoma often affects people aged < 40 years,17 but it is also reported that the median age
of patients with PTC is 45 years.19
l The peak age for the onset of FTC has been stated to be between 40 and 60 years,20 but, again,
the median age has been reported to be approximately 45 years.21
l The median age of patients with Hürthle cell carcinoma has been reported to be 55 years.21
In general, the prognosis for patients with DTC is relatively good. The overall 10-year survival rate for
middle-aged adults is reported to be 80–90%.4 It has also been reported that > 85% of patients with DTC
have a ‘normal’ life expectancy;22 however, the prognosis generally gets worse with increasing age at the
time of diagnosis, particularly for patients aged ≥ 45 years.4 In addition, young children (aged < 10 years)
are at higher risk of recurrence than older children.4 Prognosis may also be affected by DTC subtype
(histology). An analysis of US National Cancer Database data on 41,375 patients with DTC who were
treated between 1985 and 199515 has shown that the 10-year relative survival for patients with PTC is
93%, whereas for patients with FTC it is 85%, and for patients with Hürthle cell carcinoma it is 76%.
The size and spread of the tumour affect prognosis. Studies cited by the British Thyroid Association (BTA)4
are reported to show that the risk of recurrence and mortality correlates with the size of the primary
tumour. Extrathyroidal invasion, lymph node metastases and distant metastases are also reported to be
important prognostic factors.4
First-line treatment options for patients with differentiated
thyroid cancer
There are currently no National Institute for Health and Care Excellence (NICE) guidelines and no NICE
guidance for treating patients with DTC or any other type of thyroid cancer. Other clinical guidelines
do present some recommendations. In chronological order from date of publication, relevant clinical
guidelines include the European Society for Medical Oncology (ESMO) guidelines (2012),23 BTA guidelines
(2014),4 American Thyroid Association guidelines (2015)24 and National Comprehensive Cancer Network
(NCCN) guidelines (2017).25
Owing to the indolent course of the disease, many patients with DTC, even if they have metastatic disease,
do not require therapy for several years after diagnosis.26 Treatments for DTC depend on factors including
age, extent of disease, and histology, but usually involve surgery to remove all or part of the thyroid gland
(thyroidectomy) followed by lifelong thyroxine for thyroid-stimulating hormone (TSH) suppression from the
low–normal to fully suppressed range dependent on risk factors.4,23–25
Treatment options for patients with differentiated thyroid cancer that
has progressed following surgery
Following initial surgery, it is estimated that between 5% and 20% of patients with DTC develop local or
regional recurrences (approximately two-thirds of these involve cervical lymph nodes27) and between 10%
and 15% of patients with DTC develop distant metastases.4,24 The most common sites for metastases are
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reported to be the lungs (50%), bones (25%), lungs and bones (20%) or other (5%).24 It has been noted
that the presence of bone metastases has been associated with a worse prognosis than metastases in
other sites.23
The sites that DTC is most likely to spread to vary by histology. For patients aged > 40 years, it has been
reported that 10% of patients with PTC, 25% of patients with FTC and 35% of patients with Hürthle cell
carcinoma develop distant metastases.28,29 PTC tends to spread to lymph nodes in the neck, whereas FTC
usually spreads to the bones or lungs.17 Hürthle cell carcinoma is more likely than FTC to spread to lymph
nodes in the neck.30
A radioactive iodine uptake test is commonly used to determine whether or not DTC has spread. The test
involves a patient being given a liquid or capsule containing radioactive iodine (iodine-123) to swallow.
Two separate uptake measurements are then commonly obtained at different time points within a 24-hour
period. The patient is then scanned to see how much of this radioactive iodine has been absorbed by
the thyroid (radioactive uptake). Positive results (evidence of iodine-123 uptake) denote the presence of
disease, whereas negative results (no radioactive uptake) denote the absence of disease.
It is recommended in clinical guidelines4,23–25 that patients with DTC and evidence of radioactive iodine
uptake should undergo treatment with radioactive iodine (also known as radioactive iodine ablation) to
treat residual, recurrent or metastatic disease. Patients are typically tested 1–2 months after surgery.
Radioactive iodine treatment has been used for > 60 years. It is administered in hospital (during an
inpatient stay) and can be given to patients on more than one occasion, as necessary.4
Like the radioactive iodine uptake test used to diagnose DTC, radioactive iodine treatment involves
swallowing radioactive iodine in either liquid or capsule form; however, the radioactive iodine is a different
form (iodine-131) to that used for scans (iodine-123): the purpose of radioactive iodine treatment is to
destroy cancerous cells. Thus, patients with iodine-131 uptake are responsive to treatment, which can be
confirmed by imaging studies.
Approximately 33% of patients with advanced disease can be cured and many others achieve long-term
disease stabilisation.31 From published French registry data,32 the 10-year survival rate for patients with
distant metastases who successfully responded to treatment with radioactive iodine is 92%.32
Radioactive iodine-refractory differentiated thyroid cancer
Although for many patients radioactive iodine is an effective treatment, some patients become resistant to
the treatment (decreased or no radioactive iodine uptake) or are unable to safely tolerate additional doses.
These patients are considered to have radioactive iodine-refractory DTC (RR-DTC) and are the focus of this
multiple technology appraisal (MTA).
Although clinical criteria and algorithms have been developed and reported in clinical guidelines,4,23–25
there is no agreed precise definition of RR-DTC;33 however, a review of the literature published in
February 201731 highlights key features that can be considered in defining RR-DTC:
l Metastatic disease that does not take up radioactive iodine at the time of the first radioactive
iodine treatment.
l Ability to take up radioactive iodine has been lost after previous evidence of uptake of radioactive iodine.
l Radioactive iodine uptake is retained in some lesions but not in others.
l Metastatic disease that progresses despite substantial uptake of radioactive iodine.
l Absence of complete response to treatment after > 600mCi of cumulative activity of radioactive iodine.
l Evidence of high uptake of fludeoxyglucose (FDG) 18F on positron emission tomography or CT scan;
however, importantly, the authors of this review31 state that this reason alone should not be used to
abandon radioactive iodine treatment.
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Before deciding whether or not a patient’s disease can be described as being RR-DTC, it is important to
determine that decreased radioactive iodine uptake is not due to iodine contamination or insufficient TSH.34
Radioactive iodine-refractory DTC is a life-threatening form of thyroid cancer with a tendency to progress
and metastasise.14 From published French registry data,32 the 10-year survival rate and median overall
survival (OS) for patients with distant metastases who failed to respond to treatment (no iodine-131 uptake)
was 10% and 3 years, respectively. For those who appear to respond to radioactive iodine treatment
(iodine-131 uptake) but who did not then attain negative imaging studies, the 10-year survival and median
OS was 29% and 6 years, respectively. A separate analysis of patients with lung and/or bone metastases35
found that 10-year survival and median OS for those who did not have a complete response to treatment
with radioactive iodine was 14% and 5 years, respectively. Data from Canada5 have suggested that the
median OS for patients with RR-DTC may be between 2.5 and 3.5 years.
The proportion of patients whose disease becomes refractory to treatment with radioactive iodine is
relatively small, and so RR-DTC is described as an ultra-orphan condition.7,8 Estimates of the proportion of
patients who become refractory vary but commonly lie within the range of 5–15%.7,8,14,16,32,35–37
As with early-stage DTC, many patients with RR-DTC are initially asymptomatic. As highlighted in a
literature review published by Schmidt et al.,31 even patients with distant metastases may have a disease
that does not progress for many years; however, as noted by Thyroid Cancer Canada,5 the cancer
continues to progress with no obvious symptoms.
For patients with rapidly progressing disease, which is characterised by symptomatic disease, the symptoms
of RR-DTC can be severe, profoundly debilitating and result in patients becoming increasingly dependent
on carers.8 Clinical advice to the Assessment Group (AG) is that the percentage of patients with RR-DTC
with rapidly progressing disease is likely to be approximately 25% to 30%. As a result of their symptoms,
patients with clinically significant progressive RR-DTC may suffer a poor quality of life and the psychological
impact of the disease can also be substantial, resulting in low mood and fatigue.38 It has also been stated
that patients with RR-DTC often experience multiple complications.39
Treatment options for patients with radioactive iodine-refractory
differentiated thyroid cancer
Radioactive iodine-refractory DTC is typically asymptomatic, but symptoms start to occur as the disease
progresses. Symptoms associated with lymph nodes of the neck include difficulty swallowing and/or
breathing, pain or sensitivity in the front of the neck or throat, hoarseness or other voice changes,
and swelling of the lymph nodes in the neck.4 Symptoms associated with lung metastases also include
swallowing and breathing difficulties.26 Pain often presents as the principal symptom of metastatic bone
involvement.29,40 Fractures and spinal cord compression are also associated with bone metastases.
Because many treatments, particularly systemic treatments, can have severe side effects and impact
significantly on health-related quality of life (HRQoL), clinical advice to the AG is that best supportive care
(BSC) tends to be the preferred treatment option, at least until symptoms occur. BSC typically entails TSH
suppression therapy and imaging every 3 to 12 months. Palliative radiotherapy and symptom relief are also
offered when necessary.
Patients experiencing RR-DTC symptoms and/or patients with rapidly progressing disease are those in need
of systemic treatment,31 as reflected in clinical guidelines.4,23–25 The aim of systemic treatment for patients
with rapidly progressing and/or symptomatic RR-DTC is to gain local disease control in the neck and
manage systemic disease.41 Another important objective of treatment is to prolong survival;27 however,
treatment options for patients with RR-DTC are limited. Within the ESMO guidelines published in 2012,23 it
is stated that chemotherapy should not be given to patients with RR-DTC as it is associated with significant
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toxicity with no proven evidence of effectiveness. The authors of these guidelines stated that surgical
resection and external beam radiotherapy represented the only therapeutic options and they strongly
encouraged enrolment of patients in experimental trials with targeted therapy. Similarly, the authors of
the guidelines published by the BTA in 20144 only recommended chemotherapy for patients with rapidly
progressive, symptomatic RR-DTC who have good performance status (PS), and only when access to
targeted therapies in clinical trials is unavailable or when targeted therapies have proved unsuccessful. The
authors of the more recent US guidelines published by the American Thyroid Association24 and NCCN25
recommend that patients with RR-DTC should usually avoid treatment with chemotherapy. Clinical advice
received by the AG is that chemotherapy is rarely used to treat RR-DTC in UK NHS practice.
Targeted therapies were not widely available and were only the subject of clinical trials between 2012
and 2014, when the ESMO guidelines23 and the BTA guidelines4 were published. The authors of the BTA
guidelines4 considered the most promising targeted therapies at that time to be lenvatinib and sorafenib.4
By 2017, the authors of the NCCN guidelines25 recommended lenvatinib or sorafenib as the treatment of
choice for patients with progressive and/or symptomatic disease; lenvatinib is stated to be the ‘preferred’
option based on a response rate of 65% for lenvatinib, compared with 12% for sorafenib, although these
agents have not been directly compared. However, the authors state that the decision should be based on
the individual patient, taking into account the likelihood of response and comorbidities.25 In cases in which
lenvatinib or sorafenib are not available or not appropriate, drugs not regulated by the US Food and Drug
Administration (FDA) but used in the context of clinical trials are also recommended by the authors of the
NCCN guidelines.25
Description of technology under assessment
The two interventions under consideration in this MTA are lenvatinib (Lenvima), manufactured by Eisai Ltd,
and sorafenib (Nexavar), manufactured by Bayer HealthCare. Both are a type of tyrosine kinase inhibitor
(TKI) known as a multikinase inhibitor (MKI).
A brief comparison of the key features of the two interventions is given in Table 1. The AG notes that
lenvatinib and sorafenib appear to have slightly different mechanisms of action.42 Both drugs have been
approved for treating RR-DTC in the USA43,44 and Europe,49,50 with sorafenib being the first of the two
agents to be approved in both jurisdictions. In the USA and Europe, the marketing indications for both
lenvatinib and sorafenib are for identical patient populations. Approval in the USA and Europe was based
largely on evidence from two Phase III randomised controlled trials (RCTs): SELECT,51 in which lenvatinib
was compared with placebo, and DECISION (StuDy of sorafEnib in loCally advanced or metastatIc patientS
with radioactive Iodine-refractory thyrOid caNcer),52 in which sorafenib was compared with placebo.
Approval for use in NHS Scotland was granted to sorafenib in June 201548 and to lenvatinib in
September 2016.38 Both approvals are for the treatment of patients with progressive, locally advanced
or metastatic RR-DTC. In NHS Scotland, the use of both lenvatinib and sorafenib is contingent on the
continuing availability of Patient Access Scheme (PAS) prices that have been assessed by the PAS
Assessment Group.
Sorafenib has been available in England, since July 2016, via the Cancer Drugs Fund (CDF). It is currently
funded for all patients with RR-DTC for whom the treating specialist has established that treatment with
sorafenib may be beneficial. According to Bayer HealthCare, based on its analysis of notification data
from July 2013 to June 2016, sorafenib has become the standard of care for patients for whom systemic
treatment is appropriate.7 Lenvatinib is not currently available to patients treated in the English or Welsh NHS.
BACKGROUND
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TABLE 1 Comparison of the key features of lenvatinib and sorafenib
Feature Lenvatinib Sorafenib
Brand name Lenvima Nexavar
Manufacturer Eisai Ltd Bayer HealthCare
Class of drug Oral MKI Oral MKI
Mechanism of
action
Targets VEGFR1, VEGFR2, VEGFR3, FGFR1,
FGFR2, FGFR3, FGFR4, PDGFR alpha,
PDGFR beta, RET and KIT42
Targets BRAF, RET, VEGFR2 and VEGFR342
US marketing
indication
For the treatment of locally recurrent
or metastatic, progressive, RR-DTC
(15 February 2015)43
For the treatment of locally recurrent or metastatic,
progressive, differentiated thyroid carcinoma refractory




For the treatment of adult patients with
progressive, locally advanced or metastatic,
differentiated (papillary/follicular/Hürthle
cell) thyroid carcinoma, refractory to
radioactive iodine (28 May 2015)45
For the treatment of patients with progressive, locally
advanced or metastatic, differentiated (papillary/
follicular/Hürthle cell) thyroid carcinoma, refractory to
radioactive iodine (25 January 2015)46
In addition to RR-DTC, sorafenib is also indicated
for treatment of hepatocellular carcinoma and the




24mg (two 10-mg capsules and one 4-mg
capsule) once daily
AEs can be managed through dose
reduction and treatment is continued until
disease progression or unacceptable
toxicity45
400mg (two 200-mg tablets) twice daily, taken
without food or with a low-fat meal
AEs can be managed through dose reduction and




Important risks highlighted by the EMA27
include hypertension, proteinuria, renal
failure or impairment, hypokalaemia, cardiac
failure, posterior reversible encephalopathy
syndrome, hepatotoxicity, haemorrhagic
events, arterial thromboembolic events,
QTc prolongation and hypocalcaemia
Further information, including how to
manage some of the risks (e.g. the use of
hypertensives for hypertension) is provided
in the SmPC46
Important risks highlighted by the EMA26 include
severe skin AEs; hand–foot syndrome; hypertension;
posterior reversible encephalopathy syndrome;
haemorrhage including lung haemorrhage,
gastrointestinal haemorrhage and cerebral
haemorrhage; arterial thrombosis (myocardial
infarction); congestive heart failure; squamous cell
cancer of the skin; gastrointestinal perforation;
symptomatic pancreatitis and increases in lipase and
amylase; hypophosphataemia; renal dysfunction;
interstitial lung disease-like events; and drug-induced
hepatitis
Further information, including how to manage
some of the risks (e.g. the use of topical therapies,
temporary treatment interruption and/or dose
modification or treatment discontinuation for
hand–foot syndrome) is provided in the SmPC46
List price per
pack
£1437.00 for a pack of 30 4-mg capsules
and £1437.00 for a pack of 30 10-mg
capsules8
£3576.56 for a pack of 112 200-mg tablets47
Cost per yeara £52,30738 £38,74648
AE, adverse event; BRAF, B-type rapidly accelerated fibrosarcoma; EMA, European Medicines Agency; FGFR, fibroblast
growth factor receptors; PDGFR, platelet-derived growth factor receptor; QTc, QT corrected interval; RET, rearranged during
transfection; SmPC, summary of product characteristics; VEGFR, vascular endothelial growth factor receptor.
a All costs are presented based on the list price and assume that a patient receives the full dose; however, in clinical
practice, most patients will not receive the full dose throughout the course of their treatment. Based on clinical trials,
median dose intensity has been reported to be approximately 70% for lenvatinib and approximately 80% for sorafenib.
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Eisai Ltd8 has estimated the incidence of patients in England and Wales with RR-DTC who are potentially
eligible for treatment with lenvatinib or sorafenib to be approximately 280 each year. Bayer HealthCare7
has estimated the incidence to be approximately 225 patients per year. The AG notes that the estimates
given by the companies differ in how they are calculated. The estimates provided by the companies are
reflective of the population defined by the agreed final scope of this appraisal; however, neither estimate
appears to account for the fact that lenvatinib and sorafenib are likely to only be preferred for patients
with symptomatic and/or rapidly progressing disease. Clinical advice to the AG is that there are no
generally agreed definitions of ‘symptomatic’ or ‘rapidly progressive disease’ and that, in clinical practice,
definition of a patient’s disease status depends on individual patient characteristics. Therefore, it is difficult
to further segment the population.
BACKGROUND
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Chapter 2 Definition of the decision problem
Decision problem addressed by the Assessment Group
The decision problem for this appraisal, as described in the final scope issued by NICE,53 is summarised in
Table 2.
TABLE 2 Decision problem summarised in the final scope issued by NICE53 and addressed by the AG




Population Adults with progressive, locally advanced or metastatic, differentiated thyroid
carcinoma refractory to radioactive iodine
As per scope
Comparators The interventions listed above will be compared with each other
BSC














The reference case stipulates that the cost-effectiveness of treatments should
be expressed in terms of incremental cost per quality-adjusted life-year
The reference case stipulates that the time horizon for estimating clinical
effectiveness and cost-effectiveness should be sufficiently long to reflect any
differences in costs or outcomes between the technologies being compared




If the evidence allows, consideration will be given to subgroups based on
previous treatment with TKIs
Guidance will only be issued in accordance with the marketing authorisation.
When the wording of the therapeutic indication does not include specific
treatment combinations, guidance will be issued only in the context of the
evidence that has underpinned the marketing authorisation granted by the
regulator
As per scope
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The overall aims and objectives of the assessment
The aim of this research was to assess the clinical effectiveness and cost-effectiveness of lenvatinib versus
sorafenib, within their respective EU marketing authorisations,45,46 for the treatment of patients with
RR-DTC. The research objectives are given below:
l To carry out systematic reviews to compare the clinical effectiveness and cost-effectiveness of –
¢ treatment with lenvatinib with treatment with sorafenib for RR-DTC
¢ treatment with lenvatinib with BSC for RR-DTC
¢ treatment with sorafenib with BSC for RR-DTC.
l To develop an economic model to compare the cost-effectiveness of –
¢ treatment with lenvatinib with treatment with sorafenib for RR-DTC
¢ treatment with lenvatinib with BSC for RR-DTC
¢ treatment with sorafenib with BSC for RR-DTC.
DEFINITION OF THE DECISION PROBLEM
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Chapter 3 Methods for reviewing clinical
effectiveness literature
Search strategy
The AG identified clinical studies and systematic reviews by searching EMBASE, MEDLINE, PubMed and The
Cochrane Library from 1999 onwards. All databases were searched on 10 January 2017. Based on the fact
that the FDA approved sorafenib for its first indication in 2005, and lenvatinib in 2015, the AG considered
that this date span would allow all relevant clinical evidence to be identified. Searches were restricted to
publications in English language. The AG did not use any other search filters. The search strategies used by
the AG are provided in Appendix 1. In addition to the electronic database searches, information on studies
in progress was sought (on 16 May 2017) by searching the ClinicalTrials.gov website, the International
Clinical Trials Registry Platform and the European Union Clinical Trials Register. The references in the
systematic reviews included in the AG’s review of systematic reviews, and those listed in the submissions
from professional stakeholders that were submitted to NICE, as part of the NICE MTA process, were
cross-checked to identify any relevant studies not retrieved from the electronic database searches. Literature
search results were uploaded to and managed using EndNote X7.4 [Clarivate Analytics (formerly Thomson
Reuters), Philadelphia, PA, USA] software.
Study selection
The eligibility criteria listed in Table 3 were used to identify studies for inclusion in the AG’s
literature review.




Adults with progressive, locally advanced or
metastatic, differentiated thyroid carcinoma refractory
to radioactive iodine
Patients with other types of thyroid cancer or
diseases
Interventions Lenvatinib or sorafenib monotherapy (or in
combination with BSC)
Lenvatinib or sorafenib in combination with other
agents
Comparators Lenvatinib or sorafenib monotherapy (or in
combination with BSC), BSC and placebo
A comparator other than lenvatinib, sorafenib,
BSC and placebo
Outcomes The outcome measures to be considered include OS,
progression-free survival, response rate, adverse
effects of treatment and HRQoL
No study was excluded based on outcomes
Study design RCTs, systematic reviews and prospective
observational studies
Retrospective cohort studies, case series, case
reports, comments, letters, editorials, in vitro,
animal and genetic or histochemical studies
Restrictions English language only Non-English-language studies
Reproduced with permission from Fleeman et al.54 This is an Open Access article distributed in accordance with the terms
of the Creative Commons Attribution (CC BY 4.0) license, which permits others to distribute, remix, adapt and build upon
this work, for commercial use, provided the original work is properly cited. See: http://creativecommons.org/licenses/by/4.0/.
The table includes minor additions and formatting changes to the original text.
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Two reviewers (JH and RH) independently screened all titles and abstracts that were identified in the initial
searches (screening stage 1). Based on the titles and abstracts, full-text papers that appeared to be relevant
were obtained and assessed for inclusion by the same two reviewers in accordance with the AG’s eligibility
criteria (screening stage 2). When necessary, discrepancies were resolved by consultation with a third
reviewer (NF). At both stages of screening, studies that did not meet the inclusion criteria were excluded,
and, at screening stage 2, the reasons for excluding studies were noted.
The eligibility criteria in Table 3 differ slightly from those specified in the AG’s systematic review protocol.55
The AG, responding to a suggestion from NICE in relation to the final protocol,55 agreed to include
evidence from prospective observational studies that had been submitted to the European Medicines
Agency (EMA); however, as only reviewing studies included in the EMA submissions26,27 would have
introduced selection bias, the AG included all prospective observational studies of patients with RR-DTC
identified by its searches.
Data extraction and quality assessment strategy
Data relating to RCT study characteristics and outcomes were extracted by one reviewer (NF) and
independently checked for accuracy by a second reviewer (YD). Data relating to study characteristics
and outcomes of systematic reviews and observational studies were extracted by one reviewer (JH or NF)
and independently checked for accuracy by a second reviewer (JG). In all cases, a consensus was reached.
Study data reported in multiple publications were extracted and reported as a single study. Data were
extracted into tables in Microsoft Word (Microsoft Corporation, Redmond, WA, USA).
As specified in the AG’s systematic review protocol,55 the quality of included RCTs and systematic reviews
was assessed according to the criteria set out in the Centre for Review and Dissemination’s guidance56
for undertaking reviews in health care. The quality of the included RCTs was assessed by one reviewer
(YD) and independently checked for agreement by a second reviewer (NF). In all cases, a consensus
was reached. The quality of the included systematic reviews was assessed by one reviewer (JG) and
independently checked for agreement by a second reviewer (YD). When necessary, discrepancies were
resolved by consultation with a third reviewer (MR).
Methods of analysis/synthesis
The AG’s data extraction and quality assessment results are presented in structured tables and as a narrative
summary. Data from RCTs are considered to provide primary clinical effectiveness evidence, with data from
systematic reviews and observational studies considered to provide supporting evidence.
As the available evidence did not include two or more RCTs comparing the same intervention, the AG was
not able to conduct a meta-analysis of RCT data.
The AG assessed the feasibility of conducting an indirect comparison of effectiveness data (including a
comparison to assess effectiveness according to previous treatment with TKIs) by evaluating the clinical
and methodological heterogeneity of the included RCTs. Heterogeneity was assessed by comparing
(1) trial characteristics, (2) participant characteristics, (3) outcome data and (4) study quality.
METHODS FOR REVIEWING CLINICAL EFFECTIVENESS LITERATURE
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Chapter 4 Findings from the systematic review of
clinical effectiveness literature
Quantity and quality of research available
Included studies
The process of study selection is shown in the Preferred Reporting Items for Systematic Reviews and
Meta-Analyses (PRISMA) flow diagram in Figure 4. The electronic searches yielded 2358 papers, and six
additional references5–8,57,58 were identified through other sources. In total, the AG included 93 papers5–8,33,51,52,57–142
reporting on 24 separate studies and reviews: two unique RCTs,51,52 13 unique systematic reviews5–8,33,57,61,
93,97,104,127,138,141 and nine unique prospective observational studies.59,77,78,81,88,101,103,126,135
Excluded studies





















• Wrong population, n = 24
• Wrong intervention, n = 8
• Wrong study design, n = 102


















FIGURE 4 The PRISMA flow diagram: studies included in AG’s systematic review. Reproduced with permission from
Fleeman et al.54 This is an Open Access article distributed in accordance with the terms of the Creative Commons
Attribution (CC BY 4.0) license, which permits others to distribute, remix, adapt and build upon this work, for
commercial use, provided the original work is properly cited. See: http://creativecommons.org/licenses/by/4.0/.
The figure includes minor additions and formatting changes to the original text.
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Evidence from randomised controlled trials
Only two RCTs were identified as relevant for inclusion in the AG’s systematic review: SELECT and
DECISION. Except when stated otherwise, all information about these two trials has been extracted from
the two key trial publications.51,52
Trial characteristics
A summary of the characteristics of the two included trials is provided in Table 4. Both trials were Phase III,
multicentre, double-blind RCTs designed to compare the intervention of interest (lenvatinib or sorafenib)




Primary reference Schlumberger et al. 201551 Brose et al. 201452
Number of centres 117 81
Stratification
factors
Subjects were stratified by age (≤ 65 years or
> 65 years), geographical region (Europe, North
America or other) and receipt or non-receipt of
prior VEGFR-targeted therapy (0 or 1)
Subjects were stratified by age (< 60 years
or ≥ 60 years) and geographical region
(North America, Europe or Asia)
Country Centres were distributed as follows: Europe,
60 (51.3%); North America, 31 (26.5%);
Asia Pacific, 13 (11.1%); Japan, 6 (5.1%);
and Latin America, 7 (6.0%)
18 countries from Europe (59.7%) (Austria,
Belgium, Bulgaria, Denmark, France, Germany,
Italy, Poland, Russia, Spain, Sweden, the
Netherlands and the UK), the USA (17.3%) and
Asia (23%) (China, Japan, South Korea and
Saudi Arabia)
Recruitment period 5 August 2011 to 4 October 2012 5 November 2009 to 29 August 2012
Participants (n) 612 assessed, 392 randomised 556 enrolled, 419 randomised
Intervention dose
and schedule
Lenvatinib 24 mg (two 10-mg capsules and one
4-mg capsule) continuous once daily (n= 261)
Sorafenib 400 mg (two 200-mg tablets) twice
daily for a total daily dose of 800 mg (n= 207)
Comparator arm (n) Placebo: 131 Placebo: 210
Primary outcome PFS, assessed every 8 weeksa and determined by
blinded independent imaging review conducted
by the imaging core laboratory using RECIST 1.1
PFS, assessed every 8 weeks by central
independent blinded review using RECIST 1.0
Relevant secondary
outcomes
l OS, measured from the date of
randomisation until date of death from
any cause
l Investigator-assessed PFS
l ORR (defined as the proportion of subjects
who had the best overall response of
complete response or partial response as
determined by blinded independent imaging
review using RECIST 1.1) and related
outcomes including duration of response,
stable disease, disease control rate and
clinical benefit rate
l Safety
l OS, measured from the date of
randomisation until the date of death from
any cause
l Investigator-assessed PFS
l ORR (defined as the proportion of subjects
who had the best overall response of
complete response or partial response as
determined by blinded independent imaging
review using RECIST 1.0) and related
outcomes including duration of response,
stable disease and disease control rate
l Safety
l HRQoL
Primary analysis ≥ 214 progression events or deaths ≈267 progression events
Data cut-off points November 2013, June 2014 and August 2015 August 2012, May 2013 and July 2015
RECIST, Response Evaluation Criteria in Solid Tumours; VEGFR, vascular endothelial growth factor receptor.
a Every 12 weeks in the extended open-label phase of the trial.
Note
Information drawn from Schlumberger et al.,51 Eisai Ltd,8 Brose et al.52 and Bayer HealthCare.7
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with placebo. Subjects were randomised in a ratio of 2 : 1 to the intervention and comparator arms of
SELECT, whereas they were randomised in a ratio of 1 : 1 in DECISION. In both trials, the primary outcome
was progression-free survival (PFS) assessed by blinded independent review. Both trials also reported
investigator-assessed PFS. Unless otherwise specified, in the remainder of this AG report on clinical
effectiveness, PFS refers to PFS assessed by blinded independent review.
Analysis of clinical efficacy
All efficacy outcomes from both trials, including tumour response evaluations in SELECT, were undertaken
using data from the intention-to-treat (ITT) population. Tumour response evaluations in DECISION were
undertaken using data from the per-protocol population (i.e. randomised patients who were evaluable for
tumour response with imaging data, had received the intervention or placebo as allocated and had no
major protocol deviations).
Analysis of safety
Safety analyses for both trials were undertaken using data from the population of patients who were
randomised and received at least one dose of study drug and had at least one post-baseline safety
evaluation. In SELECT, the numbers of patients included in the ITT and safety populations were identical.
Patients eligible for inclusion
A summary of the criteria describing patient eligibility for entry into SELECT and DECISION is presented in
Appendix 3, Table 33. Both trials only included patients with RR-DTC and who had an Eastern Cooperative
Oncology Group (ECOG) PS of 0–2. As highlighted in Chapter 1, Radioactive iodine-refractory differentiated
thyroid cancer, there is no universally agreed definition of RR-DTC. The definitions used to define RR-DTC
in the two trials were broadly similar (see Appendix 3, Table 34, for definitions employed by the trials for
RR-DTC).
The main difference in trial eligibility was that SELECT permitted the enrolment of patients who had been
previously treated with a vascular endothelial growth factor receptor (VEGFR)-targeted therapy (including
sorafenib) and DECISION did not. Age, region and VEGFR-targeted therapy were stratification factors in
SELECT, whereas age and region were stratification factors in DECISION.
Dose modifications/interruptions and concomitant therapy
In both trials, the starting dose for treatment with lenvatinib or sorafenib was the licensed dose (24 mg
and 800 mg, respectively). Both trials permitted dose modifications or interruptions. The criteria were
not stated in the protocol for SELECT but the summary of product characteristics (SmPC)45 includes a
dose/toxicity management plan for lenvatinib. For DECISION, Brose et al.72 stated that dose modifications
or interruptions were allowed, based on specific criteria, for grade 2 to grade 3 hand–foot syndrome and
other adverse events (AEs).
A summary of the concomitant therapies permitted and prohibited in each trial is presented in Appendix 3,
Table 35. Although neither trial describes BSC for patients in either arm, permitted concomitant therapies
could be considered to be BSC and were available to patients in both arms of both trials. The main
difference between the two trials is that palliative radiotherapy, which is commonly available as part of
BSC in UK NHS clinical practice, was not permitted in either arm of SELECT.
Subgroup analyses
In SELECT, subgroup analyses were prespecified for patients previously treated with a VEGFR-targeted
therapy and for those who were not. Both trials also included prespecified subgroup analyses for age,
region, sex and histology. Subgroup analyses were prespecified for PFS, OS and objective tumour response
rate (ORR) in SELECT but only for PFS in DECISION. Other prespecified subgroup analyses in SELECT were
for race and for patients whose TSH level was highest prior to progression. Other prespecified subgroup
analyses in DECISION included site of metastasis, FDG take-up, prior radioactive iodine cumulative dosing,
tumour burden as measured by number of target or non-target lesions and as measured by the sum of
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target diameters. Many other post hoc subgroup analyses were also conducted for both trials
(see Appendix 3, Table 37).
Follow-up, dose intensity and treatment crossover and other subsequent
therapy received
At the time of the primary data cut-off points for both trials, OS data were immature. Therefore, for both
trials, OS was updated at two subsequent data cut-off points. The median duration of follow-up at each
data cut-off point was approximately 17 months at the first data cut-off point in both trials and there
were approximately 20 months of additional follow-up in both trials by the final data cut-off point
(see Appendix 3, Table 36).
Patients were eligible to receive treatment (intervention or placebo) in both trials until disease progression.
An important feature of both trials is that, on disease progression, patients were unblinded and permitted
to cross over from the placebo arm to the active treatment arm. In both trials, patients who crossed
over were entered into an open-label extension phase of the same trial. In DECISION, patients who had
progressed on sorafenib were also eligible to enter the open-label extension phase of the trial and receive
further sorafenib until further disease progression. However, patients who progressed on lenvatinib in
SELECT were not permitted to receive additional lenvatinib in the open-label extension phase. Information
on treatment crossover and subsequent treatment received is reported in Table 5; it is evident that the
majority of patients in both placebo arms, and particularly in the placebo arm of SELECT, crossed over to
receive lenvatinib or sorafenib.
In addition, some patients received subsequent anti-cancer treatments, not part of the trial protocols, on
disease progression (see Appendix 3, Table 39). In SELECT, at the first data cut-off point (November 2013),
15.7% of patients randomised to lenvatinib and 12.2% of patients randomised to placebo received
subsequent treatment. In DECISION, at the first data cut-off point (August 2012), 20.3% of patients
randomised to sorafenib and 8.6% of patients randomised to placebo received subsequent treatments.
For the most part, subsequent treatment in both trials comprised antineoplastic and immunomodulating
agents. The specific antineoplastic and immunomodulating agents were reported only for SELECT, as data
were not collected on the specific agents used during the trial follow-up for DECISION. Most commonly,
patients received pazopanib (Votrient®, Novartis) (17.1% and 18.8% of patients who received subsequent
therapy in the lenvatinib and placebo arms, respectively) and/or sorafenib (14.6% and 12.5% of patients
who received subsequent therapy in the lenvatinib and placebo arms, respectively).





Lenvatinib (N= 261) Placebo (N= 131) Sorafenib (N= 207) Placebo (N= 210)
Patients who crossed over:
first data cut-off point
N/A 109 (83.2) 55 (26.6)a 150 (71.4)
Patients who crossed over:
second data cut-off point
N/A 115 (87.8) NR 157 (74.8)
Patients who crossed over:
third data cut-off point
N/A 115 (87.8) NR 158 (75.0)
N/A, not applicable; NR, not reported.
a Patients did not cross over from the sorafenib arm to the placebo arm in DECISION but were permitted to receive
additional sorafenib. Data reported here are for those who received additional sorafenib.
Note
Information drawn from Schlumberger et al.,51 Eisai Ltd8 (including appendix 4), Brose et al.52 and Bayer HealthCare.7
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Methods used for adjusting for treatment crossover
As patients in both trials were permitted to cross over to receive the intervention drug on disease
progression, the OS results are likely to be confounded. The authors of the SELECT publication51 employed
the rank-preserving structural failure time model (RPSFTM) to adjust the OS results for patient crossover.
The OS results from DECISION have been adjusted using both the RPSFTM and the iterative parameter
estimation (IPE). The unadjusted and adjusted OS analyses have been reported in conference abstracts for
SELECT,87 DECISION58,68,110 and in the company submissions.7,8
As patients were not censored when they received postprogression treatments, the RPSFTM and IPE
methods implicitly included all subsequent therapies as an inherent part of the intervention/control
treatment effect. In other words, it is assumed that the subsequent therapy administered to patients in
each arm of the trial is reflective of the subsequent therapy that would have been offered to patients
receiving the same treatment in clinical practice.
The RPSFTM and IPE methods also both rely critically on the ‘common treatment effect’ assumption,
that is, the effect of receiving the experimental treatment is the same when received on diagnosis (i.e. in
patients initially randomised to the experimental arm) as it is in treatment switchers (i.e. patients from the
control arm who switch to receive the experimental treatment). In practice, it is unlikely that the ‘common
treatment effect’ assumption will ever be completely true; however, it is appropriate to use RPSFTM/IPE
methods if the assumption is likely to be approximately true.143 Clinical advice to the AG was that for both
SELECT and DECISION it is reasonable to assume that patients who switched from the placebo arm to
receive the experimental treatment (i.e. lenvatinib/sorafenib) would experience the same treatment effect
as patients who were originally randomised to the experimental arm.
In addition to the assumptions that are common to both the RPSFTM and the IPE methods, the IPE method
also assumes that survival times follow a parametric distribution. To implement this method, a suitable
parametric model must be identified, which can be problematic. The AG has been unable to identify
information on how the IPE analysis was carried out using data from DECISION, including details of the
parametric model chosen, and so is not able to comment on the suitability of this method.
Generally, the key assumption of a ‘common treatment effect’ that underpins RPSFTM appears to be valid,
and because a large number of placebo patients crossed over to active treatment in both trials, the AG is
of the opinion that RPSFTM is the most suitable method for adjusting for treatment switching in SELECT
and DECISION. However, a caveat to the use of the RPSFTM-adjusted OS results for both trials is that
differences in poststudy (postprogression) anti-cancer treatments administered to patients in each
treatment arm are not accounted for in this analysis.
Participant characteristics
Overall, the baseline characteristics of patients included in SELECT and in DECISION were balanced between
treatment arms (Table 6). Nevertheless, there are a few notable differences between the treatment arms and
also across the trials.
In SELECT, there was a lower proportion of males in the lenvatinib arm (47.9%) than in the placebo arm
(57.3%). The median time from diagnosis of DTC to randomisation was shorter in the lenvatinib arm
than in the placebo arm (66.0 vs. 73.9 months). Compared with the placebo arm, a smaller proportion of
patients in the lenvatinib arm had metastases in the lung [86.6% (lenvatinib) vs. 94.7% (placebo)] or liver
[16.5% (lenvatinib) vs. 21.4% (placebo)].
In DECISION, a higher proportion of patients in the sorafenib arm had metastases in the lymph node
(54.6%) or pleura (19.3%) than in the placebo arm (48.1% and 11.4%, respectively). There was a higher
proportion of males in the sorafenib arm (50.2%) than in the placebo arm (45.2%).
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Age (years), median (minimum to maximum) 64 (27 to 89) 61 (21 to 81) 63 (24 to 82) 63 (30 to 87)
Male, n (%) 125 (47.9) 75 (57.3) 104 (50.2) 95 (45.2)
Race, n (%)
White 208 (79.7) 103 (78.6) 123 (59.4) 128 (61.0)
Black of African American 4 (1.5) 4 (3.1) 6 (2.9) 5 (2.4)
Asian 46 (17.6) 24 (18.1) 47 (22.7) 52 (24.8)
Other 3 (1.2) 0 2 (1.0) 2 (1.0)
Missing or uncodeable 29 (14.0) 23 (11.0)
Region, n (%)
Europe 131 (50.2) 64 (48.9) 124 (59.9) 125 (59.5)
North America 77 (29.5) 39 (29.8) 36 (17.4) 36 (17.1)
Other 53 (20.3) 28 (21.4) 47 (22.7) 49 (23.3)










ECOG PS, n (%)
0 144 (55.2) 68 (51.9) 130 (62.8) 129 (61.4)
1 104 (39.8) 61 (46.6) 69 (33.3) 74 (35.2)
2 12 (4.6) 2 (1.5) 7 (3.4) 6 (2.9)
3 1 (0.4) 0 0 0
Not available 0 0 1 (0.5) 1 (0.5)
Histology, n (%)
Papillary 132 (50.6) 68 (51.9) 118 (57.0) 119 (56.7)
Poorly differentiated 28 (10.7) 19 (14.5) 24 (11.6) 16 (7.6)
Follicular, not Hürthle cell 53 (20.3) 22 (16.8) 13 (6.3) 19 (9.0)
Hürthle cell 48 (18.4) 22 (16.8) 37 (17.9) 37 (17.6)
Other 0 0 2 (1.0) 5 (2.4)
Missing or non-diagnosed 0 0 13 (6.3) 14 (6.7)
Metastases, n (%)
Locally advanced 4 (1.5) 0 7 (3.4) 8 (3.8)
Distant 257 (98.5) 131 (100) 200 (96.6) 202 (96.2)
Metastases site, n (%)
Lung 226 (86.6) 124 (94.7) 178 (86.0) 181 (86.2)
Lymph node 138 (52.9) 64 (48.9) 113 (54.6) 101 (48.1)
Bone 104 (39.8) 48 (36.6) 57 (27.5) 56 (26.7)
Pleura 46 (17.0) 18 (13.7) 40 (19.3) 24 (11.4)
Head and neck NR NR 33 (15.9) 34 (16.2)
Liver 43 (16.5) 28 (21.4) 28 (13.5) 30 (14.3)
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As previously highlighted, patients in SELECT could have been previously treated with a VEGFR-targeted
therapy (including sorafenib) prior to trial entry whereas patients in DECISION could not. Approximately
one-quarter (23.7%) of patients in SELECT had received prior treatment with a VEGFR-targeted therapy.
In the lenvatinib arm, of 66 patients previously treated with a VEGFR-targeted therapy, 51 patients
(77.2%) were treated with sorafenib. In the placebo arm, of 27 patients previously treated with a VEGFR-
targeted therapy, 21 patients (77.8%) were treated with sorafenib. Other VEGFR-targeted therapies used
prior to trial entry in SELECT included sunitinib (Sutent®, Pfizer) and pazopanib. The median duration of
any prior therapy was ≈11 months in both arms.
A higher proportion of enrolled patients were from North America in SELECT than in DECISION (29.6% vs.
17.3%, respectively) and a lower proportion of patients were from Europe in SELECT than in DECISION
(49.7% vs. 59.7%, respectively). A greater proportion of patients were white in SELECT (79.3%) than in
DECISION (60.2%). A higher proportion of patients had bone metastases in SELECT than in DECISION
(38.8% vs. 27.1%, respectively).
Comparison of assessments of risk of bias
A summary of the risk-of-bias assessments for both trials is reproduced in Appendix 3, Table 48. Overall,
the AG considered the risk of bias to be low in both trials.
Consideration of proportional hazards assumption
Cox proportional hazards (PHs) modelling was used to generate PFS, unadjusted OS and adjusted OS
hazard ratios (HRs) from data collected during SELECT and DECISION. The validity of this method relies
on the event hazards associated with the intervention and comparator data being proportional over
time within each trial. The AG assessed the validity of the PH assumption for all analyses, when possible,
provided in the submissions from Eisai Ltd8 and Bayer HealthCare7 that included a HR result (see Appendix 6
for methods and results). The AG concluded that the PH assumption was not valid for PFS, unadjusted
OS or RPSFTM-adjusted OS in SELECT or for PFS or RPSFTM-adjusted OS in DECISION. This means that
the majority of the survival HRs generated using data from SELECT and DECISION and, consequently,
statements about the statistical significance of results should be interpreted with caution.
Overall survival
A summary of the unadjusted and adjusted OS findings from the most recent data cut-off points from both
trials is presented in Table 7. The findings for all data cut-off points are summarised in Appendix 3, Table 38.












Thyroid surgery, n (%) 261 (100) 131 (100) 207 (100) 208 (99.0)
Median cumulative radioiodine activity (mCi) 350 400 376
Target tumour size, n (%)
< 35 65 (24.9) 28 (21.4) 44 (21.3) 51 (24.3)
36–60 72 (27.6) 32 (24.4) 34 (16.4) 48 (22.9)
61–92 63 (24.1) 34 (26.0) 51 (24.6) 34 (16.2)
> 92 61 (23.4) 37 (28.2) 78 (37.7) 77 (36.7)
Prior VEGFR-targeted therapy, n (%) 66 (25.3) 27 (20.6) 0 0
mCi, millicurie; NR, not reported.
Note
Information drawn from Eisai Ltd,8 Schlumberger et al.,51 EMA,27 Brose et al.52 and Bayer HealthCare7 (appendix 7.5, table 12).
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In both trials, there was no statistically significant difference in unadjusted OS between trial arms.
However, when RPSFTM was used, patients in the lenvatinib arm had a statistically significant improvement
in OS when compared with patients in the placebo arm in SELECT. The difference in OS between sorafenib
and placebo was not reported to be statistically significant when using either the RPSFTM or IPE method
in DECISION.
Progression-free survival
In both trials, the primary outcome was PFS by blinded independent review. The findings for PFS reported in
SELECT and DECISION are summarised for the first data cut-off points (November 2013 and August 2012,
respectively) in Table 8 because this was the only data cut-off point for which PFS results had been
published for both trials.
In SELECT, there was a median improvement in PFS (blinded independent review) of 14.7 months with
lenvatinib when compared with placebo. In DECISION, there was a 5-month median improvement in PFS
(blinded independent review) with sorafenib when compared with placebo. The differences in median PFS
assessed by investigators were marginally decreased in SELECT (12.9 months) and marginally increased in
DECISION (5.4 months). However, the HRs in both trials were similar to those from the assessments by
blinded independent review.
The SELECT trial is the only trial that also reports PFS for another data cut-off point.85,86 This was available
for investigator-assessed PFS at the third data cut-off point (August 2015). Compared with the first data
cut-off point, median PFS was reported to be slightly higher in the lenvatinib arm at the third data cut-off
point (19.4 months), but the median PFS remained the same in the placebo arm (3.7 months), a difference
of 15.7 months. However, for both data cut-off points, the HR between arms was identical (0.24) and
reported to be statistically significant (p < 0.001).
The findings for all data cut-off points are summarised in Appendix 3, Table 41.












Data cut-off pointa Third data cut-off point (August 2015) Third data cut-off point (July 2015)
Deaths, n (%) 121 (46.4) 70 (53.4) 103 (49.8) 109 (51.9)
OS (months), median (95% CI) 41.6 (31.2 to NE) 34.5 (21.7 to NE) 39.4 (32.7 to 51.4) 42.8 (34.7 to 52.6)
Unadjusted HR (95% CI); p-value 0.84 (0.62 to 1.13); nominal p= 0.2475 0.92 (0.71 to 1.21); one-sided p= 0.28
RPSFTM-adjusted HR (95% CI);
p-value, cox method
NR 0.77 (0.58 to 1.02); NR
RPSFTM-adjusted HR (95% CI);
p-value, bootstrapping method
0.54; nominal p = 0.0025 (0.36 to 0.80) 0.77 (0.42 to 1.79); NR
IPE-adjusted HR (95% CI);
p-value, cox method
N/A 0.80 (0.61 to 1.05); NR
IPE-adjusted HR (95% CI);
p-value, bootstrapping method
N/A 0.80 (0.48 to 1.71); NR
CI, confidence interval; N/A, not applicable; NE, not estimable; NR, not reported.
a See Chapter 5, Survival modelling, for details of the data cut-off points used in the AG’s economic model.
Note
Information drawn from Eisai Ltd8 (from tables 6 and 8 of the submission) and Bayer HealthCare7 (from pages 28 to 29 of
the submission).
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Objective tumour response
The findings for objective tumour response are reported in Appendix 3, Table 42. In both trials, the tumour
response assessment was conducted by blinded independent review at the first data cut-off point and
favoured patients in the intervention arms compared with patients in the placebo arms. It is noticeable that
the difference in ORR between the intervention and placebo arms was much greater for patients treated
with lenvatinib in SELECT (63.2%) than for those treated with sorafenib in DECISION (11.7%). This is
attributable to the much higher proportion of patients who were treated with lenvatinib and had a partial
response in SELECT than the proportion of patients treated with sorafenib in DECISION. Complete responses
were only reported for patients treated with lenvatinib, albeit there were very few patients (1.5%). ORR was
statistically significantly improved in both trials for patients treated with either lenvatinib or sorafenib when
compared with placebo.
The objective tumour response evaluations for SELECT were conducted using an ITT analysis. In DECISION,
patients for whom it was not possible to evaluate a tumour response were excluded from the analysis
(as per the requirements of a per-protocol analysis). If all patients are included in the evaluations using
ORR data from DECISION, the ORR is marginally decreased in both arms: 11.6% for sorafenib and 0.5%
for placebo.
Time to response was reported only for SELECT. The median time to response was 2.0 months for patients
treated with lenvatinib compared with 5.6 months for patients in the placebo arm. The median duration
of response was not estimable for patients in SELECT; however, for those treated with lenvatinib, the
restricted mean was 17.34 months. Time to response was not reported in DECISION, but the median
duration of response was 10.2 months for patients treated with sorafenib.












First data cut-off point
(November 2013)
First data cut-off point
(August 2012)
PFS by blinded independent review
Events, n (%) 93 (35.6) 109 (83.2) 113 (54.6) 137 (65.2)
Died before progression, n (%) 14 (5.4) 4 (3.1) NR NR
PFS (months), median (95% CI) 18.3 (15.1 to NE) 3.6 (2.2 to 3.7) 10.8 (NR) 5.8 (NR)
Stratified HR (95% CI);a p-value 0.21 (0.14 to 0.31); < 0.001 0.59 (0.45 to 0.76); < 0.0001
Investigator-assessed PFS
Events, n (%) 91 (34.9) 104 (79.4) 140 (67.6) 184 (87.6)
Died before progression, n (%) 16 (6.1) 6 (4.6) NR NR
PFS (months), median (95% CI) 16.6 (4.8 to NE) 3.7 (3.5 to NE) 10.8 (NR) 5.4 (NR)
Stratified HR (95% CI);a p-value 0.24 (0.16 to 0.35); < 0.001 0.49 (0.39 to 0.61); < 0.0001
CI, confidence interval; NE, not estimable; NR, not reported.
a Stratification factors for SELECT were age (≤ 65 years or > 65 years), geographical region (Europe, North America or
other) and receipt or non-receipt of prior VEGFR-targeted therapy (0 or 1). Stratification factors in DECISION were age
(< 60 years or ≥ 60 years) and geographical region (North America, Europe or Asia).
Note
Information drawn from Schlumberger et al.51 and Brose et al.,52 with additional data from Eisai Ltd8 and Bayer HealthCare.7
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Both trials also assessed disease control rates (complete response+ partial response+ stable disease), and
SELECT reported clinical benefit rate (complete response+ partial response+ durable stable disease). In each
trial, the findings were statistically significantly in favour of lenvatinib or sorafenib compared with placebo.
However, comparisons between trials cannot be easily made as the definition of disease control rate differed
across trials because of differences in the length of stable disease required for control. SELECT required a stable
disease of ≥ 7 weeks whereas DECISION required a length of ≥ 4 weeks; however, both trials did report the
proportion of patients with stable disease of ≥ 6 months. This was similar in the placebo arms of both trials
(SELECT, 29.8%; DECISION, 33.2%), whereas in the intervention arms, it was 15.3% for patients treated with
lenvatinib and 41.8% for patients treated with sorafenib. Therefore, a clinical benefit at 6 months was
reported by 79.5% of patients treated with lenvatinib compared with 31.3% of patients who received the
placebo in SELECT, and 54.0% patients treated with sorafenib compared with 33.7% who received the
placebo in DECISION. In the submission from Bayer HealthCare,7 it is noted that most sorafenib-treated
patients (77%) experienced target lesion tumour shrinkage (compared with 28% of patients in the
placebo arm).
Safety findings
Safety data from SELECT and DECISION were reported for the first data cut-off point (November 2013 and
August 2012, respectively). For the individual types of AEs experienced by patients, the published paper
for SELECT presented data for treatment-related AEs whereas the published paper for DECISION presented
data for any treatment-emergent AEs. Therefore, data for specific types of treatment-emergent AEs were
extracted from the pharmaceutical company submission (Eisai Ltd8) for SELECT.
All-grade and grade ≥ 3 adverse events
Nearly all of the patients who received lenvatinib or sorafenib reported an AE, and ≈90% of patients who
received placebo reported an AE. AEs that were reported by ≥ 30% of patients and grade ≥ 3 AEs that
were reported by ≥ 1.5% of patients in any of the arms are summarised in Appendix 3, Tables 44 and 45.
All types of AEs were more common in patients treated with lenvatinib or sorafenib than in patients in the
placebo arms of both trials. Hand–foot syndrome was reported by approximately three-quarters of patients
in DECISION. Approximately two-thirds of patients reported all-grade hypertension or diarrhoea when
treated with lenvatinib in SELECT, similar to the proportion treated with sorafenib reporting all-grade
diarrhoea or alopecia in DECISION. Weight loss was reported by approximately half of all patients treated
with either lenvatinib or sorafenib. By far the most common grade ≥ 3 AEs for patients treated with
lenvatinib and sorafenib were hypertension (> 40%) and hand–foot syndrome (> 20%), respectively.
Serious adverse events (including fatal adverse events)
Serious adverse events (SAEs) reported in SELECT and DECISION are summarised in Appendix 3, Table 45.
In SELECT, approximately half of the patients in the lenvatinib arm reported a SAE. Just over one-third of
patients reported a SAE in the sorafenib arm of DECISION. Approximately one-quarter of patients in the
placebo arms of both trials reported a SAE. The only SAE reported by ≥ 2% of patients in both trials was
dyspnoea, which was at least as common for patients who received placebo as for those who received
lenvatinib or sorafenib. The most common SAEs (reported by ≥ 3% of patients) reported for patients
treated with lenvatinib in SELECT were pneumonia and hypertension. The most common SAEs (reported by
≥ 3% of patients) reported by patients treated with sorafenib in DECISION were secondary malignancy and
pleural effusion.
Deaths from AEs were reported for 7.7% of patients treated with lenvatinib and 4.6% of patients in the
placebo arm in SELECT. Fatal AEs in DECISION were reported for 5.8% of patients treated with sorafenib
and 2.9% of patients in the placebo arm.
Treatment-related adverse events
A summary of treatment-related AEs is presented in Appendix 3, Table 46. A very high proportion of all-grade
AEs (≥ 96%) were considered to be related to treatment with lenvatinib or sorafenib. The proportion of
all-grade AEs considered to be treatment related was high (> 50%) in the placebo arms of both trials.
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In SELECT, the causes of death considered to be treatment related in the lenvatinib arm were one case
each of pulmonary embolism, haemorrhagic stroke and general deterioration of physical health; three
cases were reported as deaths or sudden deaths (not otherwise specified). DECISION was the only trial in
which a patient in the placebo arm was considered to have died because of a treatment-related AE. The
cause of death for this patient was subdural haematoma. The cause of death for a patient in the sorafenib
arm that was considered to be treatment related was myocardial infarction.
Timing of adverse events
In both trials, there have been subsequent analyses of the timing of AE occurrences in the treatment cycle
reported. For SELECT, Haddad et al.91 reported the incidence and timing of five AEs: proteinuria, diarrhoea,
fatigue/asthenia/malaise, rash and hand–foot syndrome. Hypertension was a notable AE omitted from
the analysis. For DECISION, detailed analysis of the AE occurrence patterns in patients is published in a
peer-reviewed paper by Worden et al.139 Findings from the two trials cannot be easily compared because
Haddad et al.91 reported their findings as median time to first onset and median time to last resolution,
whereas Worden et al.139 reported the proportion of AEs occurring during each cycle. The AEs reported
included hand–foot syndrome, rash/desquamation, diarrhoea, fatigue, hypertension, weight loss, increased
TSH levels and hypocalcaemia. Increased TSH levels were described as a ‘study-specific’ AE, with a
maximum severity of grade 1; this AE was reported by 69 patients (33.3%) treated with sorafenib.139
In SELECT, Haddad et al.91 found that generally AEs for patients treated with lenvatinib occurred early in
the treatment process and were resolved. Median time to onset for patients treated with lenvatinib ranged
from 3.0 weeks with fatigue/asthenia/malaise to 12.1 weeks with diarrhoea. With regard to resolution,
this ranged from a median of 5.9 weeks with rash to a median of 20.0 weeks with hand–foot syndrome.
In DECISION, Worden et al.139 found that in patients treated with sorafenib, the incidence of AEs was
usually highest in the first cycle or the first two cycles. Severity tended to diminish with each cycle (over
the first nine cycles). The prevalence of AEs (defined as the number of patients with a new or continuing
AE during a treatment cycle) tended to remain stable. Diarrhoea and TSH were notable exceptions in that
prevalence steadily increased over the first five or six cycles, at which point the prevalence peaked. Only
weight loss, which was primarily grade 1 or grade 2 and highest in the first four cycles, tended to increase
in severity over time (from grade 1 to grade 2: a greater proportion of patients experienced grade 2
toxicity in cycle 9 compared with cycles 1 and 2). The authors noted that in general, AEs with sorafenib
were manageable over time following dose modification and/or concomitant medications, such as
antidiarrhoeals, antihypertensives or dermatological preparations.
Dose modifications
Dose modifications as a result of AEs were more common for patients treated with lenvatinib and sorafenib
than for those who received placebo (Table 9). It is of note that the incidence of dose interruptions with
lenvatinib in SELECT was higher than with sorafenib in DECISION. The incidence of dose interruptions and
dose reductions were lower in the placebo arm of SELECT than in the placebo arm of DECISION.












Dose interruptions because of an AE 215 (82.4) 24 (18.3) 137 (66.2) 54 (25.8)
Dose reductions because of an AE 177 (67.8) 6 (4.6) 133 (64.3) 19 (9.1)
Discontinued treatment because of an AE 43 (16.5) 6 (4.6) 39 (18.8) 8 (3.8)
Note
Information drawn from Schlumberger et al.51 and Brose et al.52
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It is reported that, in SELECT, the most common AEs developing during treatment that led to a dose
interruption or reduction among patients receiving lenvatinib were diarrhoea (22.6%), hypertension (19.9%),
proteinuria (18.8%) and decreased appetite (18.0%). It is also noted that four patients in the lenvatinib
arm (1.5%) required dose adjustments owing to hypocalcaemia. In the submission from Eisai Ltd,8 it is
further noted that 1.1% of patients discontinued treatment because of hypertension and 1.1% of patients
discontinued because of asthenia. In DECISION, it is reported that hand–foot syndrome was the most
common reason for sorafenib dose interruptions (26.6%), reductions (33.8%) and withdrawals (5.3%).
Health-related quality-of-life findings
It was reported in the European Public Assessment Report (EPAR)27 that, although HRQoL data were not
collected in the randomised part of SELECT,51 HRQoL would be assessed in 30 patients who participated
in the open-label extension phase of the trial. The AG is unaware of whether or not these findings have
been published.
For DECISION, HRQoL was reported in a conference abstract by Schlumberger et al.120 More detailed
HRQoL results were also reported in the submission from Bayer HealthCare.7 Cancer-specific HRQoL was
measured using the Functional Assessment of Cancer Therapy – General (FACT-G) questionnaire144 and
general health status was measured using the generic EuroQol-5 Dimensions, three-level version (EQ-5D-3L)
and the EuroQol-5 Dimensions (EQ-5D) visual analogue scale (VAS).145 The FACT-G questionnaire is a
validated 27-item questionnaire designed to assess the following dimensions in cancer patients: physical
well-being, social/family well-being, emotional well-being and functional well-being. The FACT-G total score
ranges from 0 to 108 points, with higher scores representing a better HRQoL. Similarly, the EQ-5D is a
validated instrument in which higher scores represent better health status.
All questionnaires were self-administered at baseline and day 1 of every 28-day cycle. The overall
questionnaire completion rate during the trial was reported by the authors to be 96%.120 However, the
actual number of patients completing the questionnaires reduces with each cycle because only patients with
progression-free disease were asked to complete the questionnaires. Thus, for example, as shown in the
submission from Bayer HealthCare7 by the response to one of the physical well-being questions, by cycle 13
the number of patients who responded was 87: 40.1% of all patients enrolled into the trial.
Functional Assessment of Cancer Therapy – General
Minimally important differences in the FACT-G total score (i.e. a difference considered to be clinically
meaningful) have been reported to range between 3 and 7 points.144 At baseline, it was reported7,120 that
FACT-G scores were comparable to a normative adult cancer population, the mean scores being 81 points
[standard deviation (SD) 15 points] in the sorafenib arm and 82 points (SD 14 points) in the placebo arm.
However, at the first assessment (cycle 2, day 1), the score for the sorafenib arm had fallen to 76 points
(SD 15 points), whereas the score in the placebo arm remained very similar to baseline. The authors of the
conference abstract120 reported that the scores in the sorafenib arm thereafter remained similar to the
scores at the first assessment, whereas the scores remained similar to the baseline scores in the placebo
arm. A mixed linear model estimated that, compared with placebo, the FACT-G score was 3.45 points
lower in the sorafenib arm (p = 0.0006), representing a clinically meaningful difference between arms
in favour of the placebo arm. The authors attributed the diminished HRQoL score to AEs. Indeed, the
submission from Bayer HealthCare7 noted that in response to the FACT-G physical well-being domain
question ‘I am bothered by side effects’, the proportion of patients in the sorafenib arm who replied ‘quite a
bit’ or ‘very much’ increased from 1.5% at cycle 1 to 29.6% at cycle 2. However, this proportion gradually
diminished over time: it was 16.8% by cycle 6 and 8.0% by cycle 13.
EuroQol-5 Dimensions index and visual analogue scale
For UK utility scores, a change of 0.10 points on the EQ-5D index has been reported by Pickard et al.146 to
be clinically meaningful for all cancers (using ECOG PS as the anchor). Similarly, the same study reported a
change of at ≥ 7 points on the VAS to be clinically meaningful.146 It was reported in DECISION7,120 that the
patterns for EQ-5D index and VAS were similar to that of the FACT-G; after the first assessment, the scores
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in the sorafenib arm were lower than the scores in the placebo arm. Although the between-arm differences
were statistically significant (p < 0.0001 for both EQ-5D index and VAS), the treatment effects (–0.07 and
–6.75, respectively) were of a small magnitude and did not reach the threshold for a clinically meaningful
difference. It is reported in the submission from Bayer HealthCare7 that dimensions in the EQ-5D index that
are sensitive to AEs include mobility, usual activities and pain/discomfort.
Subgroup analyses from randomised controlled trials
Only subgroup analyses considered by the AG to be of direct relevance to the decision problem have been
reported in the remainder of this report. The AG considered the following subgroup analyses to be
relevant (with rationale given):
l patients previously treated and not previously treated with TKIs (prespecified subgroup in the NICE
scope53 and AG decision problem)
l patients with and without symptomatic disease at baseline (as highlighted in Chapter 1, Treatment
options for patients with radioactive iodine-refractory differentiated thyroid cancer, systemic treatment
is recommended for patients who have symptomatic disease)
l analyses of subgroups that were prespecified in the trials and in which there appeared to be
differences in baseline characteristics within or across trials (as differences in baseline characteristics
may influence results).
As previously highlighted, the AG concluded that the assumption of PH does not hold in any of the
analyses that it was able to check other than unadjusted OS in DECISION. This means that the majority of
the survival HRs generated using data from SELECT and DECISION and, consequently, statements about
the statistical significance of results should be interpreted with caution.
Patients previously treated and patients not previously treated with tyrosine
kinase inhibitors
Subgroup analyses have been reported for patients previously treated with a TKI (e.g. VEGFR-targeted
therapy) in SELECT but only for PFS and ORR.51,105,106 No patients in DECISION had received prior treatment
with a TKI.
Results from subgroup analyses using data from SELECT51,105,106 showed that PFS was statistically significantly
longer for patients treated with lenvatinib compared with placebo for patients previously treated with VEGFR-
targeted therapy (including sorafenib) (Table 10). For patients who were VEGFR-targeted therapy naive,
PFS was also statistically significantly longer for patients treated with lenvatinib compared with placebo.
TABLE 10 Progression-free survival findings in patients previously treated and not previously treated with
VEGFR-targeted therapy in SELECT: first data cut-off point (November 2013)
Outcome
Treatment with VEGFR-targeted therapy
Prior treatment No prior treatment
Lenvatinib (N= 66) Placebo (N= 27) Lenvatinib (N= 195) Placebo (N= 104)
Events, n (%) 31 (47.0) 25 (92.6) 76 (39.0) 88 (84.6)
Median PFS (months) 15.1 3.6 18.7 3.6
HR (95% CI) 0.22 (0.12 to 0.41) 0.20 (0.14 to 0.27)
CI, confidence interval.
Note
Information drawn from Schlumberger et al.51 (from figure S1 in the supplementary appendix).
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Compared with patients in the placebo arm, ORR was statistically significantly improved for patients
treated with lenvatinib whether or not they had been previously treated with a VEGFR-targeted therapy
(see Appendix 3, Table 47).51,105,106 In both subgroups, ORRs were similar to the ORRs observed in the
overall trial population (lenvatinib 64.8% and placebo 1.5%).
Newbold et al.105,106 reported that any all-grade and grade ≥ 3 AEs were similar in the two subgroups of
patients receiving lenvatinib (prior VEGFR-targeted therapy 100.0% and 87.9%, respectively; no prior
VEGFR-targeted therapy 99.5% and 86.7%, respectively). However, SAEs were more common in the
lenvatinib arm among patients who had received prior VEGFR-targeted therapy (60.6%) than among those
who had not (50.8%). For patients in the placebo arm, the opposite was the case, with SAEs being less
common among patients who had received prior VEGFR-targeted therapy (18.5%) than among those who
had not (25.0%).
Patients who had not received prior VEGFR-targeted therapy were treated with more cycles of lenvatinib
(median 16 cycles) than those who had received prior VEGFR-targeted therapy (median 12.5 cycles). The
proportion of patients who had at least one lenvatinib dose reduction was also similar between subgroups
(prior VEGFR-targeted therapy 81.8% and no VEGFR-targeted therapy 86.7%). Patients with no prior
VEGFR-targeted therapy had an earlier median time to first dose reduction (8.9 weeks) than patients with
prior VEGFR-targeted therapy (14.8 weeks). Patients with no prior VEGFR-targeted therapy also had a
lower median daily dose of lenvatinib than those with prior VEGFR-targeted therapy (16.1 vs. 20.1 mg,
respectively).
Patients with and without symptomatic disease at baseline
Subgroup analyses were not conducted for patients with symptomatic or asymptomatic disease at baseline
in SELECT. In DECISION, the median PFS for patients who were retrospectively categorised as being
symptomatic at baseline was longer for patients who were asymptomatic than those who were symptomatic
in the placebo arm but was similar in the intervention arm (Table 11). Patients were classified as being
symptomatic if they had symptoms/findings that were consistent with RR-DTC reported in the medical
history or pre-treatment AE data set at trial entry.113,119 It is noted in the EPAR26 for sorafenib that ≈20% of
patients had symptoms that were likely to be related to thyroid cancer at baseline.
Bayer HealthCare7 has stated that although tumour shrinkage was not always sufficient to be confirmed as
an objective response for some patients, it was often sufficient to alleviate symptoms. Further evidence has
not been presented to support this statement.
Safety analyses for patients with symptomatic or asymptomatic disease at baseline have not been reported
in SELECT or DECISION.
TABLE 11 Progression-free survival findings in symptomatic and asymptomatic patients in DECISION: first data
cut-off point (August 2012)
Outcome
Symptom status
Symptomatic (≈20%) Asymptomatic (≈80%)
Sorafenib Placebo Sorafenib Placebo
Events, n (%) NR NR NR NR
Median PFS (months)a 10.7 3.6 10.8 7.2
HR (95% CI) 0.386 (0.207 to 0.720) 0.602 (0.448 to 0.807)
CI, confidence interval; NR, not reported.
a Reported in source documents in days; converted to months by dividing by 365.25 and multiplying by 12.
Note
Information drawn from Bayer HealthCare7 (from appendix 7.3) and the EPAR for sorafenib.26
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Other subgroup analyses of interest
Some OS subgroup analyses in SELECT have been reported in conference abstracts.67,73,82,89 No OS subgroup
analyses have been reported using data from DECISION. For OS (first data cut-off point in November 2013)
in SELECT, it has been reported that:
l There was no statistically significant difference in OS between older and younger lenvatinib-treated
patients [HR 0.78, 95% confidence interval (CI) 0.49 to 1.26; p = 0.304] but there was a statistically
significant difference in the placebo arm, favouring younger patients (HR 0.48, 95% CI 0.27 to 0.85;
p = 0.010).67,73
l Median OS was not reached in either arm in patients treated in North America.89
l A statistically significant OS advantage was observed in patients with FTC treated with lenvatinib
compared with placebo (HR 0.41, 95% CI 0.18 to 0.97).82
In addition to the subgroup analyses, Haddad et al.91 found from a post hoc exploratory multivariate
analysis of SELECT (first data cut-off point) that ECOG PS and histology (favouring FTC vs. PTC) were
statistically significantly associated with OS.
For PFS, all prespecified and some post hoc subgroup analyses (first data cut-off points) have also been
reported in the appendix to the primary published paper for SELECT51 and in the published paper for
DECISION.52 The results for both trials showed that for all subgroups, PFS favoured lenvatinib or sorafenib
versus placebo. In the majority of instances, the differences were statistically significant. Regarding PFS for
prespecified subgroup analyses, the following results are noted:
l The effect was statistically significantly in favour of lenvatinib (compared with placebo) for patients
aged ≤ 65 or > 65 years in SELECT; the effect was statistically significantly in favour of sorafenib
(compared with placebo) for patients aged < 60 or ≥ 60 years in DECISION.
l The effect was statistically significantly in favour of lenvatinib (compared with placebo) and for sorafenib
(compared with placebo) for males and females in SELECT and DECISION.
l The effect was statistically significantly in favour of lenvatinib (compared with placebo) for patients with
PTC, poorly differentiated carcinoma, FTC or Hürthle cell carcinoma in SELECT; the effect was statistically
significantly in favour of sorafenib (compared with placebo) for patients with PTC or Hürthle cell
carcinoma but not for those with FTC or poorly differentiated carcinoma in DECISION.
l The effect was statistically significantly in favour of lenvatinib (compared with placebo) for patients
classified as white or Asian in SELECT; no subgroup analyses have been presented for race in DECISION.
l The effect was statistically significantly in favour of lenvatinib (compared with placebo) for patients
treated in Europe and North America or other regions in SELECT; the effect was statistically significantly
in favour of sorafenib (compared with placebo) for patients treated in Europe or Asia but not for
patients treated in North America in DECISION.
l The effect was statistically significantly in favour of lenvatinib (compared with placebo) for those with
and without lung metastases in SELECT and the effect was statistically significantly in favour of
sorafenib (compared with placebo) for those with lung metastases only and for those without lung
metastases only in DECISION.
l The effect was statistically significantly in favour of lenvatinib (compared with placebo) and for sorafenib
(compared with placebo) for patients with and without bone metastases in SELECT and DECISION.
It is recommended by the EMA26 that before initiating treatment, physicians should carefully evaluate the
prognosis in the individual patient, considering the maximum lesion size, symptoms related to the disease
and the progression rate.
As reported in the appendices to the submission from Bayer HealthCare,7 a post hoc analysis of investigator-
assessed PFS by number of target lesions in DECISION found statistically significant improvements with
sorafenib compared with placebo for patients with at least three lesions. For patients with fewer than three
lesions, PFS was numerically improved with sorafenib compared with placebo. It is also reported that another
DOI: 10.3310/hta24020 HEALTH TECHNOLOGY ASSESSMENT 2020 VOL. 24 NO. 2
© Queen’s Printer and Controller of HMSO 2020. This work was produced by Fleeman et al. under the terms of a commissioning contract issued by the Secretary of State for
Health and Social Care. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional
journals provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should
be addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
27
post hoc subgroup analysis of investigator-assessed PFS showed a treatment effect in favour of sorafenib
compared with placebo for patients with maximum tumour size of ≥ 1.5 cm (HR 0.54, 95% CI 0.41 to 0.71).
A numerically lower effect was reported for patients with a maximum tumour size of < 1.5 cm (HR 0.87,
95% CI 0.40 to 1.89).
Aside from the caveat surrounding the use of HRs to determine statistical significance as a result of PH
assumption being violated, it is important to note that subgroup analyses are not powered to detect
statistical significance. Therefore, when no statistically significant differences are reported, it could be that
the numbers of patients in the subgroups were not large enough to detect a difference.
Extended open-label phases of SELECT and DECISION
In the extended open-label phase of SELECT, the starting daily dose of lenvatinib was originally 24 mg.
This was later modified to 20 mg and then reverted to 24 mg. It is important to note that this phase of
the trial only included 115 patients who crossed over from the placebo arm to lenvatinib and therefore
does not present evidence from a randomised or controlled patient population. Furthermore, only
placebo-treated patients who had confirmed disease progression (independent blinded review) during
the randomisation phase and who met protocol-specified eligibility criteria were treated with lenvatinib.
Consequently, it is noted in the EPAR27 for lenvatinib that these patients had very advanced disease, because
they had experienced two sequential, confirmed disease progressions: the first before randomisation at the
time of study entry and the second during treatment with the study drug in the randomisation phase.
The extended open-label phase of DECISION differed to that of SELECT in that as well as including patients
who crossed over from the placebo arm to receive sorafenib, it also included patients who remained on
sorafenib. In total, 150 patients in the placebo arm crossed over to receive sorafenib at progression and
of these, data from 137 patients were evaluable for efficacy. In addition, 55 patients randomised to the
sorafenib arm continued on sorafenib treatment in the open-label extension phase, of which 46 patients
were evaluable for efficacy. It is reported by Schlumberger et al.122 and Paschke et al.114 that patients
evaluable for efficacy had poorer risk features at enrolment compared with patients who were not
evaluable. Like the extended open-label phase of SELECT, evidence from this patient population does
not comprise evidence from a randomised or controlled patient population.
Findings from the extended open-label phase of SELECT for only ‘. . . the more mature dataset of patients
who started treatment at the 24mg lenvatinib dose’ were reported in a conference abstract118 describing the
first data cut-off point (November 2013). Findings reported at the second data cut-off point (June 2014)
were presented for patients who started treatment at the 20-mg dose of lenvatinib and for patients who
started the 24-mg dose of lenvatinib in the EPAR for lenvatinib.27 In the EPAR,27 it is reported that patient
characteristics, previous treatments, geographical allocation, on-study placebo exposure, lenvatinib exposure
in the extended open-label phase and median follow-up times vary considerably for these two dose
regimens. Thus, patients receiving the different dose regimens are considered by the EMA to represent
different populations of patients.
In addition to conference abstracts,114,122 the findings from the extended open-label phase of DECISION
have been reported in the EPAR46 for sorafenib. Safety data for the extended open-label phase of DECISION
are reported in the submission from Bayer HealthCare.7
The efficacy and safety findings from the open-label phases of both trials are summarised in Appendix 7,
Tables 56 and 57. OS data have not been reported. With the exception of median PFS for patients
receiving sorafenib for a second time, which was 6.7 months, the efficacy findings for PFS from the
extended phase of SELECT and DECISION were similar to the findings reported in the randomised phase of
FINDINGS FROM THE SYSTEMATIC REVIEW OF CLINICAL EFFECTIVENESS LITERATURE
NIHR Journals Library www.journalslibrary.nihr.ac.uk
28
the trials. The incidence of AEs for patients treated with lenvatinib and sorafenib in the open-label phases
of the two trials tended to be slightly lower than reported during the double-blind phase.
In addition, Kappeler et al.94 and Fassnacht et al.83 have reported exploratory analyses of tumour growth
rate in the randomised double-blind and extended open-label phases of DECISION. The authors found
that the tumour growth rate (mean changes per month of sum of target lesion diameters) from baseline
to nadir was –3.9% then +2.6% from nadir to progression for patients treated with sorafenib in the
randomised phase; for those continuing with additional sorafenib in the open-label phase, from second
baseline to progression the tumour growth rate was +1.7%. For patients randomised to the placebo arm,
the tumour growth rate was +5.0% for all placebo patients and it was +6.1% for placebo patients
subsequent to crossing over to receive sorafenib. Patients in the placebo arm who crossed over to
sorafenib in the open-label phase then experienced a tumour growth rate pattern similar to that of
patients who started on sorafenib in the randomised phase: –4.4% from second baseline to nadir and
then +1.8% from nadir to progression.
Associations between tumour response, progression-free survival,
overall survival, safety and health-related quality of life
Gianoukakis et al.86 examined the association between ORR and PFS for patients treated with lenvatinib
in SELECT. The analysis is based on the third data cut-off point (August 2015) using investigator-assessed
ORR [60.2% (the proportion of patients who achieved an objective tumour response)] and investigator-
assessed mean PFS (19.4 months). The authors found that the median PFS in patients who received
lenvatinib and who demonstrated a tumour response was 33.1 months (95% CI 27.8 months to not
estimable). In lenvatinib-treated patients who did not show tumour response, the median PFS was 7.9 months
(95% CI 5.8 to 10.7 months). Robinson et al.117 reported that an exploratory multivariate analysis found that
percentage change in tumour size at the first assessment was a marginally statistically significant positive
predictor for PFS (p = 0.06).
Using data from the first data cut-off point of SELECT, Newbold et al.108 analysed PFS by patients who
had responded to treatment with lenvatinib at the first tumour assessment (median time to response
1.9 months) and by those who responded later (median time to response 3.8 months). The authors found
that there was no difference in PFS between patients who achieved objective response at the time of first
tumour assessment compared with thereafter.
Haddad et al.91 found from a multivariate analysis (first data cut-off point) that in SELECT, all-grade diarrhoea
was statistically significantly associated with OS (median OS for lenvatinib-treated patients with diarrhoea was
not reached and median OS for lenvatinib-treated patients without diarrhoea was 17.1 months). Choi et al.79
reported that the results of a post hoc analysis showed that lenvatinib-treated patients with hypertension
had higher median PFS than those without hypertension (18.8 vs. 12.9 months; p = 0.009). Haddad et al.91
also reported results from multivariate analyses of associations between five other AEs (proteinuria, diarrhoea,
fatigue/asthenia/malaise, rash and hand–foot syndrome) and PFS in SELECT. No statistically significant
associations between any of the AEs and PFS were found.
Using data from DECISION, Kappeler et al.95 carried out an exploratory analysis to explore the association
between tumour growth rate and PFS and OS. It is reported that the data cut-off points used for PFS and OS
were the first data cut-off point (August 2012) and third data cut-off point (July 2015), respectively. Values
of early tumour growth rate were split into quartiles [by median times derived from Kaplan–Meier (K–M)
curves and from modelling with a Weibull distribution] separately by treatment arm. Better prognosis for PFS
and OS with sorafenib was associated with the second and third tumour growth rate quartiles.
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No other analyses have been conducted for patients treated with either lenvatinib or sorafenib in SELECT
or DECISION examining the relationships between any of the efficacy or safety outcomes and HRQoL.
As reported earlier (see Health-related quality-of-life findings), it has been speculated that AEs did affect
HRQoL based on data from FACT-G and EQ-5D questionnaires, but no formal analyses have been
conducted in an attempt to correlate the findings.
Indirect comparison feasibility assessment
In the absence of direct clinical evidence comparing treatment with lenvatinib versus sorafenib, the AG
considered whether or not it was appropriate to carry out an indirect comparison to obtain estimates of
the relative efficacy and safety of these two treatments.
The first step was to determine whether or not SELECT and DECISION shared a common comparator.
The comparator arm of both trials was placebo. From the limited information on the placebos reported by
Eisai Ltd,8 Bayer HealthCare7 and in the published papers,51,52 the AG considered that the comparator arms
were likely to be similar and that a network could be constructed (Figure 5).
The second step was to check the comparability of the participant and trial characteristics between the
two trials. As described in Trial characteristics and Participant characteristics, the AG has noted that there
are several trial design and participant differences, both within and between SELECT and DECISION. These
differences raised concerns about whether or not data from these trials should be included in the same
network of evidence.
The final step undertaken by the AG was to examine the PFS K–M data from the placebo arms of SELECT
and DECISION to determine the extent to which the risk profiles of the populations in these arms of the
two trials were comparable. The AG concluded that the risks were not sufficiently comparable and that
these two trials should, therefore, not be included in the same network of evidence.
The Assessment Group’s detailed commentary on progression-free survival
Kaplan–Meier data from the placebo arms
An indirect comparison implicitly assumes that the randomised patients are drawn from similar populations
with reference to their risk profile for the time-to-event outcomes (PFS and OS). Because PFS is the primary
outcome specified in both clinical trials, it is important that the equivalence of the placebo arms of the
two trials can be confirmed by comparison of PFS outcomes: any significant discrepancy in progression risk
would invalidate an indirect comparison between lenvatinib and sorafenib.
Figure 6 compares the K–M PFS trial results for the placebo arms of the two trials. After similar trends over
the first 2 months, the curves separate markedly for more than a year before crossing over in the long
term. Visual examination is sufficient to establish that these data are not amenable to either a simple HR




FIGURE 5 Indirect comparison network.
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Further exploration of these data trends through a plot of cumulative hazards in the two trial arms at
common time points reveals a clear divergence from a simple linear (PH) relationship (Figure 7). The trial
data indicate a higher initial risk of disease progression in SELECT in the first 10 months, followed by a
sharp reversal in which the risk in the SELECT placebo arm reduces by > 50%.
The AG considers that the placebo arms of SELECT and DECISION exhibit unexpectedly inconsistent
patterns of temporal change that are not compatible with the assumption that these are similar patient
groups. Consequently, patients enrolled in the two trials cannot be considered to be derived from a
common population and, therefore, conducting an indirect comparison to obtain estimates of relative


























FIGURE 6 Comparison of PFS in the placebo arms of DECISION and SELECT. Reproduced with permission from
Fleeman et al.54 This is an Open Access article distributed in accordance with the terms of the Creative Commons
Attribution (CC BY 4.0) license, which permits others to distribute, remix, adapt and build upon this work, for
commercial use, provided the original work is properly cited. See: http://creativecommons.org/licenses/by/4.0/.
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FIGURE 7 Comparison of PFS hazard trends in the placebo arms of DECISION and SELECT.
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Differences in trial and participant characteristics in the placebo arms of the trials
As reported earlier (see Trial characteristics and Participant characteristics), a number of differences in trial
and participant characteristics were observed between arms within trials and across trials. Given the
apparent differences in the placebo arms of the two trials, as demonstrated by differing hazard trends,
the AG highlights the following differences in characteristics between the two placebo arms:
l The SELECT trial permitted the enrolment of patients who had been previously treated with a VEGFR-
targeted therapy (including sorafenib), whereas DECISION did not: 20.6% had received prior therapy in
the placebo arm of SELECT compared with no patients in the placebo arm of DECISION.
l Palliative radiotherapy, which is commonly available as part of BSC in UK NHS clinical practice, was not
permitted for patients in the placebo arm of SELECT.
l The proportion of patients who crossed over from the placebo arm of SELECT was 87.8% at the third
data cut-off point, compared with 75.0% in DECISION.
l There were proportionately more males in the placebo arm of SELECT than in the placebo arm of
DECISION (57.3% and 45.2%, respectively).
l A higher proportion of patients in the placebo arm of SELECT were classified as being white than were
similarly classified in the placebo arm of DECISION (78.6% and 61.0%, respectively), whereas the
opposite was the case for patients classified as Asian (18.1% and 24.8%, respectively).
l Proportionately fewer patients in the placebo arm of SELECT were from Europe (48.9%) and
proportionately more were from North America (29.8%) compared with the patients in the placebo
arm of DECISION (59.5% and 17.1%, respectively).
l A greater proportion of patients in the placebo arm of SELECT had an ECOG PS of ≥ 1 (48.1%) than in
the placebo arm of DECISION (38.6%).
l A greater proportion of placebo patients had FTC and poorly differentiated thyroid cancer in the
placebo arm of SELECT (16.8% and 14.5%, respectively) than in the placebo arm of DECISION
(9.0% and 7.6%, respectively).
l The time from diagnosis to randomisation was greater in the placebo arm of SELECT (73.9 months)
than in the placebo arm of DECISION (66.9 months).
l A greater proportion of patients in the placebo arm of SELECT had lung, bone and liver metastases
(94.7%, 36.6% and 21.4%, respectively) than in DECISION (86.2%, 26.7% and 14.3%, respectively).
Proportional hazards assumption
As discussed in Consideration of proportional hazards assumption, the AG concluded that the PH
assumption was not valid for PFS, unadjusted OS or adjusted OS in SELECT or for PFS or adjusted OS in
DECISION. The violation of the PH assumption, for all but unadjusted OS in DECISION, means that the
network of evidence is compromised for all outcomes.
Assessment Group summary statement
The AG considers that is not appropriate to conduct an indirect comparison to obtain HRs for lenvatinib
versus sorafenib for the outcomes of PFS, unadjusted OS and adjusted OS. This is because the risk profiles
of the patients in the placebo arms of the trials are not comparable and any indirect comparison would
produce results that could not be considered to be robust. This also precluded indirect comparison for
subgroups of patients according to previous treatment with TKIs.
As described in Chapter 3, Methods of analysis/synthesis, in addition to trial characteristics, participant
characteristics and outcome data, the AG stated that it would consider the quality of the included trials
when conducting its feasibility assessment. The results of the AG’s risk-of-bias assessment are reported in
Comparison of assessments of risk of bias. However, given the issues already highlighted, the quality of the
trials was not a factor in the AG’s decision to not conduct an indirect comparison.
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Systematic review evidence
The AG included 13 systematic reviews5–8,33,57,61,93,97,104,127,138,141 in its review; these reviews included the evidence
submissions reporting systematic reviews and indirect comparisons for this MTA from Eisai Ltd8 and Bayer
HealthCare,7 and also the evidence reported in a paper by Tremblay et al.57 Although Tremblay et al.57 did not
report the conduct of a systematic review, this paper was included as it did report results from an indirect
comparison and a matching-adjusted indirect comparison (MAIC) using data from SELECT and DECISION.
A summary of the characteristics of the included systematic reviews is presented in Appendix 5, Table 49.
Most of the evidence was derived from observational studies of treatment with sorafenib. However, four
of the reviews,7,8,57,97 including the submissions from Eisai Ltd8 and Bayer HealthCare,7 included evidence
from SELECT and DECISION and results from indirect comparisons, including MAICs.
The AG’s assessment of the quality of the included reviews is presented in Appendix 5, Table 50. Overall,
the AG considered that the quality of nine5–8,61,97,104,127,138 of the identified systematic reviews was good.
However, only 45–8 of the 13 reviews included a quality assessment of the included primary studies.
Four33,57,93,141 of the reviews were considered to be of poorer quality than the rest. Of these, only one33
reported the use of an adequate search strategy. In addition, methods of cross-checking during either
the study selection process or the data extraction process were not reported by the authors of three
reviews.33,57,93 No quality assessment of the primary studies was reported in any of these four reviews.33,57,93,141
The conclusions reached by the authors of the systematic reviews are presented in Appendix 5, Table 51.
The earliest of the reviews was carried out by Anderson et al.61 and was published in 2013. The authors
concluded that certain treatments, notably TKIs, showed promise in Phase II trials. Gruber and Colevas33
concluded that the most likely outcome of treatment with a TKI was stable disease. McFarland and
Misiukiewicz104 concluded that sorafenib slowed the progression of disease in the majority of cases. For
treating thyroid cancer, Ye et al.141 reported that the clinical effects of sorafenib and lenvatinib outweigh
the toxicities [relative risk (RR) 1.27, 95% CI 1.05 to 1.53] and deaths (RR 15.24, 95% CI 6.99 to 33.21).
Ye et al.141 concluded that lenvatinib and sorafenib were more useful for thyroid cancer than for RR-DTC,
based on the results of the subgroup analyses that were conducted. However, the AG considers that all of
the studies that included patients with DTC also included patients with RR-DTC and so the validity of this
subgroup analysis and the conclusions reached based on these subgroup analyses are questionable.
Jean et al.93 found AEs reported for sorafenib for treating RR-DTC to be higher than for AEs reported for
treating renal cell carcinoma (RCC) or hepatocellular carcinoma (HCC). In two reviews127,138 ORR data and
AE data were pooled for sorafenib from seven observational studies59,78,88,101,126,147,148 (five prospective and
two retrospective). In the review by Shen et al.,127 all of the studies59,78,88,101,126,147,148 included patients
with RR-DTC, whereas the review by Thomas et al.138 included five prospective observational studies of
RR-DTC,59,88,101,126,147 a retrospective study of RR-DTC149 and a Phase II study150 of patients with medullary
thyroid cancer. Although the incidences of hand–foot syndrome (≥ 73%), diarrhoea (≥ 68%) and weight
loss (≥ 50%) included in both meta-analyses were broadly similar to the incidence of the same AEs in
DECISION, it was noticeable that the incidences of rash (≥ 66%) and fatigue (≥ 60%) were higher than
reported in DECISION. Similarly, the pooled ORR (20.9% to 22%) from the two reviews127,138 was higher
than the ORR reported in DECISION. The pooled median PFS (17.9 months) from the review by Thomas
et al.138 was also higher than median PFS reported in DECISION, but the pooled analysis for PFS also included
patients with medullary thyroid cancer. The key results from these three reviews93,127,138 are summarised in
Appendix 5, Table 52.
In addition, Shen et al.127 noted that rare but severe AEs were observed mainly due to intracranial
haemorrhage, cardiac arrest, angiooedema, small cell lung cancer, carcinoma of the tongue, and grade 5
event of sudden death. Because of the limited data, the authors did not pool these high-grade AEs. Thomas
et al.138 also reported that bleeding at any site occurred in 13.6% of patients, 3.8% of patients reported acute
myocardial infarctions and 2.2% experienced congestive heart failure. Severe hypocalcaemia (grade ≥ 3)
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occurred in 2.5% of patients and 8.7% of patients developed cutaneous squamous cell carcinoma. However,
it should be cautioned that in the meta-analyses conducted by Shen et al.127 and Thomas et al.,138 the authors
did not investigate the heterogeneity of the studies included in the meta-analyses.
For RR-DTC, all of the indirect comparison results (including results from MAICs7,57) showed that lenvatinib
was statistically significantly superior to sorafenib in terms of PFS but not OS.6–8,57,97 Kawalec et al.97 also
reported lenvatinib to result in statistically significantly fewer cases of alopecia but statistically significantly
more cases of hypertension and treatment-related SAEs, when compared with sorafenib. Bayer HealthCare7
reported sorafenib to result in fewer grade ≥ 3 AEs, SAEs and withdrawals owing to AEs when compared
with lenvatinib. However, caveats about the generalisability of the results of the indirect comparisons have
been raised,6 and Kawalec et al.97 stated that indirect comparison results should be interpreted with caution
because of differences in trial characteristics. Furthermore, during the current appraisal, Bayer HealthCare
confirmed that it considered that the data from its indirect treatment comparison (ITCs)7 did not enable a
robust comparison of sorafenib and lenvatinib given important differences between SELECT and DECISION.151
Of the indirect comparisons conducted, only the indirect comparison by Kawalec et al.97 was not sponsored
by Eisai Ltd or Bayer HealthCare. A summary of the findings from the indirect comparisons is presented in
Appendix 5, Tables 53–55.
Evidence from prospective observational studies
The AG included nine prospective observational studies in its review.59,77,78,81,88,101,103,126,135 Five of these
studies59,78,88,101,126 were included in the meta-analyses conducted by Shen et al.127 and by Thomas et al.138
Seven of the studies were included in the EPARs26,27 for lenvatinib77,135 and sorafenib.59,78,88,101,126 The study
and participant characteristics and efficacy and safety findings are summarised in Appendix 8, Tables 58–68.
All studies included patients whose disease was described as being radioactive iodine-refractory59,77,78,101,126,135
or resistant to radioactive iodine,81,88 or who may have received multiple treatments of radioactive iodine.103
Two studies77,135 investigated the efficacy and safety of lenvatinib, six studies59,78,88,101,103,126 assessed the
efficacy and safety of sorafenib and one study81 considered the efficacy of sorafenib. Some patients
included in four of the studies59,88,101,135 had anaplastic or medullary carcinoma. Safety data from these four
studies59,88,101,135 are, therefore, not reported for RR-DTC only. However, all nine studies59,77,78,81,88,101,103,126,135
reported efficacy findings for patients with RR-DTC only and all efficacy data reported in this section related
to patients with RR-DTC only.
The E7080-G000-201 study (hereafter referred to as Study 20177) of lenvatinib was conducted in the UK,
France, Italy, Poland, the USA and Australia. The E7080-J081-208 study of lenvatinib (hereafter referred
to as Study 208135) was conducted in Japan. Studies of sorafenib were carried out in the UK,59 the
Netherlands,126 Italy,103 Greece,81 the USA101 and China.78 The earliest study was conducted between 2004
and 2005,101 and the most recent study was conducted between 2012 and 2015.135 The length of study
follow-up varied from a minimum of 3 months78 to a median of 51.6 months.27
The number of patients included in the studies varied from 978 to 58.77 In total, 109 patients were treated
with lenvatinib, of whom 83 had RR-DTC; 213 patients were treated with sorafenib, of whom 186 had
RR-DTC. In most studies, the majority of patients with RR-DTC had a histology of PTC,59,77,78,88,101,126 the
exception being the study by Marotta et al.103 in which the ratio of patients with FTC to patients with
PTC was 2 : 1. The average age of participants ranged from 55 years59 to 64 years.101 Four studies59,77,88,101
included a majority of males and three studies81,103,126 had a majority of females. Two studies78,135 did not
report information on sex. The authors of only two studies77,101 reported information on race and these
included a majority of white participants. Only two studies that reported ECOG status included patients
with an ECOG PS of ≥ 2 (6.9%77 and 35.3%103). The same two studies were the only studies to explicitly
state that patients could have received a prior TKI (11.8%103 to 29.3%77). There was scant and inconsistent
reporting of the sites of metastases.
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Median OS was reported in five studies.77,88,101,126,135 Median OS ranged from 31.8 months135 to 32.3 months77
for lenvatinib and from 23 months101 to 34.5 months126 for sorafenib. Median PFS was reported in six
studies77,88,101,103,126,135 and ranged from 12.6 months77 to 25.8 months135 for lenvatinib and from 12 months103
to 22.1 months for sorafenib88 (this last finding was reported in a subsequent conference abstract137).
Chen et al.78 (sorafenib) reported mean PFS (9.7 months). The ORRs ranged from 50.0%77 to 68.0%135 for
patients treated with lenvatinib, and from 15% (histology of PTC)101 to 38.3%88 for those treated with sorafenib
(this latter finding was reported in a subsequent conference abstract137). Median time to response and median
duration of response were only reported in two studies.77,126 For lenvatinib,77 median time to response was
3.6 months and, for sorafenib,126 all responses were reported to have happened within 6 months. The median
duration of response was 12.7 months for lenvatinib77 and 29.6 months for sorafenib.126
Key AEs are summarised in Appendix 8, Tables 61–66. Two studies88,101 (sorafenib) only reported
treatment-related AEs. Two of the sorafenib studies,78,81 presented only as abstracts, reported very little
information about AEs.
Incidences of the same types of AEs varied across the studies: for lenvatinib, hypertension and proteinuria
were very commonly reported; for sorafenib, hand–foot syndrome, rash and alopecia were common; and
diarrhoea and fatigue were common with both drugs. Data on SAEs were available only from Study 20177
(lenvatinib). Information on fatal AEs were reported only in two studies77,135 of lenvatinib and in one
study101 of sorafenib. For patients treated with lenvatinib, 48% reported a SAE77 and up to 8%135 died
from an AE. Only one death from AEs has been reported in one of the studies of sorafenib;101 it is unclear
if the lack of reporting of fatal AEs in the other sorafenib studies59,78,81,88,103,126 means that there were no
deaths from AEs in these studies. None of the deaths from AEs in any of the three studies77,101,135 reporting
fatal AEs were described as being treatment related.
Ongoing studies and studies for which there are no results
The AG identified four ongoing studies,152–155 as summarised in Appendix 9 (see Table 69). None of
the study results has been published or reported as a conference abstract. Only the two studies of
lenvatinib154,155 are RCTs: E7080-G000-211 (Study 211)154 is a Phase II postauthorisation study that includes
a randomised controlled phase, comparing two different starting doses of lenvatinib (24 vs. 18 mg) with
placebo; E7080-C086-308 (Study 308)155 is a Phase III RCT being conducted in China comparing lenvatinib
at its licensed dose of 24 mg with placebo. Eisai Ltd sponsors both of these trials. The other two studies
are prospective observational Phase II studies of sorafenib:152,153 a pilot study sponsored by the Royal
Marsden NHS Foundation Trust152 and a postauthorisation study sponsored by Bayer HealthCare.153
In addition, although not strictly meeting the inclusion criteria for the current MTA, the AG is aware of an
ongoing global prospective non-interventional study [Radioactive Iodine reFractory asymptomatic patients
(RIFTOS), NCT02303444]156 of asymptomatic patients with RR-DTC treated with any type of MKI. The
primary objective is to compare the time to symptomatic progression from study entry. Bayer HealthCare
sponsors this study. The planned enrolment is approximately 700 patients and the expected study end date
is 1 July 2020.
Discussion of clinical effectiveness: interpretation of results
The AG’s assessment of lenvatinib and sorafenib for the treatment of patients with RR-DTC focused on
evidence from two RCTs: SELECT (lenvatinib vs. placebo) and DECISION (sorafenib vs. placebo). Supporting
evidence was derived from 13 systematic reviews5–8,33,57,61,93,97,104,127,138,141 (including two systematic reviews
described in the submissions from Eisai Ltd8 and Bayer HealthCare7) and nine prospective observational
studies.59,77,78,81,88,101,103,126,135
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Clinical efficacy
Summary and interpretation of evidence: lenvatinib versus sorafenib
The primary objective of the AG’s systematic review was to compare the clinical effectiveness of lenvatinib
with that of sorafenib. Results from the AG’s literature search revealed that there have been no head-to-head
trials comparing the effectiveness of treatment with lenvatinib with the effectiveness of treatment with
sorafenib. However, five studies6–8,57,97 have reported results from indirect comparisons and/or MAICs. Results
from all of these analyses show that, compared with sorafenib, treatment with lenvatinib improves PFS but
not OS.
The AG explored whether or not it was appropriate to conduct an indirect comparison. Although it
was possible to construct a network, the AG identified issues that raised concerns about whether or not
evidence from SELECT and DECISION could be included in the same network. First, there were differences
between trial characteristics (prior treatment with TKIs, concurrent use of palliative radiotherapy and
differences in subsequent treatment received on disease progression). Second, there were differences
in participant characteristics (sex, race, geographic region, ECOG PS, time from diagnosis, histology and
site of metastases) both within and between the trials. Third, the analysis of the PFS K–M data from the
placebo arms of SELECT and DECISION showed that the risk profiles of the two trial populations were not
comparable. The reasons for the differences in risk are currently unknown. Fourth, the AG considered that,
for the majority of patient survival hazards assessed in the two trials, PHs were violated, the exception
being unadjusted OS in DECISION.
The AG is unable to conclude whether or not treatment with lenvatinib is more effective than treatment
with sorafenib for patients with RR-DTC. The AG considers that the results from the four published indirect
comparisons7,8,57,97 should be interpreted with caution. This warning also extends to the results from
the MAICs.7,57 It is unknown whether or not the MAIC adjustments would fully account for all of the
differences in the trial populations because the AG was unable to compare the adjusted risk profiles of
patients included in the MAIC.
The AG highlights that Kawalec et al.97 stated that their indirect comparison results should be interpreted
with caution because of differences in the characteristics of the included trials. In addition, the EMA,27
Scottish Medicines Consortium (SMC)38 and Canadian Agency for Drugs and Technologies in Health
(CADTH)6 all highlighted that differences in populations might have contributed to differences in results
observed between the two trials. The SMC38 also highlighted that the validity of the results from the MAIC
submitted by Eisai Ltd may be limited by weaknesses including heterogeneity across the studies in inclusion
criteria, assessment of disease progression and analysis of PFS. The CADTH6 highlighted that the MAIC
approach does not have the ability to control for the potential for unobserved or unrecorded differences
between trials such as differences in standards of care or baseline characteristics. Furthermore, during
the current appraisal, Bayer HealthCare confirmed that it considered that the data from its ITCs7 did not
enable a robust comparison of sorafenib and lenvatinib given important differences between SELECT and
DECISION (Bayer HealthCare response to AG report to the NICE Appraisal Committee, 6 September 2017).157
Summary and interpretation of evidence: lenvatinib and sorafenib versus best
supportive care
The secondary objective of the AG’s systematic review was to compare treatment with lenvatinib and
sorafenib with BSC. The AG has assumed that, in both trials, treatment with lenvatinib plus BSC or
sorafenib plus BSC is compared with placebo plus BSC. The unadjusted OS results from SELECT and
DECISION demonstrated that there was no statistically significant difference in OS between treatment with
lenvatinib and treatment with sorafenib versus placebo. After adjusting OS data for treatment crossover
using RPSFTM, there was a statistically significant improvement in OS from treatment with lenvatinib
compared with placebo; however, the difference in effect of sorafenib versus placebo was not statistically
significant. The AG highlights that the unadjusted median OS estimates for patients treated with lenvatinib
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and sorafenib in SELECT and DECISION are higher than those reported for patients treated with lenvatinib
and sorafenib in prospective observational studies.
For PFS and ORR, the results from SELECT and DECISION demonstrated that treatment with both lenvatinib
and sorafenib were statistically significantly better than treatment with placebo for patients with RR-DTC.
For all of the prespecified subgroups, the results from SELECT and DECISION favoured treatment with the
intervention (lenvatinib or sorafenib) when compared with placebo. Median PFS and ORR for patients
treated with lenvatinib in SELECT were higher than the prospective observational results from Study 20177
and lower than the results from Study 208.135 In contrast, median PFS and ORR results reported for
patients treated with sorafenib (DECISION) were lower than findings from any of the prospective
observational studies or the two meta-analyses.127,138
Patients in DECISION were permitted to receive concomitant palliative radiotherapy, a common component
of BSC in NHS clinical practice, whereas patients in SELECT were not; full details of the BSC provided in
the two trials are not available. Whether or not patients in the trials received BSC similar to that provided
by the NHS is unknown and this raises uncertainty about whether or not the trial results are generalisable
to NHS patients. If the BSC delivered in the two trials is not comparable, then using the placebo arms to
connect the two trials in an indirect comparison becomes even more challenging. However, as the rates
of palliative radiotherapy administered to patients in DECISION are low (10.6% of patients treated with
sorafenib and 21.4% of patients treated with placebo), then perhaps this issue is not important.
There are two important issues to consider when interpreting the RCT evidence. First, a caveat to the
use of the RPSFTM-adjusted OS results from both trials is that the method requires the assumption that
postprogression anti-cancer treatments, other than those permitted by treatment crossover, represent
routine clinical practice. For patients with RR-DTC, there is currently no standard of care for patients
with progressive disease. Therefore, it is unknown whether or not the poststudy anti-cancer treatments
administered to patients in SELECT and DECISION reflect the treatments that would be offered to patients
in the NHS. Second, the AG’s examination of the PH assumption for OS (unadjusted and adjusted) and
PFS in SELECT and DECISION showed that the PH assumption does not hold for any of these outcomes
other than unadjusted OS in DECISION. This means that the majority of the HRs reported in the company
submissions should be interpreted with caution. However, clinical advice to the AG is that the PFS results
for the overall populations of SELECT and DECISION are clinically meaningful.
Safety
Summary and interpretation of evidence: lenvatinib versus sorafenib
The AG did not conduct its own indirect comparison to facilitate a comparison of the effect of treatment
with lenvatinib with the effect of treatment with sorafenib for AEs. However, two other reviews7,97 reported
results from indirect comparisons of AEs. Kawalec et al.97 reported that treatment with lenvatinib resulted in
statistically significantly less alopecia but statistically significantly more hypertension and treatment-related
SAEs than sorafenib. Bayer HealthCare7 reported sorafenib to result in fewer grade ≥ 3 AEs, SAEs and
withdrawals owing to AEs when compared with lenvatinib.
Summary and interpretation of evidence: lenvatinib and sorafenib versus best
supportive care
When compared with placebo, treatment with both lenvatinib and sorafenib resulted in increased AEs.
However, although diarrhoea was experienced by just over two-thirds of patients treated with both drugs
in SELECT and DECISION, there were some notable differences in the safety profiles. Hypertension and
decreased appetite were reported by over half of patients in SELECT, whereas the most common AEs
reported by half or more of patients in DECISION were hand–foot syndrome, alopecia and rash. Grade
≥ 3 hypertension was very common in patients treated with lenvatinib (> 40%), and grade ≥ 3 hand–foot
syndrome was very common in patients treated with sorafenib (> 20%). Hypertension was also reported to
be one of the most common SAEs in SELECT (3.4%). Data on the median time to onset of AEs91,139 from
SELECT and DECISION suggest that AEs typically occur early, with a decrease in incidence, prevalence and
DOI: 10.3310/hta24020 HEALTH TECHNOLOGY ASSESSMENT 2020 VOL. 24 NO. 2
© Queen’s Printer and Controller of HMSO 2020. This work was produced by Fleeman et al. under the terms of a commissioning contract issued by the Secretary of State for
Health and Social Care. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional
journals provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should
be addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
37
severity over time. In DECISION, exceptions were diarrhoea that increased in prevalence over the first
six cycles and weight loss that increased in severity (from grade 1 to grade 2) over the first nine cycles.
Overall, the safety findings from the RCTs were consistent with the findings from prospective observational
studies of lenvatinib77,135 and sorafenib,59,78,81,88,101,126 although it is noticeable that the incidence of some AEs
varied quite widely in observational studies for patients treated with sorafenib. However, meta-analyses127,138
of data from observational studies for hand–foot syndrome and diarrhoea reported incidences of all-grade
and grade ≥ 3 AEs to be similar to those reported in DECISION. It has, however, been found in a systematic
review by Jean et al.93 that the incidence of common all-grade AEs tends to be higher for patients with
RR-DTC than for patients with RCC or HCC and also for some patients with grade ≥ 3 hand–foot syndrome
and rash.
After diarrhoea, hypertension was the most common reason for dose modifications, as well as being the
most common reason (alongside asthenia) for discontinuations in SELECT. In DECISION, the most common
reason for dose modifications and discontinuations was hand–foot syndrome. Dose reductions were frequent
(> 60%) for patients treated with both lenvatinib and sorafenib. Life-threatening AEs from treatment with
lenvatinib and sorafenib were rare. The AG considers that the AEs associated with treatment with lenvatinib
and sorafenib can be managed with usual medical care and dose modifications, including treatment
withdrawal. Clear guidance for managing AEs is set out in the SmPCs for lenvatinib45 and sorafenib.46
Health-related quality-of-life findings
The HRQoL data were not collected as part of SELECT, and HRQoL data from the 30 patients who
participated in the open-label extension phase of SELECT are not yet available. This is disappointing given
that the investigators in the earlier DECISION had measured and reported HRQoL outcomes and highlighted
that HRQoL may be negatively impacted by treatment with TKIs.7,120 AE rates were high in SELECT and it
would have been informative if HRQoL data had been collected. HRQoL research is much needed as HRQoL
is one of the most important outcomes to consider, both from the perspective of patients and for assessing
comparative cost-effectiveness.
The HRQoL data collected during DECISION demonstrated that the FACT-G scores were higher for patients
in the placebo arm than for patients in the sorafenib arm, indicating a higher HRQoL for patients receiving
placebo. The negative impact of treatment with sorafenib on HRQoL may be linked to the high rates of
AEs.7,120 Indeed, it has been noted by Bayer HealthCare7 that in response to the question on the FACT-G
questionnaire ‘I am bothered by side effects’, the proportion of patients in the sorafenib arm who replied
‘quite a bit’ or ‘very much’ increased from 1.5% in cycle 1 to 29.6% in cycle 2 but then gradually
diminished over time.
There are, however, limitations to the results from the HRQoL analyses. Although the overall questionnaire
completion rate during DECISION was reported to be 96%,120 the number of patients eligible to complete
the questionnaires diminished with every cycle because only those who had not experienced progression
were asked to complete the questionnaire. This also means that there are no HRQoL data available from
patients whose disease has progressed. It is also unknown whether or not there is a direct correlation
between HRQoL and AEs and how the different types of AEs experienced by patients treated with
lenvatinib (e.g. hypertension) and sorafenib (e.g. hand–foot syndrome) affect HRQoL. Finally, to what
extent a patient’s HRQoL is affected by their symptom status (symptomatic vs. asymptomatic) is unknown.
Generalisability of findings
The AG considers that the generalisability of the findings from SELECT and DECISION to NHS clinical
practice is questionable. This concern is driven by the fact that clinical advice to the AG is that in clinical
practice there are concerns about the toxicity of TKI therapy in patients and effects on the quality of life
of patients with asymptomatic disease and so treatment is more commonly given when symptomatic or
clinically significant progressive disease develops. Hence, BSC is a common treatment option for this
group. The authors of two of the meta-analyses of sorafenib127,138 concluded that the high incidence of
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AEs associated with sorafenib may affect the quality of patients’ lives and most patients with metastatic
disease do not require systemic therapy. This view is supported by several clinical guidelines4,24,25 as
patients experiencing RR-DTC symptoms and/or those with rapidly progressing disease are considered to
be in greatest need of systemic treatment.31 In addition, the EMA concluded that maximum lesion size,
symptoms related to the disease and progression rate should be carefully considered for each individual
patient before initiating treatment.26
Although all of the patients in SELECT and DECISION had RR-DTC, it is unclear how many had symptomatic
and/or rapidly progressing disease; however, it is reported in the EPAR26 for sorafenib that results from a post
hoc subgroup analysis of data from DECISION suggest that 20% of patients were likely to be symptomatic.
Clinical advice to the AG is that this is probably typical of the proportion seen in clinical practice. It is unclear
how many patients in SELECT were symptomatic and/or had progressive disease.
The post hoc retrospective analysis of data from patients participating in DECISION113,119 categorised
patients as having symptomatic disease if they had symptoms/findings that were consistent with RR-DTC
reported in the medical history or pre-treatment AE data set at baseline. Clinical advice to the AG is that
there are no generally agreed definitions of ‘symptomatic’ or ‘rapidly progressive disease’ and that, in
clinical practice, the definition of a patient’s disease status depends on individual patient characteristics.
Results from the post hoc analysis show that median PFS was similar for all patients treated with sorafenib,
irrespective of whether or not they were symptomatic or asymptomatic (10.7 months and 10.8 months,
respectively, compared with 10.8 months for all patients in the sorafenib arm of the trial).7 However, for
patients in the placebo arm, median PFS was much lower for symptomatic patients (3.6 months) than for
asymptomatic patients (7.2 months), and it was also lower than for all patients in the placebo arm of the
trial (5.8 months).
No analyses have been undertaken to compare the effectiveness of treatment with lenvatinib for symptomatic
patients with that for asymptomatic patients. In the absence of such analyses, no assumptions can be made
about relative effectiveness. However, clinical advice to the AG is that, like sorafenib, only patients with
symptomatic and/or progressive disease are likely to be treated with lenvatinib in the NHS.
The most recent published guidelines for treating RR-DTC, by the NCCN,25 recommend lenvatinib or
sorafenib as the treatment of choice for patients with progressive and/or symptomatic disease. However,
the choice between lenvatinib and sorafenib should be based on the individual patient, taking into account
the likelihood of response and comorbidities.25
There are further important caveats regarding the generalisability of the findings from SELECT and DECISION
to NHS clinical practice.
The first caveat is that, although most patients participating in the trials had a diagnosis of PTC, as would be
expected in clinical practice, there were proportionately more patients with other types of DTC than would
be expected in NHS clinical practice. Patients with these other types of DTC are reported to have a worse
prognosis than patients with PTC.15 However, subgroup and exploratory analyses of SELECT data showed that
for unadjusted OS, there was a statistically significant OS gain for patients with FTC treated with lenvatinib
compared with those treated with placebo,82 and that histology (favouring FTC vs. PTC) was statistically
significantly associated with increased OS.91 These exploratory results warrant further investigation.
The second caveat relates to the age of patients. Thyroid cancer incidence is strongly related to age,
with the highest incidence rates being in older males (aged > 60 years) and the highest incidence rates in
females being in younger and middle-aged women (aged 40–60 years).1 The median age of patients was
61 years in the lenvatinib arm and 64 years in the placebo arm of SELECT and 63 years in both arms of
DECISION, and approximately half of the patients in both trials were male. Given that the median time
from diagnosis in the trials varied from between 5.5 and 6 years, it appears that, in general, patients were
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older than may be seen in clinical practice. Moreover, the prognosis of patients tends to differ for patients
aged < 45 years and for those aged ≥ 45 years, as reflected in the staging criteria used for DTC.4 Detailed
data on the age range of included patients were not reported for either trial.
Other issues of relevance to clinical practice
The relative importance of ORR also warrants some discussion, particularly given the marked reported
differences in effect between treatment with lenvatinib and sorafenib indicated by results from SELECT
and DECISION and the prospective observational studies.59,77,78,81,88,101,103,126,135 Although studies of
lenvatinib51,77,135 suggest that at least half of all patients achieve a response, meta-analyses of data from
observational studies of sorafenib127,138 suggest that no more than 22% of patients receiving this treatment
respond. This finding reflects the finding from a systematic review of TKIs33 that shows that the most likely
outcome of treatment with a TKI is stable disease. Indeed, in DECISION, 42% of patients in the sorafenib
arm had stable disease for ≥ 6 months (and 12.2% had an objective tumour response) compared with
33% in the placebo arm (and 0.5% had an objective tumour response). However, given that lenvatinib
and sorafenib are likely to be preferred treatment options for patients with clinically significant progressive
disease, reducing the rate of disease progression may be a more relevant outcome. The AG notes that in
the submission from Bayer HealthCare,7 it is reported that most patients (77%) in the sorafenib arm of
DECISION experienced target lesion tumour shrinkage, compared with 28% of patients in the placebo
arm. The authors of a systematic review of sorafenib104 for treating RR-DTC concluded that, although the
data in the review came primarily from non-randomised Phase II trials (but also included DECISION), the
results suggest that treatment with sorafenib slows the progression of disease in the majority of cases.
The findings from the extended open-label phases of SELECT and DECISION should also be considered.
These findings show that the median PFS and ORR outcome results for patients previously randomised to
the placebo arms but who crossed over to receive lenvatinib or sorafenib at the licensed doses were similar
to the median PFS and ORR reported for patients treated with lenvatinib and sorafenib in the double-blind
phases of the trials. Given that patients in the placebo arm received no active systemic therapies during
the double-blinded phase, these results appear to support the view that patients with progressive disease
do not need to be treated immediately and can be treated when showing symptoms and/or rapidly
progressing. However, the AG cautions that data on symptoms and/or whether or not patients were
rapidly progressing are lacking, although patients were progressing to the extent that, on the basis of
RECIST (Response Evaluation Criteria in Solid Tumours) criteria, they were considered to have progressive
disease. The AG also cautions that no OS data were available for these specific cohorts of patients.
The results from the open-label phase of SELECT, which included patients who crossed over from placebo
to receive treatment with two different doses of lenvatinib, suggest that PFS may be improved for those
starting at the 20-mg dose (median PFS not reached) as opposed to the licensed dose of 24 mg (median
PFS of 17.5 months). However, the numbers of patients in each group, particularly in the 20-mg dose
cohort, were small, and definitive conclusions could not be reached. Study 211,154 an ongoing Phase II
RCT, compares two different starting doses of lenvatinib (24 vs. 18 mg) with placebo. This trial is expected
to end in October 2020.
Although patients treated with lenvatinib in SELECT were not permitted to receive additional lenvatinib in
the extended open-label phase of that trial, around one-quarter of patients had received treatment with a
VEGFR-targeted therapy, including sorafenib, prior to enrolment. SELECT subgroup PFS and ORR findings
suggest that patients benefited from treatment with lenvatinib, regardless of whether or not they had
received prior treatment with a VEGFR-targeted therapy. This result suggests that lenvatinib could be used
as a first- or second-line treatment for patients with RR-DTC. Further research is required to identify the
effect on OS of treating patients with lenvatinib followed by sorafenib. Furthermore, it has also been
reported that SAEs were more common in the lenvatinib arm among patients who had received a prior
VEGFR-targeted treatment (60.6%) than among those who had not (50.8%).105,106
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Some patients in DECISION who had experienced disease progression while receiving sorafenib were also
eligible to receive sorafenib for a second time in the extended open-label phase of DECISION. Clinical
advice to the AG was that, in NHS practice, patients could be prescribed sorafenib post progression as there
is a view that continued treatment with sorafenib will slow the progression of disease. This expectation is
supported, to some extent, by exploratory post hoc findings.83,94 These findings suggest that despite evidence
of tumour growth or prior RECIST progression, treatment with sorafenib continued to slow tumour growth
for patients who had also been treated with sorafenib during the randomised phase, when compared with
tumour growth for patients treated with placebo during the randomised phase.83,94 However, as concluded
by authors of other abstracts114,122 reporting results from the open-label extension phase of DECISION,
the effect of continued treatment with sorafenib after progression needs to be explored further.
Finally, there are no data for patients treated with sorafenib followed by lenvatinib. Further research is
needed to identify the effect on OS and other efficacy and safety outcomes of treating patients with
lenvatinib followed by sorafenib, and sorafenib followed by lenvatinib.
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Chapter 5 Assessment of cost-effectiveness
The AG conducted a systematic review of the economic literature to identify the existing evidenceassessing the cost-effectiveness of treatment with lenvatinib and sorafenib (vs. each other and vs. BSC)
for people with progressive, locally advanced or metastatic RR-DTC. The review focused on the decision
problem outlined in the final scope issued by NICE.53 The economic evaluations presented in the submissions
by Eisai Ltd8 and Bayer HealthCare7 are discussed and critiqued separately in Summary of the key features of
the companies’ economic models.
Search strategy
The AG identified cost-effectiveness studies by searching EMBASE, MEDLINE, the NHS Economic Evaluation
Database via The Cochrane Library and EconLit from 1999 onwards. The starting date for all of the searches
was 1999 and all databases were searched on 10 January 2017. Based on the fact that the FDA approved
sorafenib for its first indication in 2005, and lenvatinib in 2015, the AG considered that this date span
would allow all relevant economic evidence to be identified. The reference lists of included publications,
in addition to the NICE, SMC and CADTH websites, were hand-searched. The results of the searches were
entered into an EndNote X7.4 library and de-duplicated.
Study selection and inclusion criteria
Publications were selected for inclusion in the review based on their relevance to the decision problem
and the specific economic criteria presented in Table 12. In addition to costs, quality-adjusted life-years
(QALYs), cost–benefit and cost-effectiveness outcomes, such as cost per PFS year, were also extracted from
relevant publications.
Two reviewers (RH and NF) independently screened the titles and abstracts of all publications identified by
the searches. The same two reviewers then independently retrieved and assessed (for inclusion) the full texts
of the publications that had been identified as being potentially relevant to the review. Disagreements
about inclusion in the review were resolved through discussion and, in all cases, a consensus was reached;
it was, therefore, not necessary to consult a third reviewer during the screening and selection process.
TABLE 12 The AG’s review of economic evidence: inclusion criteria
Criteria Inclusion






Costs Direct health-care costs
Outcomes Incremental cost per life-year gained and/or incremental cost per QALY gained
Study design Full economic evaluations that consider both costs and consequences (cost-effectiveness analysis,
cost–utility analysis, cost-minimisation analysis and cost–benefit analysis)
Date span 1999 to 10 January 2017
Language English language only
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Quantity of evidence
The searches for economic evidence identified 19 citations in total: 14 were obtained from the database
searches and five were identified from other sources. Once duplicates were removed, 18 publications
remained and, after assessment of the titles and abstracts, 10 publications5,38,48,158–164 were retrieved and a
detailed assessment of their eligibility was undertaken.
Nine of these 10 publications were included in the review. The AG included four publications158–160,163
that clearly met the inclusion criteria. The AG considered that the economic evidence for lenvatinib and
sorafenib that had been submitted to the SMC38,48 and CADTH5,162 was also relevant to this review and
so these four records,5,38,48,162 one for each drug’s individual submission to each regulatory agency, were
included in the review. One further relevant publication161 was identified during the citation search of the
included publications; this publication became available online only after the AG’s database searches had
been completed.
One publication164 was a budget impact analysis and was, therefore, excluded from the review.
A Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) flow diagram showing
the process of study selection is shown in Figure 8.
A summary of the characteristics of the nine included publications5,38,48,158–163 is presented in Table 13.
Quality of the included evidence
The quality of the included evidence was assessed using the NICE reference case checklist169 and the
Drummond checklist.170 Summary tables of the AG’s quality assessments are presented in Appendices 11
(see Table 72) and 12 (see Table 73). Full details of the completed checklists are presented in Appendices 13
(see Tables 74–81) and 14 (see Tables 82–89). The publications by Huang et al.158,159 have been evaluated
























FIGURE 8 The PRISMA flow diagram: the AG economic literature review.
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Only the Wilson et al.161 publication was available as a full-text paper published in a peer-reviewed journal.
Three of the included publications158,159,163 were available only as abstracts, and one publication160 was
available as a poster. The submissions to the regulatory bodies in Scotland38,48 and Canada5,162 were
available only as summary reports. As a result, only limited information was available from most of the
included publications and this hindered the quality assessment of some of the methodologies described in
the publications.
The authors of all of the included publications produced incremental cost-effectiveness estimates enabling
a single metric [an incremental cost-effectiveness ratio (ICER) per QALY gained] to be used for comparative
purposes. All of the publications included a discussion of the certainty associated with study results;
however, full details of the sensitivity analyses and parameter values were not always available in the text.
Generally, the text describing the assumptions and data sources used to generate resource use, costs and
HRQoL estimates within the economic models was not clear. In addition, it was unclear whether or not the
costs and benefits described in the publications were discounted appropriately. Results from analyses of
the cost-effectiveness of all the relevant comparators (lenvatinib, sorafenib and BSC) were available from
only four of the reviewed publications.158–161
None of the publications considered the decision problem from the perspective of the NHS in England.
However, as the Scottish NHS provides a sufficiently similar environment to the NHS in England, the AG
considered that, for the purposes of this appraisal, the results from the SMC submissions38,48 are broadly
generalisable to patients in England. The characteristics of the health-care systems, in terms of the way
treatments are procured and used in the USA,158,159,161 Canada5,162 and Turkey,163 make the results from
analyses based on these perspectives less useful when considering treatment options for patients in the
NHS in England. However, including these studies5,158,159,161–163 in this review allows a broad range of
cost-effectiveness estimates to be considered and provides some indication of the effect of varying
assumptions, such as the model time frame and estimates of HRQoL.
Assessment Group economic review: overview of included publications
The AG identified nine relevant publications5,38,48,158–163 describing the cost-effectiveness of treatment with
lenvatinib and sorafenib in a population of patients with RR-DTC. When necessary, authors were contacted
and asked to provide further information on methodological aspects that lacked clarity in the publications;
only one lead author160 replied and provided the discount rate used in the model.
One publication163 considered the cost-effectiveness of treatment with sorafenib compared with usual
care in the Turkish setting. Four publications158–161 compared treatment with lenvatinib with treatment with
sorafenib from a US perspective. The SMC submissions38,48 considered resource use in the Scottish NHS, and
the CADTH submissions5,162 included analyses that were undertaken from the perspective of the Canadian
health-care system. The results reported in the publications5,38,48,158–162 comparing the cost-effectiveness of
lenvatinib with the cost-effectiveness of sorafenib are based on the results of indirect comparisons. This
means that the authors considered that the trial and patient characteristics of SELECT and DECISION were
sufficiently comparable for their data to be compared using this methodology. The AG discusses the
limitations of using data from SELECT and DECISION in an indirect comparison in Chapter 4, Indirect
comparison feasibility assessment.
The costs, benefits and incremental results from each of the publications are presented in Table 14. All
costs from 2014 have been inflated to 2015/16 prices using the hospital and community health services
index.171 Analyses conducted using 2015 and 2016 prices have not been inflated as the 2016/17 inflation
indices were not available. When the year that costs used within the model is not reported, the year of
publication is used as a proxy. When necessary, all cost data have been converted to Great British pounds
using the Bank of England exchange rate as of 25 May 2017.172
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TABLE 14 Results of publications that were included in the AG’s review of economic evidence
Study Interventions Costs (£) LYs QALYs
Incremental ICER (£)
Costs (£)a LYs QALYs Per LY gained Per QALY gained
Erdal et al. 2015163 BSC NR NR NR
Sorafenib NR NR NR 19,084 1.29 0.80 14,754 23,859
Huang et al. 2016158 Placebo 657,493 NR NR
Lenvatinib 152,448 NR NR –505,045 (vs. BSC)
25,491 (vs. sorafenib)
NR NR NR 61,109 (vs. sorafenib)
Sorafenib 126,957 NR NR –530,536 (vs. BSC) NR NR NR
Huang et al. 2016159 Lenvatinib vs. sorafenib NR NR NR NR NR NR 73,913
bTremblay et al. 2016160 Lenvatinib 217,527 2.71 1.77 40,697 0.33 0.42 124,843 96,671
Sorafenib 176,830 2.38 1.35
cTremblay et al. 2016160 Lenvatinib 228,637 3.38 2.10 44,626 0.58 0.54 76,835 81,338
Sorafenib 184,010 2.80 1.56
Wilson et al. 2017161 Placebo 107,898 NR 0.71
Lenvatinib 127,819 NR 1.34 7368 (vs. sorafenib)
19,921 (vs. placebo)
NR 0.37 (vs. SOR)
0.63 (vs. placebo)
NR 19,522 (vs. sorafenib)
31,566 (vs. placebo)









































































































































































TABLE 14 Results of publications that were included in the AG’s review of economic evidence (continued )
Study Interventions Costs (£) LYs QALYs
Incremental ICER (£)
Costs (£)a LYs QALYs Per LY gained Per QALY gained
SMC 201548 Sorafenib vs. BSC NR NR NR NR NR NR NR 32,083
SMC 201638 Lenvatinib vs. sorafenib NR NR NR NR NR NR NR 49,525
dCADTH 20155 Sorafenib vs. BSC NR NR NR 42,824 0.86 0.52 49,795 82,080
eCADTH 20155 Sorafenib vs. BSC NR NR NR 45,744 to 46,054 NR 0.38–0.42 NR 108,974 to 118,913
dCADTH 2016162 Lenvatinib vs. BSC NR NR NR 60,784 1.01 0.84 60,182 72,536
eCADTH 2016162 Lenvatinib vs. BSC NR NR NR 84,687 1.03 0.84 98,343 101,293
NR, not reported; LY, life-year.

























The authors described a partition survival model that used clinical evidence from DECISION, supplemented
with Turkey-specific resource use and cost information, to generate estimates of the cost-effectiveness of
treatment with sorafenib versus BSC in a population of people with locally advanced or metastatic RR-DTC.
Deterministic results were presented and the ICER per QALY gained for the comparison of treatment with
sorafenib with treatment with BSC was £23,859. The authors concluded that the results of the one-way
deterministic analyses and probabilistic sensitivity analysis (PSA) were similar to the main set of deterministic
results. However, as few details of the parameters and values that were used to estimate the level of
uncertainty around results were reported in the publication, the AG was not able to ascertain the reliability
of results generated by the sensitivity analyses. Despite not reporting a willingness-to-pay threshold, the
authors considered sorafenib to be a cost-effective treatment compared with BSC.
Huang et al.158
The Markov model described by the authors used effectiveness evidence from the Phase III trials SELECT and
DECISION. Results from one-way sensitivity analyses showed that the base-case model results were sensitive
to changes to the costs of lenvatinib and sorafenib and the utility benefit of continuing with lenvatinib. The
AG notes that the value and duration of the utility benefits were not reported. The base-case ICER for the
comparison of treatment with lenvatinib with treatment with sorafenib was £61,109 per QALY gained.
Huang et al.159
The authors reported the methods and results of an expected value of perfect information (EVPI) analysis
using the same model described in the abstract by Huang et al.158 An ICER of £73,913 per QALY gain
was reported, indicating that treatment with lenvatinib offers an increase in benefit over sorafenib,
but at an additional cost. At a willingness-to-pay threshold of approximately £77,000 per QALY gained,
the probabilities of lenvatinib and sorafenib being cost-effective were low (37% and 33%, respectively).
Owing to uncertainty around the reliability of model results, the authors were not certain that treatment
with lenvatinib was cost-effective when compared with sorafenib and placebo.
Tremblay et al.160
The poster included results from a cost-effectiveness analysis from a partition survival model designed to
compare treatment with lenvatinib and treatment with sorafenib using clinical evidence from the Phase III
SELECT and DECISION. The base-case ICER for the comparison of treatment with lenvatinib with treatment
with sorafenib was £81,338 per QALY gained when a 10-year time horizon was modelled, and £96,671
per QALY gained when a 5-year time horizon was modelled.
Costs per PFS year (£58,833 with a 5-year time horizon and £62,318 with a 10-year time horizon), costs
per responder (£77,372 with a 5-year time horizon and £84,841 with a 10-year time horizon) and life-year
saved were also reported in the publication. The authors did not set a willingness-to-pay threshold to
determine at what level the cost per responder, for example, would offer good value for money. The
authors refer to PSA in the publication but do not report the methods or the results of the analysis.
Wilson et al.161
The same set of authors who produced the abstracts by Huang et al.158,159 authored a full-text paper
comparing the cost-effectiveness of treatment with lenvatinib with that of sorafenib, in which they described
a Markov model that used effectiveness data from the Phase III trials SELECT and DECISION. ITCs to compare
the effectiveness of lenvatinib with the effectiveness of sorafenib were made following adjustments to the
placebo arms of the trials as the authors considered that the placebo arm of SELECT included patients who
appeared to be healthier than those in the comparator arm of DECISION. However, the AG does not consider
that the adjustments are sufficient to generate reliable estimates of the comparative effectiveness of lenvatinib
and sorafenib. In addition, as discussed in Chapter 4, Indirect comparison feasibility assessment, the AG does
not consider that it is appropriate to undertake an indirect comparison of the effectiveness of lenvatinib and
the effectiveness of sorafenib using data from SELECT and DECISION.
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The results of the authors’ cost–utility analysis differ from those reported in the abstracts.158,159 In the
base-case analysis, treatment with lenvatinib generated more benefits (+ 1.34 QALYs) than treatment
with sorafenib (+ 0.96 QALYs), as well as more benefits than placebo (+ 0.71 QALYs), but at an increased
cost of £7368 versus sorafenib and £19,921 versus placebo. The base-case ICER for the comparison of
treatment with lenvatinib with treatment with sorafenib was £19,522 per QALY gained. The base-case
ICERs for the comparison of treatment with lenvatinib with placebo and treatment with sorafenib with
placebo were £31,566 and £49,484 per QALY gained, respectively.
Sorafenib Scottish Medicines Consortium submission48
For the comparison of treatment with sorafenib with BSC, the ICER was £32,083 per QALY gained; the
Scottish PAS price of sorafenib was used in the analysis.48 These results were sensitive to the time horizon
of the model and the approach used to estimate OS, with the ICER increasing with a shortened time
horizon and with a change to the OS extrapolation method employed.
Lenvatinib Scottish Medicines Consortium submission38
For the comparison of treatment with lenvatinib with treatment with sorafenib, the base-case ICER was
£49,525 per QALY gained; this analysis used the Scottish PAS price for lenvatinib and Eisai Ltd’s estimate
of the Scottish PAS discount currently in place for sorafenib.38 The ICERs per QALY gained were sensitive
to the estimates of OS for lenvatinib (ranged from £29,000 to £96,000 per QALY gained with PAS prices)
and to changing the utility rates used in the model by 20% (ranged from £41,000 to £62,000 per QALY
gained with PAS prices).
Sorafenib Canadian Agency for Drugs and Technologies in Health submission5
The company’s base-case cost-effectiveness estimate was that treatment with sorafenib versus BSC
resulted in an ICER of £82,080 per QALY gained. Several other ICERs per QALY gained were also
presented as a result of reanalyses suggested by the Economic Guidance Panel. The reanalyses included
amendments to the time horizon, the duration of treatment and estimates of OS. The results from the
reanalyses ranged from £108,974 to £118,913 per QALY gained.
Lenvatinib Canadian Agency for Drugs and Technologies in Health submission162
The base-case analysis for the comparison of lenvatinib with BSC, submitted by the company, generated
an ICER of £72,536 per QALY gained. This increased to £101,293 per QALY gained when the amendments
suggested by the Economic Guidance Panel were implemented. The reanalysis included amendments to OS
estimates, time horizon, use of the intervention drug in terms of both wastage and the appropriate pack
size to reach the required dosage, and the utility values used within the model.
Although the company submitted results from additional analyses comparing the cost-effectiveness of
lenvatinib with the cost-effectiveness of sorafenib to CADTH, these results were not presented in the
available CADTH guidance report.162
The AG notes that the SMC38,48 and CADTH5,162 reports highlight concerns about the clinical effectiveness
data derived from SELECT and DECISION. Key issues of concern related to median OS not being reached
and the high rates of treatment crossover from the placebo (BSC) arms to the intervention arms (lenvatinib
or sorafenib) that took place during the trials.
The Assessment Group’s review of economic evidence:
summary and conclusions
The published economic evidence163 shows that the ICER of £23,859 per QALY gained for the comparison
of sorafenib with BSC (after conversion from Turkish lira) is within the willingness-to-pay threshold that
is considered to reflect a cost-effective use of NHS resources. However, without further details of the
economic model inputs, in particular the resource use and costs, the relevance of this finding to the NHS
setting is unclear.
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In the US setting, when compared with placebo, both treatment with lenvatinib and treatment with sorafenib
appear to provide additional health benefits while either saving resources158 or yielding ICERs per QALY
gained of < £50,000 after conversion from US$ (£31,566 per QALY gained161 for lenvatinib versus placebo
and £49,484 per QALY gained161 for sorafenib vs. placebo). When treatment with lenvatinib is compared
with sorafenib in the US setting, lenvatinib offers a health benefit over sorafenib but at an increased cost.
Cost-effectiveness results ranged from £19,522 per QALY gained161 (lenvatinib vs. sorafenib) to £96,671 per
QALY gained160 (lenvatinib vs. sorafenib), at current UK prices. Again, it is unclear whether or not these results
are relevant to the NHS setting.
In 2015, sorafenib became the standard of care for patients in Scotland with locally advanced or
metastatic RR-DTC, provided that the company supplied the drug to the NHS at the Scottish PAS price
agreed by the company with NHS Scotland.48 The SMC sorafenib report48 states that sorafenib generated
more benefit than BSC but at an increased cost. The ICER for this comparison was £32,083 per QALY
gained. In 2016, an appraisal of treatment with lenvatinib38 versus sorafenib was submitted to the SMC;
lenvatinib was considered by the SMC to be both an orphan drug and an end-of-life treatment. For the
comparison of treatment with lenvatinib with treatment with sorafenib, based on survival outcome results
generated using indirect comparison methods, and using the Scottish PAS price for lenvatinib, the ICER per
QALY gained was estimated to be £49,525 and lenvatinib was accepted for use in NHS Scotland.
The AG notes that any discount to the list prices of the drugs agreed with the NHS in Scotland does not
equate to an equivalent agreement with the NHS in England. All PAS prices are confidential and thus the
applicability of the results presented within the Scottish submissions to the appraisal of lenvatinib and
sorafenib for use in the NHS in England is unclear as it is not known whether or not the discounts agreed
with the NHS in Scotland are the same as those agreed with the NHS in England.
In 2015, sorafenib was appraised by CADTH5 and, after reanalyses suggested by the Economic Guidance
Panel, estimates of the most plausible ICERs for the cost-effectiveness of treatment with sorafenib versus
BSC ranged from £108,974 to £118,913 per QALY gained (after conversion from CA$). Lenvatinib was
considered for use by the Canadian health-care system in 2016. Estimates of the cost-effectiveness of
treatment with lenvatinib versus both BSC and sorafenib were generated but only the comparisons with
BSC are reported in the CADTH report.162 After the Economic Guidance Panel’s suggested amendments
were carried out, the best estimate for the comparison of treatment with lenvatinib versus BSC was
£101,293 per QALY gained. Both lenvatinib and sorafenib have been recommended for use in Canada.
The relevance of these results to patients in the NHS is unknown.
What is lacking from the current evidence base are any cost-effectiveness analyses of direct relevance
to the NHS in England. The SMC submissions38,48 provide an insight into the costs and consequences
associated with treatment with lenvatinib, sorafenib and BSC, and these are likely to be similar for patients
treated in England. However, the PAS prices agreed with the NHS in Scotland are confidential and this
prevents the reported cost-effectiveness estimates being directly applicable to the NHS in England.
Head-to-head comparisons of the effectiveness of treatment with lenvatinib with the effectiveness of
treatment with sorafenib depend on results from indirect comparisons, whether conducted in a formal
statistical framework5,38,48,160,162 or with adjustments made to the placebo arms of the Phase III trials,161
which provide estimates based on the pooling of the comparator arms within the SELECT and DECISION
Phase III trials. The AG considers that, because of the issues discussed in Chapter 4, Indirect comparison
feasibility assessment, it is not appropriate to employ indirect comparisons of the effectiveness of lenvatinib
and the effectiveness of sorafenib using data from SELECT and DECISION.
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Summary of the companies’ systematic reviews of economic evidence
Both of the companies carried out systematic reviews to identify published cost-effectiveness studies that
included lenvatinib and/or sorafenib. Both companies concluded that there are no cost-effectiveness studies
conducted in the UK from the perspective of the NHS that were relevant to decision-making in England.
Therefore, both companies produced their own de novo economic evaluations.
Summary of the key features of the companies’ economic models
This section includes summary details of the key features of the economic models submitted to NICE, from
Eisai Ltd and Bayer HealthCare, as part of the MTA process. All of the company data presented in this
section are drawn from the company submissions7,8 and models.
Population
Both companies state that their economic evaluations focus on patients with progressive RR-DTC. However,
in the submission from Eisai Ltd,8 it is highlighted that the SELECT definition of progressive RR-DTC was
locally advanced or metastatic DTC confirmed by radiographic evidence of disease progression within the
prior 13 months and that some patients participating in this trial had received prior vascular endothelial
growth factor (VEGF) therapy. Eisai Ltd8 points out that, in contrast, no patients recruited to DECISION had
received prior VEGF therapy and that, to be eligible for recruitment, evidence of disease progression within
the 14 months prior to commencing the trial was required. The AG describes other differences in the two
trial populations in Chapter 4, Trial characteristics, Participant characteristics and Indirect comparison
feasibility assessment.
Model structure
Key elements of the structure of the economic models submitted by Eisai Ltd and Bayer HealthCare are
included in Table 15. The structure of the two company models is similar and is in line with the structure of
models that have previously been submitted to NICE to inform appraisals of interventions used to treat
patients with cancer. The structure of both models conforms to specifications detailed in the final scope
issued by NICE.53
TABLE 15 Model structure






Model structure A four-state (stable disease, response, progressive
and death) partitioned survival cost–utility model
developed in Microsoft Excel® (Microsoft
Corporation, Redmond, WA, USA)
A three-state (progression-free, progressed and
death) partitioned survival cost–utility model
developed in Microsoft Excel®
Cycle length 1 month (30.43 days) 28 days
Model time
horizon
33.35 years (5 years and 10 years are considered
as scenario analyses)
30 years
Discounting Costs and benefits were discounted at a rate of 3.5% annually in line with the NICE reference case169
Perspective The perspective is stated to be that of the NHS and PSS. However, no specific PSS elements are
considered to be relevant to the RR-DTC population and none is included in either model
PSS, Personal Social Services.
Note
Information drawn from Eisai Ltd8 (section 5.2) and Bayer HealthCare7 (section 4.2).
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Therapies
Details about the intervention and comparators included in the company models are provided in Table 16.
Both models included the therapies listed in the final scope issued by NICE.53 The AG highlights that the
lenvatinib and sorafenib doses in the models are based on average levels of use in SELECT and DECISION
and are lower (approximately 17 mg for lenvatinib and 651 mg for sorafenib) than the licensed doses
(24 mg for lenvatinib and 800 mg for sorafenib). Possible reasons include dose interruptions/reductions
as a result of AEs; in some cases, intolerance may lead to a treatment being stopped.
Survival modelling
Summary details of the general approach the companies used to model patient survival (OS and PFS)
are provided in Tables 17 and 18, respectively.
Measurement and valuation of health effects
Sources of utility values
The base-case utility values used in the Eisai Ltd model were stated to be taken from EQ-5D values for
sorafenib from DECISION. Disutilities were then applied as a weighted proportion, based on values
obtained from a vignette study carried out by Fordham et al.168 The AG notes that only the utility values
used in the progressive state were the same as the utility values derived from DECISION.
The source of the utility values used in the Bayer HealthCare model7 was the EQ-5D data collected during
DECISION. No additional utility decrements associated with AEs were included in the model.
The use of utility values derived from EQ-5D data collected during clinical trials is in line with the approach
set out in the NICE Guide to the Methods of Technology Appraisal 2013.169
TABLE 16 Modelled therapies
Parameter Eisai Ltd’s model (lenvatinib) Bayer HealthCare’s model (sorafenib)
Lenvatinib Price: list price used in the CS; however, a
completed PAS submission template was made
available to the ERG during the review period
Daily dose: 17.4mg (based on SELECT data,
Eisai Ltd8). Treatment duration: SELECT TTD data
Price: list price
Daily dose: 17.4 mg (based on published data;8
estimate does not account for dose interruption)
Treatment duration: the sorafenib TTD K–M data
were adjusted to fit the SELECT median duration
of treatment
Sorafenib Price: MiMS price
Daily dose: 651 mg (based on data from
DECISION)
Treatment duration: assumed until disease
progression
Price: CMU price
Daily dose: 651 mg (based on data from
DECISION)
Treatment duration: DECISION TTD K–M data
(these data are complete and, therefore, no
extrapolation was required)
Placebo/BSC Assumption: no additional costs BSC is defined as concurrent use of radiotherapy
(10.6% in the sorafenib arm and 21.4% in the
placebo arm of DECISION)
Administration
cost
Deliver oral chemotherapy (SB11Z): £183.50 None
Subsequent
therapies
None (assumption based on expert advice)
CMU, Commercial Medicines Unit; CS, company submission; ERG, Evidence Review Group; MiMS, Monthly Index of
Medical Specialities; TTD, time to treatment discontinuation.
Note
Information drawn from Eisai Ltd8 (section 5.2) and Bayer HealthCare7 (section 4.2).
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Utility values
The utility values used in the companies’ models are provided in Table 19.
Health-care costs
Levels of resource use
Eisai Ltd obtained estimates of the level of health-care utilisation inputs for the pre-progression and
progressive disease states from physician surveys conducted in Europe; these estimates were then validated
by four practising clinical experts employed by NHS England. Mortality-related costs were obtained from
the Nuffield Trust173 and adjusted for inflation to 2016 values based on PSSRU171 inflation rates for 2016.
TABLE 17 Overall survival modelling
Model Lenvatinib Sorafenib Placebo/BSC
Eisai Ltd SELECT data from third data
cut-off point (August 2015)
extrapolated using piecewise
exponential curve
The curve, generated to represent
OS for patients receiving
sorafenib, was adjusted using the
HR generated by the company’s
ITC using data from the third
data cut-off points of DECISION
and SELECT (July 2015 and
August 2015, respectively)
SELECT data from third data
cut-off point (August 2015),
recensored and RPSFTM-




The curve, generated to represent
OS for patients receiving
sorafenib, was adjusted using the
HR generated by the company’s
ITC using data from the second
data cut-off points of SELECT and
DECISION (June 2014 and
May 2013, respectively)
DECISION data from second data
cut-off point (May 2013) allowed
a direct comparison. The data
were extrapolated using an
exponential distribution
DECISION-adjusted ITT data
from second data cut-off point
(May 2013) allowed a direct




Information drawn from Eisai Ltd8 (section 5.3) and Bayer HealthCare7 (section 4.3).
TABLE 18 Progression-free survival modelling
Model Lenvatinib Sorafenib Placebo/BSC
Eisai Ltd SELECT data from first data
cut-off point (November 2013)
extrapolated using piecewise
gamma curve
The curve, generated to represent
PFS for patients receiving
sorafenib, was adjusted using the
HR generated by the company’s
ITC using data from the third
data cut-off points of DECISION
and SELECT (July 2015 and
August 2015, respectively)
Not affected by crossover –
SELECT data from first data





The curve, generated to
represent PFS for patients
receiving sorafenib, was
adjusted using the HR
generated by the company’s ITC
using data from SELECT and
DECISION
DECISION data from second data
cut-off point (May 2013) allowed
a direct comparison. The data
were extrapolated using an
exponential distribution
DECISION data (May 2013 data
cut-off point) allowed a direct
comparison. The data from each
arm were extrapolated using
exponential distributions
Note
Information drawn from Eisai Ltd8 (section 5.3) and Bayer HealthCare7 (section 4.3).
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Expert advice from oncologists was the basis for Bayer HealthCare’s resource use estimates. Unit costs
were obtained from the NHS Reference Costs 2015 to 2016174 and the Unit Costs of Health and Social
Care 2016.171 In the model, it is assumed that resource use associated with treatment with lenvatinib is the
same as the resource use associated with treatment with sorafenib.
The monthly routine care costs used in both company models are provided in Appendix 10 (see Table 70).
Eisai Ltd’s routine costs included physician visits and disease-associated hospitalisation days. Bayer HealthCare’s
routine costs included inpatient stay, outpatient appointments and pharmaceutical costs.
Eisai Ltd’s end-of-life costs (£7450) included secondary care, local-authority-funded social care, district
nursing and GP contacts.
Adverse event costs
The Eisai Ltd model includes the following AEs:
l lenvatinib – grade 3 and 4 treatment-emergent AEs and AEs that required hospitalisation in SELECT
l sorafenib – grade 3 and 4 treatment-emergent AEs in DECISION and AEs that required hospitalisation
based on proportions from SELECT.
The Bayer HealthCare model7 only includes grade 3 and 4 AEs occurring in > 5% of patients in the
lenvatinib arm of SELECT or in the sorafenib arm of DECISION.
Bayer HealthCare also included AE management costs (per 28 days), see table 29 in the company
submission for details.7
Frequencies/rates and costs associated with AEs included in the company models are presented in
Appendix 10 (see Table 71). Eisai Ltd’s cost sources are a mix of NHS Reference Costs 2015 to 2016174 and
Unit Costs of Health and Social Care 2016.171 Bayer HealthCare’s cost sources are a mix of NHS Reference
Costs 2014 to 2015,175 Unit Costs of Health and Social Care 2015176 and British National Formulary
(BNF) costs.47
TABLE 19 Utility values
Health state Lenvatinib Sorafenib Placebo/BSC
Eisai Ltd’s model
Stable disease 0.76 0.68 0.77
Response 0.82 0.74 0.83
Progressive 0.64 0.64 0.64
Bayer HealthCare’s model
Progression-free 0.72 (SE 0.08) 0.72 (SE 0.08) 0.8 (SE 0.07)
Post progression 0.64 (SE 0.06) 0.64 (SE 0.06) 0.64 (SE 0.06)
SE, standard error.
Note
Information drawn from Eisai Ltd8 (table 18) and Bayer HealthCare7 (table 27).
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The base-case cost-effectiveness results from the Eisai Ltd8 and Bayer HealthCare7 submitted economic
models are shown in Table 20.
Bayer HealthCare also carried out cost-effectiveness analyses using the adjusted MAIC HRs. The effect
on the company’s ICERs was small. The resultant base-case ICERs per QALY gained for the comparison
of treatment with sorafenib with BSC and the comparison of treatment with lenvatinib with BSC are
commercial in confidence and cannot be reported.
Probability of being the most cost-effective
For the Eisai Ltd model, the PSA results suggest that, at a willingness-to-pay threshold of £50,000 per
QALY gained, the probability of lenvatinib being more cost-effective than sorafenib or BSC is 60%.
For the Bayer HealthCare model,7 the PSA results suggest that, at a willingness-to-pay threshold of £30,000
per QALY gained, the probability of sorafenib being cost-effective is 30%, the probability of BSC being
cost-effective is 54% and the probability of lenvatinib being cost-effective is 16%.
The PSA results from the Eisai Ltd and Bayer HealthCare submitted economic models are shown in Table 21.
Sensitivity and scenario analyses
Both companies carried out a range of deterministic sensitivity analyses and scenario analyses.
In the Eisai Ltd model, for the comparison of lenvatinib and sorafenib, the two most influential parameters
in the deterministic sensitivity analysis were OS HR versus sorafenib (lenvatinib dominates) and PFS HR versus
sorafenib (£5000 to £35,000 per QALY gained). In the scenario analyses, the most influential parameters
were the treatment duration for lenvatinib (treatment to progression rather than clinical trial duration;
£71,978 per QALY gained) and the cut-off point for OS and PFS extrapolation (20 weeks for OS and PFS;
£29,874 per QALY gained).
TABLE 20 Base-case pairwise comparisons
Technology
Total Incremental ICER per QALY gained
Costs (£) LYG QALYs Costs (£) LYG QALYs Deterministic
Eisai Ltd’s model results
Lenvatinib 107,182 4.34 3.18
Sorafenib 82,839 3.18 2.10 24,342 1.16 1.08 £22,491
Placebo/BSC 42,115 2.80 1.84 65,067 1.54 1.34 £48,569
Bayer HealthCare’s model results
Placebo/BSC CiC 3.49 2.35
Sorafenib CiC 4.79 3.16 CiC 1.30 0.81 CiC
Lenvatinib CiC 5.92 4.04 CiC 1.12 0.88 CiC
CiC, commercial in confidence; LYG, life-year gained.
Note
Information drawn from Eisai Ltd8 (table 31) and Bayer HealthCare7 (table 38).
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In the Bayer HealthCare model, for the comparison of sorafenib and lenvatinib, the largest deviations from
the base-case ICER per QALY gained were attributable to variation in the OS HR for lenvatinib and lower
lenvatinib progression-free utility. The scenario analyses that had the biggest effects on the companies’
cost-effectiveness results were the time horizon (reduction to 10 years) and lower lenvatinib progression-
free utility. The ICERs per QALY gained for these analyses are commercial in confidence and cannot be
reported here.
The Assessment Group’s independent cost-effectiveness assessment
Model design
In common with the two companies, the AG has used a standard partitioned survival model structure,
applied to the patient population specified in the final scope issued by NICE,53 to consider the
cost-effectiveness of treatment with lenvatinib and sorafenib compared with BSC (as represented by data
from the placebo arms of SELECT and DECISION).
Two particular differences should be noted:
1. The AG has not included a separate health state for patients who respond to treatment. On clinical
advice, the AG considers that there is little merit in this addition to the standard three-state structure
(in which patients begin in the progression-free health state and, following assessed disease progression,
transfer to the postprogression state in which they receive only BSC prior to death). For responding
patients, who are mostly symptom-free, response alone is unlikely to have a measurable effect on
patient-perceived quality of life/utility and has no effect on resource use.
2. The AG has designed a model that allows each intervention (lenvatinib and sorafenib) to be represented
in its natural time metric: 30-day cycles for lenvatinib and 28-day cycles for sorafenib. This involved
creating two parallel models using the same assumptions and model parameters, but each with its own
placebo arm calibrated from its respective clinical trial data. Although not ideal, the AG has provided
an illustrative structural sensitivity analysis (Figure 9) based on applying data from the counterfactual
placebo arm of both trials to illustrate the extent of uncertainty involved in comparisons between the
active treatments with the currently available clinical evidence. The reason for this unusual approach is
to demonstrate non-equivalence of the placebo arms of the two clinical trials, which renders indirect
comparison of the two treatments via a common comparator invalid (as discussed in Chapter 4, Indirect
comparison feasibility assessment, and illustrated graphically in Figure 9).
TABLE 21 The probabilistic cost-effectiveness results
Technology




gainedCosts QALYs Costs QALYs
Eisai Ltd’s model
Lenvatinib vs. sorafenib NS NS NS NS NS £21,578
Lenvatinib vs. placebo/BSC NS NS NS NS £48,683
Bayer HealthCare’s model (all based on results of indirect comparison)
BSC CiC 2.41 (1.00 to 5.19)
Sorafenib CiC 3.25 (1.81 to 5.30) CiC 0.84 CiC CiC
Lenvatinib CiC 4.11 (2.02 to 6.67) CiC 0.86 CiC CiC
CiC, commercial in confidence; NS, not stated.
Note
Information drawn from Eisai Ltd8 (table 34) and Bayer HealthCare7 (table 42).
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Resource use estimation, the sources for unit costs and selection of health-related utility values used in
the AG’s model are presented in this section. Standard discount rates of 3.5% per annum are used for
discounting both costs and benefits (measured as QALYs), but not for life-years (survival). The AG model
is structured with a maximum time horizon of 40 years.
Effectiveness data
Modelling long-term outcomes from trial data
Both companies have followed a conventional approach to the general problem of identifying an appropriate
method by which to extrapolate time-limited follow-up trial data for PFS, OS and time to treatment
discontinuation. This involves attempting to fit a range of prespecified statistical functions to the available
evidence, and selecting one that appears to be optimal according to particular ‘measures of fit’ (principally
the Akaike information criterion and the Bayesian information criterion).
This paradigm is wholly dependent on the limited data available and the restricted armoury of ‘standard’
models. In particular, it fails to take into account a wider evidence base specifically related to the natural
history of the disease, and the influence of particular characteristics of both the recruited patient group
and of the trial design.
The AG has investigated long-term survival trends in patients diagnosed with Stage 3 or 4 (locally advanced
or metastatic) thyroid cancer in the USA and recorded on the Surveillance Epidemiology and End Results
(SEER) database.177 A total of 32,818 patients (male and female) followed for 15 years yielded a persistent
trend from 18 months after diagnosis. Figure 10 demonstrates the very close match between these data and
a simple linear model, indicating that the risk of death remained unchanged throughout this period, which






FIGURE 9 Model structure featuring two simple trial-based comparisons, with additional cross-trial comparisons as
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FIGURE 10 Cumulative hazard data from follow-up of patients diagnosed with stage III/IV thyroid cancer for
15 years.
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This evidence is sufficiently compelling to give the AG confidence to employ exponential extrapolation as
the default method of modelling incomplete trial data in this appraisal. The nature of clinical trials (selecting
patients who have suffered a recent disease progression, and administering a novel treatment that takes
time to reach full effectiveness) means that the initial period post randomisation will give rise to temporary
distortions to the underlying disease process. However, thereafter, it is likely that the natural history of the
condition will be re-established, so that a long-term exponential function will reappear. The mean time since
diagnosis of patients randomised in DECISION was 7.24 years, suggesting that the trial cohort lies in the
middle of the follow-up range shown in Figure 10. The AG is therefore confident that outcome data
extrapolation should be focused on fitting exponential models to estimate lifetime survival expectation.
Data issues
Following the initial stakeholders’ meeting for this appraisal (17 February 2017), the AG submitted identical
requests to the two companies, asking for a set of detailed analyses of the latest data available from the
two clinical trials, based on common analytical methods to allow comparative analyses to be carried out by
the AG; thus, minimising the risk of methodological bias. Eisai Ltd provided the requested data relating to
SELECT as an appendix to the submission.8 Unfortunately, Bayer HealthCare chose not to address the AG’s
request. As a consequence, the AG was unable to conduct some comparative analyses based on common
assumptions, and the potential for bias and uncertainty in the data available to the AG remains.
The two clinical trials that provide the effectiveness evidence for this appraisal share common features,
which result in interpretive complexity and uncertainty. In particular, in both trials patients were permitted
to cross over from the placebo control to the active treatment (lenvatinib or sorafenib) following disease
progression. As a consequence, randomisation was broken in both trials and some outcome variables may
not be mutually compatible, even after attempts to adjust for crossover effects.
Both companies assume that, in addition to the active treatments, a third comparator (BSC) may be
represented by the placebo arms of the two trials. Moreover, it is implicitly assumed that the randomised
patients are drawn from similar populations with reference to their risk profile for the various time-to-event
outcomes measured [PFS, OS, postprogression survival (PPS) and time-to-treatment discontinuation]. In
Chapter 4, Indirect comparison feasibility assessment, the non-equivalence of PFS data from the placebo
arms of the two clinical trials has been clearly demonstrated. This is of crucial importance to attempts to
employ relative effectiveness measures reliant on the PHs assumption in relation to PFS, which is the only
standard outcome variable reported in these trials that is free from any contamination by crossover effects
(both trial protocols required confirmation of disease progression before patients were allowed to enter the
open-label phase in which patients in the placebo arm were offered crossover treatment).
The problem of devising a credible approach to indirect comparison between lenvatinib and sorafenib for
PFS cannot be resolved by appeal to technical argument alone. The pattern of hazard over time for disease
progression in the two active arms is sufficiently similar to justify a simple HR approach. However, the
placebo arms exhibit unexpectedly inconsistent patterns of temporal change, not compatible with the
assumption of similarity between the patient groups not receiving active treatment. The AG, therefore,
considers that the patients enrolled in the two trials cannot be considered to derive from a common
population. This degree of difference precludes the use of either placebo arm as being representative of
untreated patients across both trials.
The data for both placebo arms exhibit an unexpected improvement in long-term survival (reducing
progression hazard) for which there is no obvious explanation. The effect of this phenomenon is to
produce a varying differential in performance when comparing survival components across the two trials
without any clear confirmatory evidence. Therefore, the AG is unable to support the use of a conventional
ITC in this appraisal. The AG considers that it is preferable to model the relative effectiveness and
cost-effectiveness of each active treatment against its own placebo comparator, and then generate results
for each drug relative to the placebo of the other clinical trial as a sensitivity analysis, in order to allow
assessment of the uncertainty associated with the choice of comparator.
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Progression-free survival
The AG chose to use data for locally assessed PFS rather than centrally assessed PFS, as local assessment is
generally more closely related to normal clinical practice.
Lifetime mean PFS for patients in DECISION who received placebo may be readily estimated from trial data
(for the period available) and a simple exponential curve that conforms closely to the reported trial data
(Figure 11). The AG estimated lifetime mean PFS from the area under the K–M data to 16.5 months of
elapsed time followed by the area under the exponential function thereafter, giving a lifetime mean PFS
estimate of 7.56 months. The sorafenib PFS arm of DECISION exhibits a simple constant hazard (exponential)
relationship (see Figure 11), allowing the lifetime mean PFS to be estimated in a similar fashion, using the
area under the curve (AUC) of the K–M data until 25 months, and the exponential extrapolation thereafter.
This shows a lifetime mean PFS estimate of 47.18 months for patients receiving sorafenib, and a mean gain
in PFS of 39.62 months compared with receiving placebo.
The SELECT data for PFS exhibit a more complex pattern in each arm. The cumulative hazard plots (Figure 12)
reveal two distinct phases, both of which follow a constant hazard. Patients in the placebo arm who remain
progression-free after 312 days experience a reduction in hazard of about 53%, which is sustained thereafter.
Similarly, patients in the lenvatinib arm experience a reduction of progression hazard of about 47% at 529 days.
As before, the estimated mean lifetime PFS for these patient groups was estimated as the sum of the AUC in
each trial arm, followed by lifetime extrapolation using the long-term exponential hazard of progression or
death. This approach yields estimates of mean lifetime PFS of 41.00 months for patients receiving lenvatinib and
6.92 months for patients in the placebo arm of SELECT. Thus, the estimated net lifetime gain in PFS for patients
receiving lenvatinib is estimated to be 34.08 months.
Time to treatment discontinuation
As illustrated in Figure 13, the SELECT data are virtually complete for the cycles of lenvatinib dispensed
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FIGURE 11 Progression-free survival K–M data from DECISION modelled by an exponential function.
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The DECISION trial data are also complete for the cycles of sorafenib dispensed during the trial, as
illustrated in Figure 14. The AG estimates mean usage of sorafenib as 14.36 28-day cycles per patient.
Overall survival
Data provided by the company for lenvatinib-treated patients in SELECT (Figure 15) show a simple long-term
exponential trend indicating a constant mortality risk throughout the trial period (19.6% per year). This allows
the mean lifetime OS for patients treated with lenvatinib to be estimated using the AUC of the trial K–M curve
until 34.7 months plus a simple exponential extrapolation thereafter, giving a total mean OS of 55.1 months.
Both companies have employed RPSFTM adjustments to data from the placebo arms of their clinical trials
to correct for patients crossing over to the active treatment following disease progression. Adjusted OS
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FIGURE 13 The 30-day cycles of lenvatinib dispensed in SELECT.
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a similar long-term exponential (constant risk) trend also applies to the placebo arm beyond 6 months.
Using the AUC of the adjusted K–M curve until 19.1 months plus the exponential extrapolation thereafter
yields a lifetime estimated mean OS for the corrected placebo arm of 29.9 months and a net estimated
OS gain attributable to treatment with lenvatinib of 25.3 months.
An examination of the OS data from DECISION (Figure 16) indicates that both patients in both treatment
arms were subject to a period of relatively low mortality hazard, followed by transition to a higher constant
risk of death. This transition took place after 11.2 months for sorafenib patients and 6.4 months for
placebo patients.
Using the AUC of the RPSFTM-adjusted K–M curve for the placebo arm until 6.4 months plus the AUC


















































































FIGURE 15 Overall survival: lenvatinib-treated patients in SELECT with a fitted exponential model, and RPSFTM
adjusted for placebo patient crossover with a long-term exponential-fitted model.
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of 47.18 months. Similarly, combining the AUC of the sorafenib arm up to 11.96 months with the
exponential trend thereafter yields an estimated lifetime mean OS of 56.66 months. Thus, the net mean
OS gain attributable to sorafenib is 9.48 months.
Postprogression survival
Assessment of PPS may be carried out at an aggregate level by calculating the difference between model
estimates of OS and PFS. However, it can also be informative to consider this outcome at the level of
individual patients, at which it may provide useful insight into possible post-treatment long-term effects of
treatments even after active treatment has ceased. The AG asked both companies to provide PPS data
from their respective primary clinical trials. Unfortunately, only data from SELECT have been received.
As with OS, it is important to allow for the effects of crossover on PPS by using RPSFTM-adjusted data.
In Figure 17, the beneficial effect of crossover to lenvatinib for patients initially randomised to the placebo
arm is clearly apparent. Both trial arms exhibit a similar early pattern, albeit at different absolute levels of
survival, and thereafter show similar long-term exponential trends after 15 to 18 months from the time of
disease progression. When the RPSFTM adjustment is applied, the corrected placebo arm very closely
follows the trajectory of the lenvatinib arm (although the effect of RPSFTM revised censoring does not
allow direct comparison beyond 16 months). Nonetheless, these data suggest that, after crossover
adjustment, there is probably no additional benefit to individual patients crossing from placebo to
lenvatinib beyond what would have been gained by treatment prior to disease progression.
Summary of time-to-event outcome data analysis
Estimates of PFS, OS and PPS and mean cycles of active treatment received in the two clinical trials
are displayed in Table 22. The main difference occurs in the PFS results in which lenvatinib provides
substantially greater benefit than sorafenib (34.1 additional months before progression compared with
only 6.3 months, respectively). However, the estimated OS results are very similar (55.1 for lenvatinib vs.
56.8 months for sorafenib), and, consequently, estimated PPS is reduced with lenvatinib treatment but
increased for sorafenib treatment). Thus, it appears that lenvatinib shows effect more strongly in initially
delaying progression, but does not offer additional benefit over sorafenib in terms of long-term survival.
The duration of active treatment in the two trials is very similar when measured in days rather than cycles,








































FIGURE 16 Cumulative mortality hazard for sorafenib-treated patients in DECISION with a fitted two-phase
exponential model, and for RPSFTM-adjusted placebo patients with a fitted two-phase exponential model.
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Health-related utility data
The AG has carefully considered the opposing approaches used by the two companies to estimate
appropriate health-related utility values to assign to health states and to AEs. The Eisai Ltd model relies
heavily on the Fordham et al.168 vignette study (which it sponsored), whereas the Bayer HealthCare model
draws on EQ-5D-3L data collected during DECISION.
On theoretical grounds, directly collected evidence from patients with the condition (as used in the Bayer
HealthCare model7) should always be preferred to the results of an artificial study without recourse to the
views of patients either in design or calibration (as used in the Eisai Ltd model). Of particular concern is the
serious overestimation of baseline utility values in the Fordham et al.168 study when compared with UK
general population values for people of a similar age. The contrary position argues that DECISION data
include the disutility of AEs in estimates of health-state utilities, and, therefore, are biased without any
objective means of adjusting the health-state estimates.
On balance, the AG considers that the data from DECISION should be used in the base case (Table 23)
with a sensitivity analysis using the Eisai Ltd model values.
TABLE 22 The AG estimated mean time-to-event outcome variables
Study, treatment arm PFS (months) OS (months) PPS (months) TTD (cycles)
SELECT
Lenvatinib 41.0 55.1 14.1 12.6 (30-day cycle)
Placebo 6.9 30.2a 23.3 N/A
Change attributable to lenvatinib + 34.1 + 24.9 –9.2 N/A
DECISION
Sorafenib 13.8 56.8 42.9 14.4 (28-day cycle)
Placebo 7.6 43.8a 36.2 N/A
Change attributable to sorafenib + 6.3 + 13.0 + 6.7 N/A
N/A, not applicable; TTD, time to treatment discontinuation.











































FIGURE 17 Postprogression survival: lenvatinib in SELECT with a fitted exponential model, and RPSFTM adjusted for
placebo patient crossover with a long-term exponential-fitted model.
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Resource use and cost data used in the Assessment Group’s model
Active treatments (lenvatinib and sorafenib)
The lenvatinib full acquisition cost is £4311.00 per 30-day treatment (NHS Indicative Price, BNF June 2017).47
This is reduced by the SELECT dose intensity factor (72.5%) so the true cost per cycle is £3089.55.
The sorafenib full acquisition cost is £3576.56 per 28-day treatment (NHS Indicative Price, BNF June 2017).47
This is reduced by the DECISION dose intensity factor (81.40%) so the true cost per cycle is £2911.32.
There is no administration cost associated with either drug, both of which can be safely taken unsupervised.
The NHS Reference Costs174,175 figures quoted by both companies for administration of oral treatment relate
to particular drugs that may cause serious rapid-onset reactions, and so the patient must be monitored
following administration. Thus, it is not appropriate to use these costs when estimating the cost of either
sorafenib or lenvatinib.
Routine care costs
Table 24 summarises the schedule of itemised routine care tests, treatments and specialist visits identified
by the AG’s clinical advisor, in terms of use per quarter (3 months), per 28-day cycle and per 30-day cycle.
These items are considered to be applicable to all patients.
Adverse events
Three common AEs feature in the two company models for which treatment types and resource use were
estimated by the AG’s clinical advisor. The cost estimates shown in Table 25 are for only a single cycle
(28 days or 30 days) and take no account of AE episodes that do not resolve within that time or that
subsequently recur.
End-of-life care
Health-care costs during the last 90 days of life were estimated using the results presented in Table 9 of
the paper by Georghiou and Bardsley;173 costs were uplifted from 2010/11 to 2015/16 using the Hospital
and Community Heath Services inflation index178 as shown in Table 26.
Cost-effectiveness results
Deterministic cost–utility results from the AG model using public list prices are compared with submitted
results from the two companies in Tables 27 (vs. the Eisai Ltd model) and 28 (vs. the Bayer HealthCare
model). Overall, the estimates of incremental costs from the three models are not very different,
but estimates of outcomes (life-years and QALYs) show larger discrepancies across the models, reflecting
the different assumptions and estimation methods employed. The ICERs per QALY gained reported from
the AG model are substantially greater than those obtained from the Bayer HealthCare model, but the
Eisai Ltd’s model results show a much larger ICER per QALY gained for sorafenib versus BSC than that
obtained from either of the other models.
Inevitably, the relative economic performance of the treatments in all three models will change significantly
when final discounted acquisition prices are applied.
TABLE 23 The AG-preferred health-related utility values





PFS Lenvatinib/sorafenib 0.72 0.08 0.76/0.68 0.08
PFS BSC 0.80 0.07 0.80 0.019
PPS All 0.64 0.06 0.50 0.028
SE, standard error.
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TABLE 24 The AG-estimated mean routine care resource use and cost per patient
Resource item
Number
per quarter Unit cost (£) SE (£)
Reference cost (source: NHS Reference
Costs 2015 to 2016174)
Blood test 1 3.10 0.07 NHS Reference Cost DAPS05
Coagulation test 1 3.10 0.07 NHS Reference Cost DAPS05
Urine test 1 7.63 0.22 NHS Reference Cost DAPS07
Liver function test 7 1.18 0.03 NHS Reference Cost DAPS04
Thyroid function
test
3 1.18 0.03 NHS Reference Cost DAPS04
Protein test 1 1.18 0.03 NHS Reference Cost DAPS04
Bone scan 1 242.39 7.56 NHS Reference Cost NMOP/RN15A
MRI scan 1 204.67 5.07 NHS Reference Cost IMAGOP/RD03Z
CT scan 1 118.53 2.92 NHS Reference Cost IMAGOP/RD22Z
Thyroxine (4-weekly) 3.26 4.04 NS BNF NHS indicative prices
Calcium and
vitamin D
3 7.13 NS BNF NHS indicative prices
Specialist oncology
visit
1 162.84 4.37 NHS Reference Cost 370/WF01A







NS, not stated; SE, standard error.
TABLE 25 The AG-estimated AE resource use and treatment costs











10.00 (typical retail price) 20.29 3.45 0.00 0.00
Proteinuria 2.5 mg of
Ramipril × 28
0.27 (eMIT, April 2016179) 0.00 3.45 0.00 0.00
Hypertension 10mg of
Amlodipine × 28
0.19 (eMIT, April 2016179) 0.00 42.91 1.91 3.82
10mg of
Ramipril × 28




162.84 per visit (NHS
Reference Costs 2015 to
2016174)
0.00 42.91 1.91 3.82
Total cost (£)
Per 28 days 33.55 140.37 6.24 12.45
Per 30 days 35.95 150.40 6.69 13.34
eMIT, electronic market information tool.
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TABLE 26 The AG-estimated end-of-life (final 90 days) resource use and treatment costs
Care item Mean cost per patient (£) SE (£)
GP consultation 391.78 4.98
District nursing 631.14 53.77
Local authority social care 476.57 11.28
Emergency inpatient episode 4369.67 6.28
Non-emergency inpatient episode 1459.78 5.06
Outpatient attendance 405.73 1.10
Accident and emergency visit 85.87 0.15
Total 7820.54
GP, general practitioner; SE, standard error.
TABLE 27 Cost-effectiveness estimated results comparing the AG’s model and Eisai Ltd’s model using published
list prices47
Results component
AG’s model preferred scenario
Eisai Ltd’s model estimatesLenvatinib vs. BSC Sorafenib vs. BSC
Lenvatinib BSC Sorafenib BSC Lenvatinib Sorafenib BSC
Costs (£)
Drug acquisition 68,217 0 41,281 0 68,061b 37,267 0
Drug administration 0 0 0 0 0 0 0
Routine care 12,742 7495 13,227 10,523 31,022 38,937 35,582
AEs 7385 385 1833 274 107 21 0
End-of-life care 6758 7314 6848 7157 6316 6615 6532
Total 95,102 15,195 63,188 17,954 107,182 82,839 42,115
Life-years
Response (in PFS) yearsa N/A N/A N/A N/A 0.533 0.325 0.017
Progression-free yearsa 3.413 0.565 1.064 0.635 3.062 0.922 0.640
Postprogression yearsa 1.171 1.967 3.661 3.014 1.277 2.258 2.159
Totala 4.584 2.532 4.725 3.649 4.339 3.180 2.800
QALYs
PFS 2.182 0.446 0.755 0.504 2.380 0.746 0.447
PPS 0.633 1.156 1.997 1.720 0.800 1.351 1.393
Total 2.815 1.602 2.752 2.224 3.179 2.097 1.840
Incremental cost (£) 79,907 45,234 65,067 40,724 N/A
Incremental life-years 2.052 1.076 1.539 0.380 N/A
Incremental QALYs 1.213 0.528 1.339 0.257 N/A
ICER per QALY vs. BSC (£) 65,872 85,644 48,569 158,232 N/A
N/A, not applicable.
a Life-years undiscounted.
b AG-corrected half-cycle error.
Note
The AG drug costs are at list prices (no discounts).
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Structural sensitivity analysis
The AG cross-trial ICERs per QALY gained can be readily calculated by interchanging the results shown in
the two AG BSC columns of Tables 27 and 28. For sorafenib, this results in an incremental cost per patient
of £47,993 and incremental QALYs per patient of 1.150, leading to an exploratory ICER of £41,716 per
QALY gained. However, for lenvatinib, the incremental cost per patient is £77,148 and the incremental
QALYs per patient are 0.591, leading to an amended ICER of £130,592 per QALY gained.
These very large changes (an increase of 105% in the lenvatinib ICER per QALY gained, and a decrease of
54% in the sorafenib ICER per QALY gained) serve to illustrate that the choice of BSC comparator is of
major importance in this appraisal, and that the absence of credible indirect comparison results precludes
any simple resolution of this difficulty.
Deterministic sensitivity analyses
Sensitivity analyses have been conducted on the cost-effectiveness results obtained using the AG model
and the results from these analyses are shown in Tables 29–31.




Bayer HealthCare model estimatesLenvatinib vs. BSC Sorafenib vs. BSC
Lenvatinib BSC Sorafenib BSC Lenvatinib Sorafenib BSC
Costs (£)
Drug acquisition 68,217 0 41,281 0 41,641 33,187 0
Drug administration 0 0 0 0 0 0 0
Routine care 12,742 7495 13,227 10,523 46,018 37,886 25,695
AEs 7385 385 1833 274 141 81 17
End-of-life care 6758 7314 6848 7157 0 0 0
Total 95,102 15,195 63,188 17,954 87,800 71,154 25,712
Life-years
Response years N/A N/A N/A N/A N/A N/A N/A
Progression-free years 3.413 0.565 1.064 0.635 3.767 1.342 0.808
Postprogression years 1.171 1.967 3.661 3.014 3.589 4.381 3.161
Total life-yearsa 4.584 2.532 4.725 3.649 7.356 5.723 3.969
QALYs
PFS 2.182 0.446 0.755 0.504 2.394 0.920 0.628
PPS 0.633 1.156 1.997 1.720 1.645 2.237 1.724
Total 2.815 1.602 2.752 2.224 4.039 3.158 2.352
Incremental cost (£) 79,907 45,234 62,088 45,441 62,088
Incremental life-yearsa 2.052 1.076 3.487 1.754 3.487
Incremental QALYs 1.213 0.528 1.687 0.805 1.687




The AG drug costs are at list prices (no discounts).
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TABLE 29 Effects of non-stochastic uncertainty on estimated ICER per QALY gained
Treatment Source of uncertainty
AG-preferred scenario: cost
per QALY gained (£)
Option A Option B
Cost per QALY
gained (£)




Effect on ICER per
QALY gained (£)
Lenvatinib vs. BSC Discount rate – costs: A = 0%, B= 5% 65,872 70,033 4161 64,368 –1504
Discount rate – outcomes: A= 0%,
B= 5%
65,872 53,592 –12,280 71,274 +5402
Drug use data source: A= PFS,
B= least of TTD and PFS
65,872 106,178 +40,306 65,872 0
Drug dose intensity ratio: A= not
used
65,872 87,203 +21,331 N/A N/A
Utility value set: A= Eisai Ltd 65,872 54,981 –10,891 N/A N/A
Sorafenib vs. BSC Discount rate – costs: A = 0%, B= 5% 85,644 88,747 +3104 84,561 –1082
Discount rate – outcomes: A= 0%,
B= 5%
85,644 67,645 –17,999 93,751 +8108
Drug use data source: A= PFS, B least of
TTD and PFS
85,644 85,814 +170 83,076 –2568
Drug dose intensity ratio: A= not
used
85,644 103,503 +17,859 N/A N/A
Utility value set: A= Eisai Ltd 85,644 105,666 +20,023
N/A, not applicable; TTD, time to treatment discontinuation.
Note


























































































































































































Dose intensity ratio 65,872 63,892 –1980 67,852 +1980
Blood/coagulation
test cost
65,872 65,871 –2 65,874 +2
Urine test cost 65,872 65,871 –1 65,876 +4
Liver/thyroid/protein
test cost
65,872 65,870 –2 65,877 +5
Bone scan cost 65,872 65,792 –80 65,955 +83
CT scan cost 65,872 65,842 –30 65,905 +33
MRI scan cost 65,872 65,819 –53 65,928 +56
Oncology visit cost 65,872 65,524 –348 66,223 +351
Hand–foot syndrome
incidence: lenvatinib
65,872 65,866 –6 65,888 +15
Proteinuria
incidence: lenvatinib
65,872 65,873 +1 65,874 +2
Hypertension
incidence: lenvatinib




65,872 66,074 +202 65,431 –441
End-of-life care costs 65,872 65,883 +11 65,864 –8
PFS utility values 65,872 77,475 +11,603 42,352 –23,520
PPS utility values 65,872 60,739 –5133 71,956 +6084
PFS lenvatinib
hazard rate
65,872 63,127 –2745 63,853 –2019
PFS BSC hazard rate
(SELECT)
65,872 63,672 –2200 63,389 –2483
OS lenvatinib hazard
rate
65,872 63,231 –2641 63,791 –2081
OS BSC hazard rate
(SELECT)
65,872 68,374 +2502 65,455 –417
TTD lenvatinib
hazard rate
65,872 65,006 –866 63,201 –2671
LCL, lower confidence limit; TTD, time to treatment discontinuation; UCL, upper confidence limit.
Note
Bold text denotes variables modifying the estimated value by > £5000 per QALY gained.
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The AG identified five modelling issues, which do not involve stochastic uncertainty, and the implications,
in terms of changes to the size of the estimated ICER per QALY gained in the AG model, that result from
changes to these parameter values are shown in Table 29. Assuming that a change in the estimated
ICER per QALY gained of < £5000 is not considered substantial, all but one of the five issues generated
important changes in the ICER per QALY gained estimates for either sorafenib or lenvatinib (the exception
being the discount rate applied to costs).
The AG identified 18 parameter values for which stochastic uncertainty could be quantified in the AG
model, and the findings from adjusting these values are summarised in Tables 30 and 31. Only three
parameters (the utility values for the PFS and PPS health states estimated from EQ-5D-3L patient data in
DECISION, and the sorafenib OS AG extrapolation hazard) were found to lead to substantial effects on the


















Dose intensity ratio 85,644 83,009 –2635 88,278 +2635
Blood/coagulation
test cost
85,644 85,642 –2 85,645 +2
Urine test cost 85,644 85,643 –1 85,648 +5
Liver/thyroid/protein
test cost
85,644 85,641 –2 85,649 +6
Bone scan cost 85,644 85,549 –94 85,741 +98
CT scan cost 85,644 85,608 –35 85,682 +39
MRI scan cost 85,644 85,581 –63 85,710 +66
Oncology visit cost 85,644 85,446 –198 85,845 +201
Hand–foot syndrome
incidence: sorafenib
85,644 85,592 –51 85,710 +66
Hypertension
incidence: sorafenib




85,644 85,999 +355 84,782 –862
End-of-life care costs 85,644 85,657 +14 85,633 –10
PFS utility values 85,644 97,212 +11,568 59,422 –26,221
PPS utility values 85,644 95,450 +9806 77,668 –7976
PFS sorafenib hazard
rate
85,644 85,294 –349 85,367 –277
PFS BSC hazard rate
(DECISION)
85,644 85,298 –346 85,383 –261
OS sorafenib
hazard rate
85,644 78,853 –6790 92,528 +6884
OS BSC hazard rate
(DECISION)
85,644 89,074 +3430 82,063 –3581
LCL, lower confidence limit; TTD, time to treatment discontinuation; UCL, upper confidence limit.
Note
Bold text denotes variables modifying the estimated value by > £5000 per QALY gained.
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size of the estimated ICER per QALY gained when varied between the lower and upper 95% confidence
limits. In particular, the AG considers that uncertainty in specific unit costs (other than drug acquisition
costs) is not an important factor when generating uncertainty in ICER per QALY gained estimates.
Probabilistic sensitivity analyses
The AG carried out PSA varying model parameters subject to quantifiable stochastic sampling uncertainty:
l nine routine care cost variables
l seven AE incidence rates
l seven health-related utility values
l seven end-of-life health and social care costs.
In most cases, probabilistic values were drawn from normal distributions around the standard error of the
mean, except for incidence rates, for which beta distributions were employed.
Using list prices, the in-trial comparisons of lenvatinib and BSC (Figure 18) and of sorafenib and BSC
(Figure 19) yielded similar deterministic and probabilistic ICERs per QALY gained.
Unfortunately, information relating to the key outcome variables (PFS, OS and time to treatment
discontinuation) provided to the AG by one of the companies was not in the form requested, and
information on uncertainty in the estimated treatment dose intensity was not included by the other
company in its submission or their model. Without these key data items, it was not possible to incorporate
these important components of the normal PSA on this occasion. Therefore, the results presented below
should be treated with caution.
For the comparison of lenvatinib with BSC, the deterministic ICER is £65,872 per QALY gained and the
probabilistic ICER is £66,038 per QALY gained.
For the comparison of sorafenib with BSC, the deterministic ICER is £85,644 per QALY gained and the
probabilistic ICER is £83,547 per QALY gained.
The variation in additional cost per patient is much smaller relative to the uncertainty in outcomes (QALYs)
gained because of the dominance of drug acquisition costs, which constitute 85–90% of the incremental
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FIGURE 18 Probabilistic sensitivity analysis: lenvatinib vs. BSC in SELECT.
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Clearly, both treatments exhibit estimated ICERs well above £50,000 per QALY gained if list prices are
applied. This is confirmed by the cost-effectiveness acceptability curves (CEACs) presented in Figures 20
and 21. An examination of the CEACs shows that, compared with BSC, the probability of sorafenib being
cost-effective at a threshold of £50,000 per QALY gained is < 0.05% and the probability of lenvatinib
being cost-effective is 5.4%.
Discussion and summary of cost-effectiveness results
The comparison of data from the placebo arms of SELECT and DECISION indicated that the experience
of patients differed markedly for PFS, the principal outcome of both trials, to the extent that the PHs
assumption is violated. This invalidates the derivation and application of HRs in order to model an indirect
comparison to compare the effectiveness of lenvatinib with that of sorafenib. As a consequence, the
AG was only able to carry out separate economic assessments of each active treatment against its trial
comparator, using common methods and shared parameter values.
Sorafenib
BSC
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FIGURE 19 Probabilistic sensitivity analysis: sorafenib vs. BSC in DECISION.
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In order to assess the importance of the available placebo data (used to represent long-term BSC),
a structural sensitivity analysis was carried out substituting the placebo arm data from each trial as the
comparator for the intervention treatment. These analyses resulted in very large changes to the AG’s
estimated base-case ICERs per QALY gained, and confirmed the suspicion that the two trial populations
are not equivalent.
Using published list prices47 in the AG model, neither treatment was found to be cost-effective at a
willingness-to-pay threshold of £50,000 per QALY gained. Moreover, neither treatment meets the NICE
end-of-life criteria for special consideration [the AG analyses show that both are indicated to have a
lifetime mean estimated OS of 55 to 57 months, and a survival gain versus standard of care (BSC/placebo)
of > 9 months].
A comparison of the patterns of clinical effectiveness of the two treatments suggests that the proportion
of the average gain in PFS, which is subsequently translated to a gain in OS, is very different between the
treatments (73% for lenvatinib vs. 24% for sorafenib). This suggests quite different modes of action,
which may have important consequences for patients’ long-term prognoses.
The estimated mean time spent in the PFS and OS health states in the AG model show little difference
between the two active treatments, so that apparently different net outcome gains are mainly attributable
to large differences in the experience of patients in the comparator arms of the two trials. This consistency
of outcomes for the active treatments, and the apparently different modes of action, may suggest that
these treatments could be used sequentially to generate additional long-term benefit.
Assessment of factors relevant to the NHS and other parties
Lenvatinib and sorafenib are both MKIs and have been approved for use for treating RR-DTC in NHS
Scotland (contingent on the continuing availability of PAS prices). Sorafenib is currently available in NHS
England via the CDF. Therefore, it is not anticipated that, if recommended by NICE, the use of lenvatinib
and sorafenib would have major implications for NHS service provision, particularly as the administration
and AEs from both therapies are broadly in line with those of other TKIs already used to treat patients with
cancer in the NHS.
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FIGURE 21 Cost-effectiveness acceptability curves for lenvatinib vs. BSC (SELECT).
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Chapter 6 Discussion
Statement of principal findings
Clinical effectiveness results
The main sources of clinical effectiveness evidence were two good-quality RCTs (SELECT51 and DECISION52).
Results from these trials show that treatment with either lenvatinib or sorafenib statistically significantly
improves median PFS and ORR when compared with placebo. Median OS results demonstrate that there is
no statistically significant difference in effect when treatment with lenvatinib or sorafenib are compared
with placebo. Treatment crossover confounds the OS results from both trials and, to adjust for this effect,
OS data were modified using RPSFTM. The results from the adjusted analyses show that, when compared
with placebo, treatment with lenvatinib statistically significantly improves OS but there is still no statistically
significant improvement in OS from treatment with sorafenib. However, the AG considers that the assumption
of PH for unadjusted OS, adjusted OS and PFS is violated in SELECT and is violated for adjusted OS and PFS in
DECISION; therefore, these results should be interpreted with caution. Nonetheless, clinical advice to the AG
is that the improvements in PFS and the benefits from active treatment do appear to be clinically meaningful.
The AG considers that the improvements in OS and PFS for patients treated with lenvatinib and sorafenib
when compared with placebo are likely to reflect improvements in OS and PFS when compared with BSC,
notwithstanding the possible differences in the BSC received by the patients in the two trials.
The AG highlights that differences exist between the median OS and PFS results from the observational
studies,59,77,78,81,88,101,103,126,135,137 and those from SELECT and DECISION: OS for patients treated with
lenvatinib and sorafenib in SELECT and DECISION was longer than the OS reported in the observational
studies. In contrast, in DECISION, PFS for patients treated with sorafenib was shorter than for in any of the
prospective observational studies and the two meta-analyses.127,138 Median PFS for patients treated with
lenvatinib in SELECT was longer than suggested by the prospective, observational results from Study 20177
and shorter than in Study 208.135
Results from indirect comparisons and MAICs7,8,57,97 show that treatment with lenvatinib leads to better
PFS (but not OS) than treatment with sorafenib. The AG did not conduct an indirect comparison as
preliminary analyses suggested that using data from SELECT and DECISION in the same network would
generate unreliable results. The AG’s preliminary analyses showed that the PFS risk profiles (as demonstrated by
a comparison of K–M data) of the SELECT and DECISION populations receiving placebo were not comparable.
In addition, results from the AG’s analyses showed that, within SELECT and DECISION, the PH assumption
did not hold for the majority of survival outcomes. For data to be included in a network, the assumption of
PH should hold both across trials and within trials. The AG’s analyses have demonstrated that this assumption
is often violated. As a consequence of this violation, the AG has been unable to compare lenvatinib with
sorafenib. The AG considers that the relative clinical effectiveness of these two drugs cannot currently be
reliably determined.
As expected, both treatment with lenvatinib and with sorafenib resulted in more AEs than treatment
with placebo. Both all-grade and grade ≥ 3 diarrhoea were common for patients treated with lenvatinib
and those treated with sorafenib. However, the most common AE experienced by patients treated with
lenvatinib was hypertension and the most common AE experienced by patients treated with sorafenib
was hand–foot syndrome. Dose reductions were frequent for patients treated with lenvatinib (67.8%) and
for patients treated with sorafenib (64.3%). The results of published indirect comparisons97 suggest that
when treatment with sorafenib is compared with lenvatinib, the incidence of alopecia is higher but the
incidence of hypertension is reduced, and those treated with sorafenib experience fewer grade ≥ 3 AEs,
SAEs and withdrawals owing to AEs.
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The impact of treatment with lenvatinib on HRQoL was not assessed in SELECT and is, therefore,
unknown; this is a limitation of the trial given the difference in the safety profiles for some of the AEs
associated with lenvatinib and sorafenib. Sorafenib is reported7,120 to have a ‘mild’ negative impact on
patients’ HRQoL, possibly attributable to the high rates of AEs experienced by patients in DECISION.
Cost-effectiveness evidence
The two submitting companies and the AG agree that there are no published cost-effectiveness studies
relevant to the decision problem set out in the final scope issued by NICE.53 The AG considered that none
of the cost-effectiveness studies identified via the AG’s literature review were carried out from a NHS
England perspective and that, when treatment with lenvatinib and sorafenib were compared, the results
were based on the results of flawed indirect comparisons. In addition, the prices of the drugs reported
in the studies were generally not consistent with the discounted prices that will likely be charged
in the NHS in England. As a result of the absence of relevant published evidence, the AG developed a
de novo cost-effectiveness model for the specific purpose of this appraisal and carried out several
cost-effectiveness comparisons.
As the AG did not consider that it was appropriate to carry out an indirect comparison, the AG compared
the cost-effectiveness of treatment with lenvatinib with the cost-effectiveness of BSC (using data from
SELECT) and the cost-effectiveness of treatment with sorafenib with the cost-effectiveness of BSC (using
data from DECISION). The AG also compared the cost-effectiveness of each of the SELECT and DECISION
intervention drugs with BSC data from the other trial as a sensitivity analysis.
In the AG’s base-case analysis, using list prices only, the comparison of treatment with lenvatinib versus
BSC yields an ICER per QALY gained of £65,872, and the comparison of treatment with sorafenib versus
BSC yields an ICER per QALY gained of £85,644. The base-case deterministic and probabilistic results were
similar for both comparisons. The AG’s deterministic sensitivity analysis involved varying 18 parameters; the
results showed that none of the variations lowered the AG’s base-case ICERs to < £50,000 per QALY gained.
When the AG compared the cost-effectiveness of treatment with lenvatinib with the cost-effectiveness of
BSC (using placebo data from SELECT) and the cost-effectiveness of treatment with sorafenib with the
cost-effectiveness of BSC (placebo data from DECISION), the ICERs per QALY gained were approximately
doubled (£130,592) and halved (£41,716), respectively. These results confirm that the choice of BSC
comparator is hugely influential in this appraisal.
Strengths and limitations of the assessment
Strengths
A key strength of this review is that it has brought together all of the available relevant evidence (RCTs,
observational studies, systematic reviews, indirect comparisons and cost-effectiveness studies) for assessing
the clinical and cost-effectiveness of treatment with lenvatinib versus sorafenib in patients with RR-DTC.
The wide array of clinical results available demonstrate that treatment with lenvatinib is more effective
when compared with placebo/BSC for all patients and that prior VEGFR-targeted therapy (or even a
treatment delay) does not influence the potential for a patient to benefit from treatment.
Another strength of the research is the AG’s detailed investigation of the PFS (and OS) risk profiles of the
patients in the two main trials. The AG’s analytical critique shows that the assumptions of PH underpinning
the indirect comparison calculations are violated and explains why data from these two trials should not
be compared in an indirect comparison. The AG’s critique challenges the validity of published indirect
comparison results7,8,57,97 as well as those from published economic evaluations7,8,38,160,162 that have used
indirect comparison results in their analyses.
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The results from the AG’s economic analyses demonstrate that the choice of BSC comparator has a big
influence on the size of the estimated ICERs per QALY gained.
Limitations
The main limitation of this review is that the AG was unable to compare the clinical effectiveness and
cost-effectiveness of lenvatinib with those of sorafenib. The AG did not consider that it was appropriate to
conduct an indirect comparison because of key differences in the intervention and placebo arms of SELECT
and DECISION (both within and across the trials) and because the results of AG analyses demonstrated that
the risk profiles of the patients in the placebo arms were different. Therefore, the AG concluded that it was
not possible to determine the comparative clinical effectiveness and cost-effectiveness of lenvatinib versus
sorafenib; this is problematic as lenvatinib and sorafenib are two relatively new treatments that appear to
work well compared with placebo/BSC for patients with RR-DTC who have limited treatment options.
Uncertainties
Although it is recommended4,23–25 that only patients who are symptomatic and/or have rapidly progressing
disease are treated with lenvatinib or sorafenib, it is unclear how many patients in SELECT and DECISION
met these criteria. As there are no universally accepted objective criteria for describing patients who are
symptomatic and/or rapidly progressing, it is difficult to retrospectively identify these groups of patients
with any confidence.
Therefore, it is unclear whether or not the efficacy findings from SELECT and DECISION differ in patients
who are symptomatic and/or rapidly progressing compared with those who are not. It is also unknown
whether or not the frequency and type of AEs differ between these groups of patients and/or whether
patient HRQoL is also influenced by symptom status.
There is considerable uncertainty around the HRQoL of patients with RR-DTC in general. Although it
appears that treatment with sorafenib may have a ‘mild’ negative impact on HRQoL, the HRQoL data
collected during DECISION were limited. As HRQoL data were not collected as part of SELECT, the impact
of treatment with lenvatinib on HRQoL, whether positive or negative, is unknown. To what extent a
patient’s HRQoL is affected by their symptom status (symptomatic vs. asymptomatic) is also unknown.
Although, for patients with RR-DTC, RCT evidence has shown clinically meaningful improvements in PFS
for those treated with lenvatinib and sorafenib compared with placebo, the question remains whether
treatment with lenvatinib or sorafenib can deliver a true OS benefit to patients. The adjusted RPSFTM OS
estimates suggest that this may be the case for patients treated with lenvatinib but not for patients treated
with sorafenib.
Other relevant factors
The AG considers that it is important to reiterate that the cost–utility analyses presented in this MTA report
are based on list prices only. As lenvatinib has a confidential PAS price and sorafenib has a confidential
Commercial Unit Access price, the cost-effectiveness comparisons presented in this AG report cannot be
used as the basis for decision-making. The AG provided cost-effectiveness results generated using the
discounted prices for lenvatinib and sorafenib in a confidential appendix presented to NICE.
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Compared with placebo, treatment with lenvatinib or sorafenib results in an improvement in PFS, ORRand, possibly, OS. However, compared with placebo, both drugs also increase the incidence of AEs,
in particular hypertension, hand–foot syndrome and diarrhoea. Dose reductions with both drugs are,
therefore, frequently required.
The AG considers that it is not possible to compare the clinical effectiveness or cost-effectiveness of
lenvatinib with those of sorafenib. Primarily, this is because the risk profiles of the patients in the placebo
arms of SELECT and DECISION do not appear to be comparable.
Using list prices, compared with BSC, both treatments exhibit estimated ICERs of > £50,000 per QALY
gained. Compared with BSC, the probability of sorafenib being cost-effective at a threshold of £50,000
per QALY gained is < 0.05% and the probability of lenvatinib being cost-effective is 5.4%.
Suggested research priorities
In order of priority, the AG suggests the following further research priorities:
1. Head-to-head RCT evidence.
i. Clinical advice to the AG is that only RR-DTC patients experiencing symptoms, or those who have
clinically significant progressive disease, are likely to be treated in routine clinical practice. Subgroup
analyses suggest that the effects on PFS are similar for patients treated with sorafenib regardless of
whether they are symptomatic or asymptomatic. However, these findings are post hoc and include
only a minority of symptomatic patients. It is unclear if other outcomes, such as OS, ORR, AEs and
HRQoL, differ by symptomatic or asymptomatic disease. Future studies of patients should aim to
include a greater proportion of patients with symptomatic disease and investigate possible differences.
Consideration should be given to using the classification of patients as symptomatic or asymptomatic
as a randomisation stratification factor.
ii. It would be useful to record, and report, HRQoL outcomes from any future clinical study of
lenvatinib and sorafenib. In particular, data should be collected, using the EQ-5D questionnaire,
throughout the whole trial period, not only from patients whose disease has not progressed. Further
research on HRQoL from treating patients who have symptomatic disease compared with those who
do not is also required.
iii. Currently, evidence does not allow a comparison of the effectiveness of treatment with lenvatinib
with the effectiveness of treatment with sorafenib. A head-to-head trial considering these treatments
and placebo would generate results that would be valuable to decision-makers.
iv. It would be useful to explore how lenvatinib, sorafenib and BSC should be positioned in the treatment
pathway.
2. Statistical research.
i. The AG considers that it is important to explore more than just standard differences in participant
and trial characteristics when considering the heterogeneity of studies that may be included in an
indirect comparison. The AG suggests that, before undertaking an indirect comparison, the risk
profiles of patient populations for the relevant outcome should be checked to confirm that they are
proportional both within and across all trials that are being considered for inclusion in the network.
This assessment would avoid generating indirect comparison results that are of unknown reliability.
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Appendix 1 Literature search strategies
This appendix is reproduced with permission from Fleeman et al.54 This is an Open Access articledistributed in accordance with the terms of the Creative Commons Attribution (CC BY 4.0) license,
which permits others to distribute, remix, adapt and build upon this work, for commercial use, provided
the original work is properly cited. See: http://creativecommons.org/licenses/by/4.0/. The text below
includes minor additions and formatting changes to the original text.
Search strategies for evidence of clinical effectiveness
EMBASE
Date searched: 10 January 2017.
Search from 1980 to 2017 week 2.
1 exp Thyroid Neoplasms/
2 ((thyroid* or papillar* or follicular*) adj4 (Neoplasm* or Cancer* or Carcinoma* or Adenocarcinom* or Tumour* or
Tumor* or Malignan* or Lump* or adenoma*)).tw.
3 (DTC or FTC or PTC).tw.
4 adenocarcinoma, follicular/ or carcinoma, papillary, follicular/ or adenocarcinoma, papillary/
5 1 or 2 or 3 or 4
6 (Lenvatinib or Lenvima or E7080).tw.
7 (Nexavar or Sorafenib or bay439006).tw.
8 lenvatinib/
9 sorafenib/
10 6 or 7 or 8 or 9
11 5 and 10
12 limit 11 to yr=‘1999 -Current’
MEDLINE
Date searched: 10 January 2017.
1 exp Thyroid Neoplasms/
2 ((thyroid* or papillar* or follicular*) adj4 (Neoplasm* or Cancer* or Carcinoma* or Adenocarcinom* or Tumour* or
Tumor* or Malignan* or Lump* or adenoma*)).tw.
3 (DTC or FTC or PTC).tw.
4 adenocarcinoma, follicular/ or carcinoma, papillary, follicular/ or adenocarcinoma, papillary/
5 1 or 2 or 3 or 4
6 (Lenvatinib or Lenvima or E7080).tw.
7 (Nexavar or Sorafenib or bay439006).tw.
8 6 or 7
9 5 and 8
10 limit 9 to yr=‘1999 -Current’
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PubMed
Date searched: 10 January 2017.
#1 Search (((thyroid* or papillar* or follicular*))) AND ((Neoplasm* or Cancer* or Carcinoma* or Adenocarcinom* or
Tumour* or Tumor* or Malignan* or Lump* or adenoma*))
#2 Search (DTC or FTC or PTC)
#3 Search (#1 or #2)
#4 Search (Lenvatinib or Lenvima or E7080 or Nexavar or Sorafenib or bay439006)
#5 Search (#3 and #4)
#6 Search (‘2016/07/01’[Date - Entrez] : ‘3000’[Date - Entrez])
#7 Search (#5 and #6)
The Cochrane Library (Cochrane Database of Systematic Review/Cochrane Central
Register of Controlled Trials/Database of Abstracts of Reviews of Effects/Health
Technology Assessment Database)
Date searched: 10 January 2017.
#1 MeSH descriptor: [Thyroid Neoplasms] explode all trees
#2 ((thyroid* or papillar* or follicular*) near/4 (Neoplasm* or Cancer* or Carcinoma* or Adenocarcinom* or Tumour*
or Tumor* or Malignan* or Lump* or adenoma*))
#3 (DTC or FTC or PTC)
#4 MeSH descriptor: [Adenocarcinoma, Follicular] explode all trees
#5 MeSH descriptor: [Carcinoma, Papillary, Follicular] explode all trees
#6 MeSH descriptor: [Adenocarcinoma, Papillary] explode all trees
#7 #1 or #2 or #3 or #4 or #5 or #6
#8 (Lenvatinib or Lenvima or E7080)
#9 (Nexavar or Sorafenib or bay439006)
#10 #8 or #9
#11 #7 and #10 Publication Year from 1999 to 2017
Economic filter for database search
EMBASE
Date searched: 10 January 2017.
1 exp Thyroid Neoplasms/
2 ((thyroid* or papillar* or follicular*) adj4 (Neoplasm* or Cancer* or Carcinoma* or Adenocarcinom* or Tumour* or
Tumor* or Malignan* or Lump* or adenoma*)).tw.
3 (DTC or FTC or PTC).tw.
4 adenocarcinoma, follicular/ or carcinoma, papillary, follicular/ or adenocarcinoma, papillary/
5 1 or 2 or 3 or 4
6 (Lenvatinib or Lenvima or E7080).tw.
7 (Nexavar or Sorafenib or bay439006).tw.
8 lenvatinib/
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9 sorafenib/
10 6 or 7 or 8 or 9
11 5 and 10
12 limit 11 to yr=‘1999 -Current’
13 Socioeconomics/
14 Cost benefit analysis/
15 Cost effectiveness analysis/




20 Health care cost/
21 Health care financing/
22 Health economics/
23 Hospital cost/
24 (fiscal or financial or finance or funding).tw.
25 Cost minimization analysis/
26 (cost adj estimate$).mp.
27 (cost adj variable$).mp.
28 (unit adj cost$).mp.
29 or/13-28
30 12 and 29
MEDLINE
Date searched: 10 January 2017.
1 exp Thyroid Neoplasms/
2 ((thyroid* or papillar* or follicular*) adj4 (Neoplasm* or Cancer* or Carcinoma* or Adenocarcinom* or Tumour* or
Tumor* or Malignan* or Lump* or adenoma*)).tw.
3 (DTC or FTC or PTC).tw.
4 adenocarcinoma, follicular/ or carcinoma, papillary, follicular/ or adenocarcinoma, papillary/
5 1 or 2 or 3 or 4
6 (Lenvatinib or Lenvima or E7080).tw.
7 (Nexavar or Sorafenib or bay439006).tw.
8 6 or 7
9 5 and 8
10 Economics/
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15 Cost savings/
16 Cost of illness/
17 Cost sharing/
18 ‘deductibles and coinsurance’/
19 Medical savings accounts/
20 Health care costs/
21 Direct service costs/
22 Drug costs/




27 Value of life/
28 exp economics, hospital/
29 exp economics, medical/
30 Economics, nursing/
31 Economics, pharmaceutical/
32 exp ‘fees and charges’/
33 exp budgets/
34 (low adj cost).mp.
35 (high adj cost).mp.
36 (health?care adj cost$).mp.
37 (fiscal or funding or financial or finance).tw.
38 (cost adj estimate$).mp.
39 (cost adj variable).mp.
40 (unit adj cost$).mp.
41 (economic$ or pharmacoeconomic$ or price$ or pricing).tw.
42 or/10-41
43 9 and 42
The Cochrane Library (NHS Economic Evaluation Database)
Date searched: 10 January 2017.
#1 MeSH descriptor: [Thyroid Neoplasms] explode all trees
#2 (thyroid* near/4 (Neoplasm* or Cancer* or Carcinoma* or Adenocarcinom* or Tumour* or Tumor* or Malignan* or
Lump* or adenoma*))
#3 DTC or FTC or PTC
#4 #1 or #2 or #3
#5 (Lenvatinib or Lenvima or E7080 or Nexavar or Sorafenib or bay439006)
#6 #4 and #5
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EconLit
Date searched: 10 January 2017.
(thyroid* N4 (Neoplasm* or Cancer* or Carcinoma* or Adenocarcinom* or Tumour* or Tumor* or
Malignan* or Lump* or adenoma*))
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Appendix 2 Table of excluded studies with
rationale
The studies excluded by the AG at screening stage 2 are summarised in Table 32.
TABLE 32 References excluded at screening stage 2 (full-text stage)
Study and year of publication Reason for exclusion
Abbadessa et al. 2006180 Wrong study design
Alonso-Gordoa et al. 2015181 Wrong study design
Andrews 2013182 Wrong study design
Anonymous 2013183 Wrong study design
Anonymous 2013184 Wrong study design
Anonymous 2014185 Wrong study design
Anonymous 2015186 Wrong study design
Anonymous 2015187 Wrong study design
Anonymous 2016188 Wrong study design
Anonymous 2016189 Wrong study design
Antonelli 2014190 Wrong study design
Baudin et al. 2005191 Wrong study design
Belum et al. 2015192 Wrong population
Benvenga 2011194 Wrong study design
Bernet and Smallridge 2014195 Wrong study design
Bible 2012196 Wrong study design
Bikas et al. 2016197 Wrong study design
Blair and Plosker 2015198 Wrong study design
Boudou-Rouquette 2015199 Wrong study design
Bradford Carter et al. 2011200 Wrong study design
Brose 2009201 Wrong study design
Brose et al. 2015156 Wrong study design
Butler 2015202 Wrong study design
Cabanillas and Habra 2016203 Wrong study design
Cabanillas et al. 2011204 Wrong study design
Capdevila et al. 2010205 Wrong study design
Cappagli et al. 2011206 Wrong study design
Clayman 2015207 Wrong study design
Cooper et al. 2009208 Wrong study design
Corrado et al. 2017209 Wrong study design
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TABLE 32 References excluded at screening stage 2 (full-text stage) (continued )
Study and year of publication Reason for exclusion
Costa et al. 2016210 Wrong study design
Covell and Ganti 201542 Wrong study design
Cully 2015211 Wrong study design
De La Fouchardiere et al. 2013212 Wrong study design
De Lartigue 2015213 Wrong study design
Deshpande et al. 2008214 Wrong study design
Dezso 2015215 Wrong study design
Droz et al. 2010216 Wrong study design
Duntas and Bernardini 2010217 Wrong study design
Fala 2015218 Wrong study design
Fallahi et al. 2013219 Wrong study design
Féliz and Tsimberidou 2013220 Wrong population
Funakoshi 2013221 Wrong population
Gadaleta-Caldarola et al. 2015222 Wrong study design
Ghatalia et al. 2015223 Wrong population
Ghatalia et al. 2015 224 Wrong population
Giuffrida et al. 2012225 Wrong population
Gyawali et al. 2016226 Wrong population
Haddad 2014227 Wrong study design
Hannallah et al. 2013228 Wrong study design
Haraldsdottir and Shah 2014229 Wrong study design
Hasskarl 2014230 Wrong study design
Haugen et al. 201624 Wrong study design
Hesselink 2014231 Wrong population
Hewett et al. 2018232 Wrong study design
Ho and Sherman 2011193 Wrong study design
Hodak and Carty 2009233 Wrong study design
Hoftijzer et al. 2011234 Wrong study design
Hong et al. 2010235 Wrong population
Hong et al. 2014236 Wrong population
Ibrahim et al. 2012237 Wrong study design
Ito et al. 2016238 Wrong study design
Iwasaki et al. 2015239 Wrong study design
Iwasaki et al. 2016240 Wrong intervention (no data for lenvatinib or sorafenib alone)
Iyer et al. 2010241 Wrong study design
Kapiteijn et al. 2012242 Wrong population (too broad)
Killock 2015243 Wrong study design
Klein Hesselink et al. 2015244 Wrong population (too broad)
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TABLE 32 References excluded at screening stage 2 (full-text stage) (continued )
Study and year of publication Reason for exclusion
Kojic et al. 2012245 Wrong study design
Krajewska and Jarzab 2014246 Wrong study design
Krajewska et al. 2015247 Wrong study design
Krajewska et al. 2016248 Wrong study design
Krajewska et al. 2015249 Wrong study design
Launay-Vacher et al. 2015250 Wrong study design
Lerch and Richter 2012251 Wrong population (too broad)
Liu et al. 2016252 Wrong population (too broad)
Liu et al. 2014253 Wrong study design
Lorusso and Newbold 2015254 Wrong study design
Lorusso et al. 2016255 Wrong study design
Ma et al. 2015256 Wrong population
Majethia et al. 2016257 Wrong study design
Marotta et al. 2013148 Wrong study design
Mayor 2015258 Wrong study design
Moreo et al. 2016259 Wrong population
Nair et al. 2015260 Wrong study design
Nixon et al. 2013261 Wrong study design
Okamoto et al. 2015262 Wrong study design
Pacini et al. 2009263 Wrong study design
Pall 2013264 Wrong study design
Pall 2014265 Wrong study design
Pfister and Fagin 2008266 Wrong study design
Puxeddu et al. 2011267 Wrong study design
Qi et al. 2013268 Wrong intervention (no data for lenvatinib or sorafenib alone)
Qi et al. 2013269 Wrong intervention (no data for lenvatinib or sorafenib alone)
Qi et al. 2014270 Wrong intervention (no data for lenvatinib or sorafenib alone)
Ramadan et al. 2012271 Wrong study design
Sacks and Braunstein 201434 Wrong study design
Safavi 2012272 Wrong population
Saiyed et al. 2015273 Wrong population
Schlumberger 2010274 Wrong study design
Schlumberger 2011275 Wrong study design
Schutt and Eberhardt 2010276 Wrong population
Sherman 2008277 Wrong study design
Sherman 2009278 Wrong study design
Sherman et al. 2012279 Wrong intervention (not sorafenib monotherapy)
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TABLE 32 References excluded at screening stage 2 (full-text stage) (continued )
Study and year of publication Reason for exclusion
Sherman et al. 2013280 Wrong intervention (not sorafenib monotherapy)
Sherman et al. 2015281 Wrong intervention (not sorafenib monotherapy)
Shojaei 2012282 Wrong study design
Smit et al. 2016283 Wrong study design
Takahashi 2014284 Wrong study design
Terada et al. 2015285 Wrong study design
Thanigaimani et al. 2011286 Wrong study design
Tracy and Roman 2016287 Wrong study design
Tremblay et al. 2015288 Wrong study design (reports the findings from a matched ITC but no reporting
of a systematic review)
Tremblay et al. 2015289 Wrong study design [reports the findings (number needed to treat) from an ITC
but no reporting of a systematic review]
Tremblay et al. 2015290 Wrong study design (reports the findings from a matched ITC but no reporting
of a systematic review)
Tremblay et al. 2016291 Wrong study design (cost-effectiveness methods paper)
Tsimberidou et al. 2009292 Wrong interventions
Tu et al. 2016293 Wrong study design
Tuttle and Leboeuf 2007294 Wrong study design
Tuttle et al. 2014295 Wrong study design
Vetter 2014296 Wrong study design
Wagner et al. 2015297 Wrong study design
Warpakowski 2014298 In German
Wendling 2013299 Wrong study design
Wirth 2015300 Wrong study design
Wong and Lang 2012301 Wrong study design
Worcester 2015302 Wrong study design
Yang et al. 2015303 Wrong population
Yang et al. 2017304 Wrong population
Yeung and Cohen 2015305 Wrong study design
Yimaer et al. 2016306 Wrong population
Zhu et al. 2016307 Wrong population
Zygulska et al. 2013308 Wrong study design
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Appendix 3 Data extraction tables from
randomised controlled trials not presented in the
main body of the report




Inclusion l Adults with histologically or cytologically
confirmed diagnosis of DTC
l Measurable disease as confirmed by central
radiographic review within the past 13 months
l Radioactive iodine-refractory/resistant
(see Table 34 for definition)
l Disease progressed within 12 (+ 1) months
according to RECIST 1.1, assessed and confirmed by
central radiographic review of CT and/or MRI scans
l ECOG PS 0 to 2
l None or one prior VEGFR-targeted therapy
l Adequately controlled blood pressure with or
without antihypertensive medications
l Adequate bone marrow, blood coagulation,
liver and renal function
l Adults with differentiated and poorly DTC
l One or more measurable lesion by CT or MRI
according to RECIST 1.0
l Disease progressed within the past 14 months
according to RECIST 1.0
l Radioactive iodine resistant (see Table 34 for
definition)
l ECOG PS of 0–2
l Patients must not be candidates for curative
surgery or radiation therapy
l Adequate TSH suppression (< 0.5 mlU/L)
l Adequate bone marrow, liver and renal function
Exclusion l Anaplastic or medullary carcinoma of the thyroid
l Active malignancy (except for differentiated
thyroid carcinoma, or definitively treated
melanoma in-situ, basal or squamous cell
carcinoma of the skin, or carcinoma in situ of the
cervix) within the past 24 months
l Prior treatment with lenvatinib
l Two or more prior VEGFR-targeted therapies or
any ongoing treatments for RR-DTC other than
TSH-suppressive thyroid hormone therapy
l Major surgery within 3 weeks prior to the first
dose of study drug
l Patients with urine protein of ≥ 1 g/24 hours
l Gastrointestinal malabsorption or any other
condition that might affect the absorption of
lenvatinib in the opinion of the investigator
l Significant cardiovascular impairment
l Prolongation of QTc to > 480ms
l Bleeding or thrombotic disorders or use of
anticoagulants, such as warfarin, or similar agents
requiring therapeutic international normalised
ratio (INR) monitoring (treatment with
low-molecular-weight heparin is allowed)
l Active haemoptysis within 3 weeks prior to the
first dose of study drug
l Active infection (any infection requiring treatment)
l Any medical or other condition that, in the
opinion of the investigator, would preclude
participation in a clinical trial
l Women who are pregnant or breastfeeding
l Known intolerance to any of the study drugs
(or any of the excipients)
l Concurrent cancer distinct in primary site or
histology from thyroid cancer ≤ 5 years prior to
randomisation (except for cervical cancer in situ,
treated basal cell carcinoma, and superficial
bladder tumours) and patients with foci of
undifferentiated thyroid cancer
l Patients who had received previous targeted
therapy, thalidomide, or chemotherapy for thyroid
cancer (low-dose chemotherapy for radio
sensitisation was allowed)
l Patients who undergo major surgery, open biopsy
or significant traumatic injury ≤ 30 days prior
to randomisation
l Presence of a non-healing wound, ulcer, bone
fracture, or grade ≥ 2 infection according to
NCI-CTCAE v3.0309
l Grade ≥ 3 haemorrhage or bleeding event
according to NCI-CTCAE ≤ 3 months prior
to randomisation
l Evidence or history of bleeding diathesis or
coagulopathy; or the presence of tracheal, bronchial
or oesophageal infiltration with significant risk of
bleeding (but without having received local treatment
prior to enrolment in the study)
l Patients with clinically significant cardiac disease
and/or uncontrolled hypertension (> 150/90 mmHg)
despite optimal treatment
l Patients known to be infected with HIV or hepatitis B
or C virus
l Women who are pregnant or breastfeeding
l Patients with a known or suspected allergy to
sorafenib or hypersensitivity to sorafenib or any
agent given during the course of the study
HIV, human immunodeficiency virus; NCI-CTCAE, National Cancer Institute Common Terminology Criteria for Adverse Events;
QTc, QT corrected interval.
Note
Information drawn from Schlumberger et al.,51 including supplementary material (protocol), Brose et al.52,72
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required to meet at
least one of the
criteria specified
l At least one measurable lesion that does
not demonstrate iodine uptake on any
radioactive iodine scan
l At least one measurable lesion that had
progressed, according to RECIST 1.1,
within 12 months of radioactive iodine
therapy, despite demonstration of
radioiodine avidity at the time of that
treatment by pre- or post-treatment
scanning (these were patients who were
not eligible for possible curative surgery)
l Cumulative activity of radioactive iodine
of > 600mCi or 22 GBq, with the last
dose administered ≥ 6 months prior to
study entry
l At least one target lesion without iodine
uptake
l Tumours had iodine uptake and progressed
after one radioactive iodine treatment
[≥ 3.7 GBq (≥ 100mCi)] within the past
16 months
l Disease progression after each of two
radioactive iodine treatments [≥ 3.7 GBq
(≥ 100mCi)] within 16 months of each other
(with the last such treatment administered
> 16 months ago)
l Cumulative radioactive iodine activity of
≥ 22.2 GBq (≥ 600mCi)
GBq, gigabecquerels; mCi, millicurie.
Note
Information drawn from Schlumberger et al.,51 including supplementary material (protocol), Brose et al.52,72






Permitted l Thyroxine suppression therapy
l Over-the-counter medications
l Treatment of complications or AEs or
therapy to ameliorate symptoms
(including blood products, blood
transfusions, fluid transfusions,
antibiotics and antidiarrheal drugs) may
be given at investigator discretion, unless
expected to interfere with the evaluation
of (or to interact with) study drug
l Aspirin, nonsteroidal anti-inflammatory
drugs and low-molecular-weight heparin
are permissible but should be used
with caution
l G-CSF or equivalent may be used in
accordance with ASCO, institutional or
national guidelines
l Erythropoietin may be used according
to ASCO, institutional or national
guidelines, but the patient should be
carefully monitored for increases in red
blood cell counts
l Thyroid hormone replacement with
suppressed TSH levels (target of < 0.5 mU/l)
l Treatment with non-conventional therapies
(e.g. herbs with the exception of Saint John’s
wort or acupuncture) and vitamin/mineral
supplements provided that they do not
interfere with the study end points, in the
opinion of the investigator
l Bisphosphonate treatment in patients
with bone metastasis at discretion of the
investigator
l G-CSF and other haematopoietic growth
factors may be used during the study of the
management of acute toxicity, such as febrile
neutropenia, when clinically indicated or at
the discretion of the investigator; however,
they may not be substituted for a required
dose reduction (patients taking chronic
erythropoietin are permitted)
l Narrow therapeutic index medication
(e.g. warfarin) permitted with monitoring
Prohibited l Anti-cancer therapies, such as
chemotherapy, palliative radiotherapy
or immunotherapy
l Concomitant radioactive iodine,
chemotherapy or other investigational
therapy
l Substances known to induce CYP3A4
ASCO, American Society of Clinical Oncology; G-CSF, granulocyte colony-stimulating factor.
Note
Information drawn from Schlumberger et al.51 [supplementary material (protocol)], Brose et al.72 and Bayer HealthCare.310
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First data cut-off point November 2013 August 2012





Average dose (mg) 17.2 NR 651 793
Dose intensity (% of maximum dose) 71.7 NR 81.4 99.1
Second data cut-off point June 2014 May 2013





Average dose (mg) NR NR NR NR
Dose intensity (% of maximum dose) NR NR NR NR
Third data cut-off point August 2015 July 2015
Length of follow-up (months), median (95% CI) 37.8 (NR) 37.9 (NR) 36.0 (NR) NR
Average dose (mg) 16.5a NR 651.2 793.6
Dose intensity (% of maximum dose) 68.8a NR 81.4 99.2
NR, not reported.
a Eisai Ltd’s response to the AG’s report to the NICE Appraisal Committee (7 September 2017).311
Note
Information drawn from Schlumberger et al.,51 Eisai Ltd,8 Brose et al.,52 Bayer HealthCare7 and Eisai Ltd’s response to the
AG’s report to the NICE Appraisal Committee (7 September 2017).




Age (≤ 65 years or > 65 years)
Geographic region (Europe, North America or
other)
Prior VEGF-targeted therapy (0 or 1)
Sex (male or female)
Race (white or non-white)
Histology (PTC or FTC)
TSH (≤ 0.5, > 0.5 to 2.0, > 2.0 to 5.5 or
> 5.5 ml/UL)
Age (< 60 years or ≥ 60 years)
Geographical region (North America, Europe or Asia)
Sex (male or female)
Histology (PTC, FTC: Hürthle cell, FTC: other subtypes, or poorly
differentiated)
Site of metastasis [bone (yes or no) and lung only (yes or no)]
2-[18F]fluoro-2-deoxy-D-glucose-positron emission tomography
(FDG-PET) uptake (negative or positive)
Prior radioactive iodine cumulative dosing [< 600mCi (22.2 GBq) or
≥ 600mCi (22.2 GBq)]
Tumour burden as measured by number of target or non-target lesions
(fewer than median or at least median)
Tumour burden as measured by sum of target diameters (less than
median or at least median)
continued
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TABLE 37 Subgroup analyses conducted in SELECT and DECISION (continued )
Study
SELECT DECISION
Post hoc subgroup analyses
Number of sites of metastasis (1, 2, 3 or ≥ 4)a
Site of metastasis (brain, bone, liver, lung or
lymph node)a
Site of metastasis [bone (yes or no) and lung
(yes or no)]
Target tumour size (≤ 35mm, 36–60 mm,
91–92mm or ≥ 92mm)
BRAF status (wild type or mutant)
RAS status (wild type or mutant)
TSH levels (≤ 0.5, 0.5 to 2.0 or > 2.0 ml/UL)
Pharmacodynamic biomarkers [TG and CAF
levels (Ang2, VEGF, sTie2, and FGF23)]a
Body mass index [underweight and normal
weight (< 25 kg/m2), overweight (25 kg/m2 to
29.99 kg/m2) and obese (≥ 30 kg/m2)]a
With or without treatment-emergent
hypertensiona
BRAF status (wild type or mutant)a
RAS status (wild type or mutant)a
TSH levels [less than median (449.4 ng/mL) or at least median (449.4 ng/m)]a
Maximum tumour size (< 1.5 cm or ≥ 1.5 cm)
Category of lesion size (< 1.5 cm, ≥ 1.5 cm, < 2 cm, ≥ 2 cm, < 3 cm,
≥ 3 cm, < 4 cm or ≥ 4 cm)
Lesion category: number of target lesions (< 3, ≥ 3, < 4, ≥ 4, < 5 or ≥ 5)b
Symptomatic or asymptomatic at baselineb,c
Subgroup analyses on safety parameters by region, body mass index, sex
and age (full details not reported)d
Subgroup analyses of baseline factors predictive of HRQoL (full details not
reported)d
BRAF, B-type rapidly accelerated fibrosarcoma; CAF, cytokine and angiogenic factor.
a Reported in conference abstracts.71,84,90,112,132–134,312
b Reported in Bayer HealthCare7 (appendix 7.3).
c Reported in the EPAR for sorefanib.26
d Reported in Bayer HealthCare.7
Note
All of the analyses were reported in the primary published papers unless otherwise stated.
















41 (15.7) 16 (12.2) 42 (20.3) 18 (8.6)
OS: first data cut-off point November 2013 August 2012
Patients who crossed over,
n (%)
N/A 109 (83.2) 55 (26.6) 150 (71.4)
Deaths, n (%) 71 (27.2) 47 (35.9) 45 (21.7) 54 (25.7)
Median OS (months)
(95% CI)
NE (22.0 to NE) NE (14.3 to NE) NE NE
Unadjusted HR (95% CI);
p-value
0.73 (0.50 to 1.07); 0.1032 0.80 (0.54 to 1.19); 0.14
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TABLE 38 Overall survival findings from SELECT and DECISION, including information on treatment crossover and













(95% CI); p-value, cox method




0.62 (0.40 to 1.00); 0.0510 0.61 (0.18 to 2.16); NR
IPE-adjusted HR (95% CI);
p-value, cox method
N/A 0.70 (0.47 to 1.04); 0.0388
IPE-adjusted HR (95% CI);
p-value, bootstrapping method
N/A 0.70 (0.40 to 1.38); NR
OS: second data cut-off
point June 2014 May 2013
Patients who crossed over,
n (%)
N/A 115 (87.8) NR 157 (74.8)
Deaths, n (%) 93 (35.6) 55 (42.0) 66 (31.9) 72 (34.3)
Median OS (months)
(95% CI)
NE (30.9 to NE) 19.1 (21.7 to NE) NE 36.5
(32.2 to NE)
Unadjusted HR (95% CI);
p-value
0.80 (0.57 to 1.12) nominal p= 0.1993 0.88 (0.63 to 1.24); 0.24
RPSFTM-adjusted HR
(95% CI); p-value, cox method
NR 0.69 (0.49 to 0.99); NR
RPSFTM-adjusted HR (95% CI);
p-value, bootstrapping method
0.53; nominal p = 0.0051 (0.34 to 0.82) 0.69 (0.33 to 1.65); NR
IPE-adjusted HR (95% CI);
p-value, cox method
N/A 0.79 (0.57 to 1.11); NR
IPE-adjusted HR (95% CI);
p-value, bootstrapping method
N/A 0.79 (0.46 to 1.61); NR
OS: third data cut-off point August 2015 July 2015
Patients who crossed over,
n (%)
N/A 115 (87.8) NR 158 (75.0)
Deaths, n (%) 121 (46.4) 70 (53.4) 103 (49.8) 109 (51.9)
Median OS (months)
(95% CI)
41.6 (31.2 to NE) 34.5 (21.7 to NE) 39.4 (32.7 to 51.4) 42.8
(34.7 to 52.6)
Unadjusted HR (95% CI);
p-value
0.84 (0.62 to 1.13) nominal p= 0.2475 0.92 (0.71 to 1.21) one-sided p= 0.28
RPSFTM-adjusted HR
(95% CI); p-value, cox method
NR 0.77 (0.58 to 1.02); NR
RPSFTM-adjusted HR (95% CI);
p-value, bootstrapping method
0.54; nominal p = 0.0025 (0.36 to 0.80) 0.77 (0.42 to 1.79); NR
IPE-adjusted HR (95% CI);
p-value, cox method
N/A 0.80 (0.61 to 1.05); NR
IPE-adjusted HR (95% CI);
p-value, bootstrapping method
N/A 0.80 (0.48 to 1.71); NR
N/A, not applicable; NE, not estimable; NR, not reported.
Note
Information drawn from Eisai Ltd8 (table 8), Eisai Ltd’s Data on File. 2016; not publically available. SELECT August 2015
Data Cut (table 14.2.2.1.1a and table 14.2.2.1.2a) and Bayer HealthCare7 (table 7 and text on pages 29 and 30).
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Any anti-cancer treatment 41 (15.7) 16 (12.2) 42 (20.3) 18 (8.6)
Antineoplastic and
immunomodulating agents
29 (11.1) 13 (9.9) 38 (18.4) 17 (8.1)
Variousa 17 (6.5) 5 (3.8) 4 (1.9) 2 (1.0)
a Various includes the following categories: other therapeutic radiopharmaceuticals, all other therapeutic products,
diagnostic agents and diagnostic radiopharmaceuticals.
Note
Information drawn from SELECT clinical study report (table 14.3.8.1) and DECISION clinical study report (table 14.1.2/11).












PFS by blinded review: first
data cut-off point
November 2013 August 2012
Events, n (%) 93 (35.6) 109 (83.2) 113 (54.6) 137 (65.2)
Died before progression, n (%) 14 (5.4) 4 (3.1) NR NR
Median PFS (months) (95% CI) 18.3 (15.1 to NE) 3.6 (2.2 to 3.7) 10.8 5.8
Stratified HR (95% CI); p-value 0.21 (0.14 to 0.31); < 0.001 0.59 (0.45 to 0.76); < 0.0001
NE, not estimable; NR, not reported.
Notes
Only investigator-assessed PFS has been reported for subsequent data cut-off points (see Table 41).
Information drawn from Schlumberger et al.51 and Brose et al.52













first data cut-off point November 2013 August 2012
Events, n (%) 91 (34.9) 104 (79.4) 140 (67.6) 184 (87.6)
Died before progression, n (%) 16 (6.1) 6 (4.6) NR NR
Median PFS (months) (95% CI) 16.6 (4.8 to NE) 3.7 (3.5 to NE) 10.8 5.4
Stratified HR (95% CI); p-value 0.24 (0.16 to 0.35); < 0.001 0.49 (0.39 to 0.61); < 0.0001
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second data cut-off point June 2014 May 2013
Events, n (%) N/A N/A N/A N/A
Died before progression, n (%) N/A N/A N/A N/A
Median PFS (months) (95% CI) N/A N/A N/A N/A
Stratified HR (95% CI); p-value N/A N/A
PFS by investigator:
third data cut-off point August 2015 July 2015
Events, n (%) 121 (46.4) 107 (81.7) N/A N/A
Died before progression, n (%) 19 (7.3) 6 (4.6) N/A N/A
Median PFS (months) (95% CI) 19.4 (14.8 to 29.3) 3.7 (3.5 to 5.4) N/A N/A
Stratified HR (95% CI); p-value 0.24 (0.17 to 0.35); < 0.001 N/A
N/A, not applicable; NE, not estimable; NR, not reported.
Note
Information drawn from Schlumberger et al.,51 Eisai Ltd’s Data on File. 2016; not publically available. SELECT August 2015
Data Cut (table 14.2.2.1.5a) and Brose et al.52












ORR (%) (95% CI) 64.8 (59.0 to 70.5) 1.5 (0.0 to 3.6) 12.2 (8.0 to 17.7) 0.5 (0.0 to 2.7)
Difference (%) (95% CI) 63.2 (57.1 to 69.4) 11.7 (7.0 to 16.5)
Odds ratio (95% CI); p-value 28.87 (12.46 to 66.86); < 0.0001 NR; < 0.0001
Complete response, n (%) 4 (1.5) 0 0 0
Partial response, n (%) 165 (63.2) 2 (1.5) 24 (12.2) 1 (0.5)
Stable disease for ≥ 4 weeks ≥ 7 weeks: 60
(23.0)
≥ 7 weeks: 71
(54.2)
145 (74.0) 149 (74.1)
Durable stable disease (stable
disease for ≥ 23 weeks or
6 months)
40 (15.3) 39 (29.8) 82 (41.8) 67 (33.2)
Progressive disease, n (%) 18 (6.9) 52 (39.7) 20 (10.2) 46 (22.9)
Patients unevaluable for
response/not known, n (%)






Time to response (months)
Median (95% CI) 2.0 (1.9 to 3.5) 5.6 (1.8 to 9.4) NR NR
Restricted mean (SD) 3.38 (0.18) 5.63 (3.79) NR NR
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Any AE 260 (99.6) 118 (90.1) 204 (98.6) 183 (87.6)
Hypertension 181 (69.3) 19 (14.5) 84 (40.6) 26 (12.4)
Diarrhoea 173 (66.3) 22 (16.8) 142 (68.6) 32 (15.3)
Decreased appetite/anorexia 139 (53.3) 24 (18.3) 66 (31.9) 10 (4.8)
Weight loss 132 (50.6) 19 (14.5) 97 (46.9) 29 (13.9)
Nausea 121 (46.4) 33 (25.2) 43 (20.8) 24 (11.5)
Fatigue 110 (42.1) 32 (24.4) 103 (49.8) 53 (25.4)
Headache 100 (38.3) 15 (11.5) 37 (17.9) 15 (7.2)
Stomatitis (oral mucositis) 93 (35.6) 9 (6.9) 48 (23.2) 7 (3.3)
Vomiting 92 (35.2) 19 (14.5) 23 (11.1) 12 (5.7)
Proteinuria 84 (32.2) 4 (3.1) 2 (1.0) 0 (0.0)
Hand–foot syndrome 84 (32.2) 1 (0.8) 158 (76.3) 20 (9.6)
Dysphonia 82 (31.4) 7 (5.3) 25 (12.1) 6 (2.9)
Rash or desquamation 48 (18.4) 2 (1.5) 104 (50.2) 24 (11.5)
Alopecia 32 (12.3) 7 (5.3) 139 (67.1) 16 (7.7)
Note
Information drawn from Eisai Ltd8 and Brose et al.52 [with additional data on proteinuria from the clinical study report for
DECISION (table 14.3.3/4)].












Duration of response (months)
Median (95% CI) NE (16.8 to NE) NE 10.2 (7.4 to 16.6) NR
Restricted mean (SD) 17.34 (0.76) NE NR NR
N/A, not applicable; NR, not reported.
a Unlike SELECT, patients who were unevaluable for response were excluded from the analyses in DECISION. There were
18 patients (4.3%) who were excluded from the objective tumour response analyses in DECISION: nine patients (4.3%)
in each arm.
Note
Information drawn from Eisai Ltd,8 EPAR for lenvatinib,27 Bayer HealthCare and EPAR for sorafenib.26
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Any grade ≥ 3 AE 223 (85.4) 39 (29.8) 133 (64.3) 63 (30.1)
Hypertension 112 (42.9) 5 (3.8) 20 (9.7) 5 (2.4)
Weight loss 31 (11.9) 1 (0.8) 12 (5.8) 2 (1.0)
Proteinuria 26 (10.0) 0 (0.0) 0 (0.0) 0 (0.0)
Diarrhoea 22 (8.4) 0 (0.0) 12 (5.8) 2 (1.0)
Decreased appetite/anorexia 15 (5.7) 1 (0.8) 5 (2.4) 0 (0.0)
Asthenia 15 (5.7) 3 (2.3) 0 (0.0) 0 (0.0)
Fatigue 12 (4.6) 2 (1.5) 12 (5.8) 3 (1.4)
Stomatitis (oral mucositis) 11 (4.2) 0 (0.0) 2 (1.0) 0 (0.0)
Hand–foot syndrome 9 (3.4) 0 (0.0) 42 (20.3) 0 (0.0)
Headache 8 (3.1) 1 (0.8) 0 (0.0) 0 (0.0)
Nausea 6 (2.3) 1 (0.8) 0 (0.0) 0 (0.0)
Hypocalcaemia 14 (5.4) 0 (0.0) 19 (9.2) 3 (1.4)
Dyspnoea 4 (1.5) 4 (3.1) 10 (4.8) 6 (2.9)
Dysphagia 4 (1.5) 4 (3.1) 3 (1.4) 2 (1.0)
Rash/desquamation 1 (0.4) 0 (0.0) 10 (4.8) 0 (0.0)
Note
Information drawn from Eisai Ltd,8 Brose et al.52 and Worden et al.139 [with additional data from the clinical study report for
SELECT (table 33) and from the clinical study report for DECISION (tables 14.3.3/4 and 14.3.3/1)].












SAEs 133 (51.0) 31 (23.7) 77 (37.2) 55 (26.3)
Pneumonia 10 (3.8) 3 (2.3) 1 (0.5) 0 (0.0)
Hypertension 9 (3.4) 0 (0.0) 0 (0.0) 0 (0.0)
Dehydration 7 (2.7) 0 (0.0) 0 (0.0) 2 (1.3)
General physical
health deterioration
6 (2.3) 0 (0.0) 2 (1.0) 0 (0.0)
Dysphagia 3 (1.1) 3 (2.3) 2 (1.0) 1 (0.7)
Dyspnoea 3 (1.1) 5 (3.8) 7 (3.4) 6 (2.9)
Haemoptysis 0 (0.0) 3 (2.3) 0 (0.0) 2 (1.3)
Secondary malignancy NR NR 9 (4.3) 4 (1.9)
Pleural effusion 3 (1.1) 1 (0.8) 6 (2.9) 4 (1.9)
NR, not reported.
a SAEs are only reported as treatment-related SAEs for SELECT.
Notes
The majority of individual SAEs reported in both trials were reported by < 2% of patients.
Information drawn from Eisai Ltd8 and Brose et al.,52 Eisai Ltd’s communication with the AG via NICE (2017, personal
communication) and Bayer HealthCare’s response to the AG’s report to the NICE Appraisal Committee (6 September 2017).157
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Treatment-related all-grade AEs 254 (97.3) 78 (59.5) 200 (96.6) 112 (53.6)
Treatment-related grade ≥ 3 AEs 198 (75.9) 13 (9.9) 113 (54.6) 15 (7.2)
Treatment-related SAEs 79 (30.3) 8 (6.1) 26 (12.6) 8 (3.8)
Treatment-related fatal AEs 6 (2.3) 0 (0.0) 1 (0.5) 1 (0.5)
Note
Information drawn from Schlumberger et al.51 and Brose et al.52 [with additional data from the clinical study report for
DECISION (table 14.3.3/3)].
TABLE 47 Tumour objective response findings in patients previously treated and not previously treated with












ORR (%) (95% CI) 62.1 (50.4 to 73.8) 3.7 (0.0 to 10.8) 65.6 (59.0 to 72.3) 1.0 (0.0 to 2.8)
HR (95% CI) 15.57 (4.06 to 59.72) 58.88 (18.95 to 182.91)
Note
Information drawn from Schlumberger et al.51 (supplementary appendix, table S4).
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Appendix 4 Risk-of-bias assessment of
included trials




Was the method used to assign participants to the treatment groups really random? ✓ ✓
Was the allocation of treatment concealed? ✓ ✓
Was the number of participants who were randomised stated? ✓ ✓
Were details of baseline comparability presented in terms of prognostic factors? ✓ ✓
Was baseline comparability achieved in terms of prognostic factors? ✓/✗a ✓/✗a
Were the eligibility criteria for study entry specified? ✓ ✓
Were any co-interventions identified that may influence the outcomes for each group? ✓ ✓
Were the outcome assessors blinded to the treatment allocation? ✓ ✓
Were the individuals who administered the intervention blinded to the treatment allocation? ✓b ✓
Were the participants who received the intervention blinded to the treatment allocation? ✓c ✓d
Was the success of the blinding procedure assessed? ✗ ✗
Were ≥ 80% of the participants originally included in the randomisation process followed up in
the final analysis?
✓ ✓
Were the reasons for withdrawals stated? ✓ ✓
Is there any evidence to suggest that the authors measured more outcomes than they reported? ✓ ✓
Was an ITT analysis included? ✓ ✓
✗, no (item not properly addressed); ✓, yes (item properly addressed); ✓/✗, partially (item partially addressed).
a In SELECT, median time from diagnosis of DTC to randomisation was shorter in the lenvatinib arm than in the placebo
arm (66.0 vs. 73.9 months, respectively). Compared with the placebo arm, a smaller proportion of patients in the
lenvatinib arm had metastases in the lung (86.6% vs. 94.7%, respectively) or liver (16.5% vs. 21.4%, respectively).
In DECISION, a higher proportion of patients in the sorafenib arm had metastases in the lymph node (54.6%) or pleura
(19.3%) than in the placebo arm (48.1% and 11.4%, respectively).
b Study drugs administered by clinicians who remained unaware of the study-drug assignments until the occurrence of
unacceptable toxic effects or disease progression as assessed by independent radiologic review.
c If independent radiologic review confirmed disease progression, the patients who were receiving placebo could elect to
enter the open-label lenvatinib phase.
d In the event of protocol-defined progression determined by the investigator, treatment could be unmasked and patients
from both groups could begin open-label sorafenib and continue until treatment was no longer beneficial, based on
investigator judgement.
Reproduced with permission from Fleeman et al.54 This is an Open Access article distributed in accordance with the terms
of the Creative Commons Attribution (CC BY 4.0) license, which permits others to distribute, remix, adapt and build upon
this work, for commercial use, provided the original work is properly cited. See: http://creativecommons.org/licenses/by/4.0/.
The table includes minor additions and formatting changes to the original text.
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TABLE 49 Summary of the characteristics of the systematic review evidence included
Study and year of









Anderson et al. 201361 RR-DTC Potential treatment
options for RR-DTC
45 45 1 3 1 44 0 SLR
Gruber and Colevas 201533 RR-DTC TKIs 18 18 2 6 2 16 0 SLR
Jean et al. 201693 DTC vs. other
cancer
Sorafenib 9 4 0 4 4 5 0 SLR (PubMed only)
Kawalec et al. 201697 RR-DTC Lenvatinib and sorafenib 2 2 1 1 2 0 0 SR and ITC
McFarland and
Misiukiewicz 2014104
RR-DTC Sorafenib (single or in
combination)
18 18 0 18 1 12 5 SLR
Shen et al. 2014127 RR-DTC Sorafenib 7 7 0 7 0 5 2 SLR
Thomas et al. 2014138 Metastatic
thyroid cancer
Sorafenib 7 6 0 7 0 6 1 SLR
Tremblay et al. 201657 RR-DTC Lenvatinib vs. sorafenib 2 2 1 1 2 0 0 Does not report SLR or
SR methodology, but
reports ITC and MAIC
results
Ye et al. 2015141 Thyroid cancer Lenvatinib and sorafenib 10 9 2 8 2 8 0 SR and meta-analysis
CADTH (lenvatinib) 20166 RR-DTC Lenvatinib 2 2 1 1 2 0 0 Includes only SELECT
but reports on ITC
from Eisai Ltd8
CADTH (sorafenib) 20155 RR-DTC Sorafenib 1 1 0 1 1 0 0 Includes only DECISION
Eisai Ltd 20178 RR-DTC Lenvatinib 2 2 1 1 2 0 0 Includes ITC
Bayer HealthCare 20177 RR-DTC Sorafenib 2 2 1 1 2 0 0 Includes ITC



























































Was the review question clearly defined
in terms of population, interventions,
comparators, outcomes and study designs?
✓ ✓/✗ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓
Was the search strategy adequate and
appropriate?
✓ ✓ ✗a ✓ ✓ ✓ ✓ NR ✓ ✓ ✓ ✓ ✓
Were preventative steps taken to minimise
bias and errors in the study selection process?
✓ NR NR ✓ ✓ ✓ NR NR ✓ ✓ ✓ ✓ ✓
Were appropriate criteria used to assess the
quality of the primary studies, and were
preventative steps taken to minimise bias and
errors in the quality assessment process
NR NR NR ✗b NR ✗ ✗ NR NR ✓c ✓c ✓ ✓d
Were preventative steps taken to minimise
bias and errors in the data extraction process?
✓ NR NR ✓ ✓ ✓ ✓ NR ✓ NR NR NR ✓
Were adequate details presented for each of
the primary studies?
✓ ✓/✗ ✓ ✓ ✓ ✓ ✓/✗ ✓ ✓ ✓ ✓ ✓ ✓
Were appropriate methods used for data
synthesis?
✓ ✓ ✓ ✓ ✓ ✓/✗e ✓/✗e ✓ ✓/✗f ✓ ✓ ✓ ✓
Do the authors’ conclusions accurately reflect
the evidence that was reviewed?
✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓/✗f ✓ ✓ ✓ ✓
Was the review published in a peer-reviewed
journal?
✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✗ ✗ ✗ ✗




✗ ✗ ✗ ✗ ✗ ✓/✗
g
✓/✗h ✗ ✗ ✗ ✓h ✓
g
✗, no (item not properly addressed); ✓, yes (item properly addressed); ✓/✗, partially (item partially addressed); NR, not reported.
a Only PubMed was searched.
b Used the Jadad scale (not an appropriate assessment tool).
c Results of the assessment were not presented.
d Only DECISION was assessed.
e No investigation of heterogeneity of studies included in meta-analysis.
f Subgroup analyses were conducted based on patients with and without RR-DTC; however, the AG considers that all studies of patients with DTC included a majority of, if not all, patients with RR-DTC.
g Bayer HealthCare.
h Eisai Ltd.
Reproduced with permission from Fleeman et al.54 This is an Open Access article distributed in accordance with the terms of the Creative Commons Attribution (CC BY 4.0) license, which permits others to
distribute, remix, adapt and build upon this work, for commercial use, provided the original work is properly cited. See: http://creativecommons.org/licenses/by/4.0/. The table includes minor additions and formatting








































































































































































TABLE 51 Overall findings/conclusions recorded by the authors of the included systematic review evidence
Study and year of
publication Analysis Overall findings/conclusions
Anderson et al. 201361 Descriptive analysis Certain treatments, notably TKIs, have shown promise in
Phase II trials, and two Phase III randomised placebo
controlled trials (SELECT and DECISION) are ongoing
Gruber and Colevas
201533
Descriptive analysis The most likely outcome of treatment with a TKI is stable
disease. Lenvatinib appears to be the most active agent
but is not yet available, with a PFS vs. placebo triple that of
sorafenib and a RECIST response rate five times that of
sorafenib in the Phase III setting
Jean et al. 201693 Descriptive analysis There is a distinct increase in the rate of occurrence of AEs of
sorafenib when used in DTC compared with RCC and HCC.
Although many theoretical explanations have been proposed,
the exact mechanism for this differential in toxic effects
remains unclear
Kawalec et al. 201697 Indirect comparison (conducted
using the Bucher et al.313
method)
Lenvatinib and sorafenib are drugs with strong evidence on
efficacy in treatment of RR-DTC. Based on the currently
available clinical data, lenvatinib appeared to be more
efficacious then sorafenib in RR-DTC therapy. The safety
profiles of the drugs were acceptable and quite comparable.
Indirect comparison results should be interpreted with caution
because of the differences in trial characteristics
McFarland and
Misiukiewicz 2014104
Descriptive analysis Although the data are based primarily on non-randomised
Phase II trials and on only one randomised Phase III trial,
it has been convincingly shown that sorafenib slows the
progression of disease in the majority of cases
Shen et al. 2014127 Descriptive analysis and
meta-analysis
As far as PR and AEs are concerned, the results of this
meta-analysis indicate that sorafenib has a modest effect
in patients with RR-DTC and the high incidence of AEs
associated with this agent may affect the quality of patients’
lives
Thomas et al. 2014138 Descriptive analysis and
meta-analysis
ORR from meta-analysis is higher than recently reported in
DECISION. The difference could be explained by the study
design of DECISION and the challenges that arise from using
RECIST criteria. The targeted therapy agents are associated
with significant incidence of AEs and a small risk of death.
Although there is evidence of efficacy with TKIs, these drugs
may diminish quality of life because of significant toxicities;
therefore, it is important to assess the need for treatment.
Most patients with metastatic disease do not require systemic
therapy
Tremblay et al. 201657 Indirect comparison (conducted
using the Bucher et al.313
method) and MAIC
Based on a MAIC of individual patient data from SELECT and
aggregate data from DECISION, lenvatinib was associated
with statistically significantly longer PFS compared with
sorafenib. However, only patient characteristics common to
both trials that were reported in DECISION could be matched.
The results may therefore have been influenced by other
unobserved factors. The conclusions are limited to patients
not previously treated with a VEGFR-targeted therapy as
these were excluded from the analysis
Ye et al. 2015141 Descriptive analysis and
meta-analysis
Lenvatinib and sorafenib are useful in the treatment of TC.
Although their toxicities remain high (57.4%) in the patients,
the death rate is controlled (4.1%). Lenvatinib and sorafenib
are more useful for thyroid cancer compared with RR-DTC
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TABLE 51 Overall findings/conclusions recorded by the authors of the included systematic review evidence
(continued )
Study and year of
publication Analysis Overall findings/conclusions
CADTH (lenvatinib)
20166
Descriptive analysisa The Endocrine Clinical Guidance Panel concluded that there is
a net overall clinical benefit of lenvatinib in the treatment of
RR-DTC. In making this conclusion, the Clinical Guidance
Panel also noted that OS was a secondary end point and
confounded by crossover; HRQoL was not studied but AE
profiles were similar to AEs seen with sorafenib in DECISION.
Hypertension was more common with lenvatinib but hand-foot




Descriptive analysis The Endocrine Clinical Guidance Panel concluded that there
is a net overall clinical benefit of sorafenib compared with
placebo in patients with clinically progressive RR-DTC. Toxicity
was increased with sorafenib compared both with placebo
and with other trials studying sorafenib in cancer, and there
may be an increased risk of squamous cell cancers of the skin
during sorafenib use. As HRQoL was reduced by sorafenib,
the decision to initiate treatment and the monitoring of
treatment should be by a clinician experienced in the use of
targeted agents and in the treatment of thyroid cancer
Eisai Ltd 20178 Descriptive analysis and indirect
comparison (conducted using
the Bucher et al.313 method)
Lenvatinib was shown to be of superior efficacy to placebo
in SELECT (crossover-adjusted OS, PFS and ORR) and to
sorafenib (PFS) from an ITC. Comparative safety information
with sorafenib has shown that sorafenib and lenvatinib share
many of their AEs, although their safety profiles are not
identical and lenvatinib is associated with lower rates of some
AEs that have been shown to impact patients’ daily lives
Bayer HealthCare
20177
Descriptive analysis and indirect
comparison (conducted using
the Bucher et al.313 method)
and MAIC
Crossover makes it difficult to detect and attribute
improvements in OS in DECISION. Although there were no
statistically significant differences between arms, analyses of
OS, at 9 months and 36 months after the original data cut-off
point, showed a consistent separation of the K–M curves in
favour of sorafenib. Results from the indirect comparison
show the safety profile of sorafenib to be statistically superior
to that of lenvatinib with respect to AEs. Overall, AEs in
DECISION were consistent with the known safety profile of
sorafenib in other indications, and effectively managed by
supportive care, pharmacological treatment, dose interruption
or dose reduction. In addition, sorafenib was shown to be
associated with a lower risk of treatment discontinuation
attributable to AEs. Sorafenib is an efficacious treatment
option, especially for patients presenting with comorbidities
or in circumstances in which managing and maintaining
quality of life is a primary treatment objective. The results of
DECISION are directly relevant to the progressive RR-DTC
patients within routine clinical practice in England. The safety
results from the indirect comparison support sorafenib as a
tolerable treatment option. This may be important in patients
with comorbidities in whom managing and maintaining
quality of life is a primary treatment objective. Please note
that Bayer HealthCare has since clarified that it considers
indirect comparison results to be unreliable owing to
important differences between SELECT and DECISION
(communication with the AG via NICE, 2017, personal
communication)
PR, partial response.
a The CADTH did not include an indirect comparison of lenvatinib with sorafenib as part of the evidence summarised as
part of its systematic review. It did however note that the manufacturer had submitted a MAIC to compare lenvatinib
with sorafenib and these results were also presented.
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TABLE 52 Results from three systematic reviews of sorafenib
Outcome
Systematic review
Jean et al. 201693
Shen et al. 2014127
(95% CI)





(HCC)315 DECISION Meta-analysisa Meta-analysisa
Efficacy
PFS (months) 5.5b 5.5b,c 10.8 – 17.9 (17.9 to 18.0)d




30b 21b 76b 80 (68 to 91) 73.5 (64 to 83)
Rash 40b 16b 50b 66 (50 to 82) 66.7 (51.7 to 81.7)
Diarrhoea 43b 39b 69b 68 (59 to 77) 70.3 (62.3 to 78.3)
Hypertension 17b 5b 41b 52 (33 to 72) 36.1 (26.6 to 45.6)
Fatigue 37b 22b 50b 67 (57 to 78) 60.6 (44.8 to 76.4)
Weight loss 10b 9b 51b 52 (33 to 72) 56.8 (38.8 to 74.8)
Mucositis NR NR 36b – 35.4 (23.1 to 47.7)
Grade ≥ 3 AEs (%)
Hand–foot
syndrome
6 8 20 – 19.4 (8.3 to 30.5)
Rash 1 1 5 – 6.8 (2.7 to 10.9)
Diarrhoea 2 8 6 – 6.8 (3.3 to 10.3)
Hypertension 4 2 10 – 7.3 (2.5 to 12.1)
Fatigue 5 4 6 – 10.3 (4.4 to 16.2)
Weight loss < 1b 2b 12b – 5.2 (1.2 to 90.2)
Mucositis NR NR 4b – 3.9 (0.6 to 7.2)
Dose modifications owing to AEs (%)
Dose reductions 13b 26b 64b 62 (36 to 89) 56 (43.4 to 69.3)
Discontinued 10b 38b 19b – 16 (8.6 to 23.4)
NR, not reported; SHARP, Sovafenib Hepatocellular Carcinoma Assessment Randomised Protocol; TARGET, Treatment
Approaches in Renal Cancer Global Evaluation Trial.
a The meta-analyses in both reviews included seven studies (six studies for RR-DTC only in the review by Thomas et al.138).
b Data not reported in the review by Jean et al.93 or did not match the data reported in the source papers and so data
were extracted by the AG from source papers.52,314,315
c The SHARP trial315 reports time to symptomatic progression (median of 4.1 months) and time to radiological progression
(median of 5.5 months); the latter is reported here.
d PFS includes patients with medullary thyroid cancer. From all studies, including the study of patients with medullary
thyroid cancer, median ORR was 20.7% (95% CI 13.0% to 28.0%).
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Grade ≥ 3 AE NR Academic in confidencea
SAE 1.54 (0.99 to 2.40) Academic in confidencea
Treatment-related SAE 4.02 (1.69 to 9.60) Academic in confidencea
Discontinuation owing to AE 1.26 (0.32 to 4.96) Academic in confidencea
NR, not reported.
a Bayer HealthCare considers that the data from this analysis are unreliable given important differences between SELECT
and DECISION and therefore do not wish the results to be presented (communication with the AG via NICE, 2017,
personal communication).
Note
Data are also reported for 17 specific types of AEs by Kawalec et al.97 The difference between lenvatinib and sorafenib was
statistically significant for hypertension (HR 2.31, 95% CI 1.18 to 4.53) and alopecia (HR 0.33, 95% CI 0.12 to 0.94).
TABLE 53 Efficacy results from indirect comparisons: lenvatinib vs. sorafenib
Outcome Relative effectiveness Source
OS (RPSFTM adjusted) HR 0.78 (95% CI 0.42 to 1.42) Kawalec et al. 201697
OS (RPSFTM adjusted) HR 0.77 (95% CI 0.44 to 1.35) Tremblay et al. 2015289
OS (RPSFTM adjusted) Academic in confidencea Eisai Ltd 20178
OS (MAIC and RPSFTM adjusted) HR 0.73 (95% CI 0.40 to 1.35) Tremblay et al. 2015289
PFS HR 0.36 (95% CI 0.22 to 0.57) Kawalec et al. 201697
PFS HR 0.36 (95% CI 0.22 to 0.57) Tremblay et al. 2015289
PFS Academic in confidencea Eisai Ltd 20178
PFS (MAIC-adjusted) HR 0.33 (95% CI 0.22 to 0.57) Tremblay et al. 2015289
MAIC, Matching-Adjusted Indirect Comparison.
a It is anticipated that the data will be published in April 2018 (Eisai Ltd’s communication with the AG via NICE, 2017,
personal communication).
TABLE 54 Efficacy results from indirect comparisons: sorafenib vs. lenvatinib
Outcome Relative effectiveness Source
OS (MAIC and RPSFTM adjusted) Academic in confidencea bTremblay et al. 2015289
OS (MAIC and RPSFTM adjusted) Academic in confidencea Bayer HealthCare 20177
PFS (MAIC adjusted) Academic in confidencea bTremblay et al. 2015289
PFS (MAIC adjusted) Academic in confidencea Bayer HealthCare 20177
MAIC, Matching-Adjusted Indirect Comparison.
a Bayer HealthCare considers that the data from this analysis are unreliable owing to important differences between
SELECT and DECISION and therefore do not wish the results to be presented (communication with the AG via NICE,
2017, personal communication).
b Direction of analysis inverted from publication, as reported in Bayer HealthCare7 (Table 19).
DOI: 10.3310/hta24020 HEALTH TECHNOLOGY ASSESSMENT 2020 VOL. 24 NO. 2
© Queen’s Printer and Controller of HMSO 2020. This work was produced by Fleeman et al. under the terms of a commissioning contract issued by the Secretary of State for
Health and Social Care. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional
journals provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should
be addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
135

Appendix 6 Proportional hazards assumption
The AG assessed the validity of the PH assumptions in DECISION and SELECT.
The H–H (cumulative hazard vs. cumulative hazard) plot for PFS by investigator assessment from SELECT
(final data cut-off point) is provided in Figure 22. The estimated constant for a linear relationship is statistically
significantly different from zero (–0.0589, 95% CI –0.075 to –0.043; p = 6.73 E-12). Comparison by analysis
of variance (ANOVA) of the linear trend with a quadratic trend shows an improved fit [F(146,1) = 252.3;
p = 1.25 E-33], indicating that the assumption of PH does not hold for investigator-assessed PFS data
from SELECT.
The H–H plot for OS unadjusted for treatment crossover from SELECT (final data cut-off point) is provided
in Figure 23. The estimated constant for a linear relationship is statistically significantly different from zero
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y = 0.0399x2 + 0.1570x + 0.0018
R2 = 0.9820
y = 0.2861x – 0.0589
R2 = 0.9645
ANOVA comparing linear relationship with 
quadratic trend indicates that simple proportionality
is strongly rejected (p < 1.25 E-33)
Non-zero constant confirmed – 0.0589 (p = 7.18 E-19)
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y = 0.3717x2 + 0.5724x + 0.0202
R2 = 0.9765
y = 0.8461x – 0.0103
R2 = 0.9680
Significant non-zero constant for
linear trend confirmed – 0.0103
(95% CI – 0.0200 to – 0.0005;
p = 0.039)
ANOVA comparing linear
relationship with quadratic 
trend indicates that simple 
proportionality is strongly 
rejected (p = 1.86 E-13)
FIGURE 23 The H–H plot for unadjusted OS data from SELECT.
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quadratic trend shows a significantly improved fit for the quadratic relationship [F(146,1) = 63.6; p = 1.86
E-13), indicating that the assumption of PH does not hold for unadjusted OS data from SELECT.
The H–H plot for OS adjusted by RPSFTM for treatment crossover using data from SELECT (final data cut-off
point) is provided in Figure 24. In this case, the estimated constant for the fitted linear trend does not show
a significant deviation from zero (–0.0041, 95% CI –0.0166 to 0.0084; p = 0.52). However, a comparison
by ANOVA of the linear trend with a fitted quadratic trend shows an improved fit for the quadratic
relationship [F(166,1) = 12.03; p = 0.000665], indicating that the assumption of PH is questionable on the
basis of evidence of non-linearity in the relationship between the two arms of the trial following adjustment
for crossover.
The linear trend fitted to the PFS DECISION data (final data cut-off point) in Figure 25 shows a statistically
significant non-zero constant of –0.1263 (95% CI –0.1635 to –0.0892; p = 2.59 E-10). In addition, the
ANOVA test for non-linearity indicates a statistically significant deviation from linearity [F(177,1) = 6.722;
p = 0.0103]. On both criteria, the PH assumption is called into question.
The linear trend fitted to the unadjusted OS data from the DECISION trial (final data cut), shown in
Figure 26, shows a very small constant of 0.0018 (95% CI –0.0036 to 0.0073; p = 0.505), consistent
with the PH requirement for a zero constant. In addition, the ANOVA test for non-linearity indicates no
statistically significant deviation from linearity [F(89,1) = 0.0675; p = 0.796]. On both criteria, the PH
assumption is supported for unadjusted OS trial data.
Figure 27 shows the linear trend fitted to the RPFST-adjusted OS DECISION data (final data cut-off point),
which shows a statistically significant non-zero constant of 0.0115 (95% CI 0.0026 to 0.0204; p = 0.0117).
In addition, the ANOVA test for non-linearity indicates a statistically significant deviation from linearity
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y = 0.1745x2 + 0.4480x + 0.0176
R2 = 0.9388
y = 0.6086x – 0.0041
R2 = 0.9343
The linear-fitted trend does not show
a statistically significant non-zero
constant (– 0.0041, 95% CI – 0.0166
to 0.0084; p = 0.52)
ANOVA quadratic trend comparison
indicates that a non-linear trend is
superior to the linear model
[F(166,1) = 12.03; p = 0.000665]
FIGURE 24 The H–H plot for OS data adjusted by RPFST for treatment crossover from SELECT.
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y = 0.0242x2 + 0.5327x – 0.0806
R2 = 0.9354
Linear trend requires a statistically
significant non-zero constant
– 0.1263 (95% CI – 0.1635 to – 0.0892;
p = 2.59 E-10)
ANOVA test of non-linearity shows that
quadratic trend gives statistically
significant better fit to data
[F(177,1) = 6.722; p = 0.0103]
y = 0.6185x – 0.1263
R2 = 0.9329







































0.05 0.10 0.15 0.20 0.25
y = 0.8239x + 0.0018
R2 = 0.9699
0.30 0.35
Cumulative-unadjusted mortality hazard: placebo
DECISION trial data
Linear trend
Linear trend is consistent with a zero
constant. Estimated value is 0.0018
(95% CI – 0.0036 to 0.0073; p = 0.505)
ANOVA comparison with quadratic
trend indicates no significant
difference in data fit
[F(89,1) = 0.0675; p = 0.796]
FIGURE 26 The H–H plot for unadjusted OS data from DECISION.
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y = – 0.2835x2 + 0.8354x – 0.0124
R2 = 0.9620
y = 0.6260x + 0.0115
R2 = 0.9442
Linear trend requires a statistically
significant non-zero constant 0.0115
(95% CI 0.0026 to 0.0204; p = 0.0117)
ANOVA test of non-linearity 
shows that quadratic trend gives 
statistically significant better fit to 
data [F(122,1) = 56.915; p = 9.03 E-12]
FIGURE 27 The H–H plot for RPFST-adjusted OS from DECISION.
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Appendix 7 Data extraction tables from extended
open-label phases of the trials not presented in the
main body of the report



















Data cut-off point Second data cut-off point: June 2014 First data cut-off point:
August 2012
OS NR NR NR NR NR
Median PFS (months)
(95% CI)
17.5 (8.3 to NE) NE (10.9 to NE) 22.1 (9.4 to NE) 6.7 9.6
ORR (%) (95% CI) 52.9 (41.8 to 63.9) 60.0 (40.6 to 77.3) 54.8 (45.2 to 64.1) 12.2 9.5
NE, not estimable; NR, not reported.
Notes
Results are reported from the start of the open-label treatment.
Information drawn from the EMA,26,27 Schlumberger et al.122 and Paschke et al.114




Lenvatinib: 24-mg dose (n= 82) Sorafenib after placebo (n= 150)
Data cut-off point First data cut-off point:
November 2013
First data cut-off point:
August 2012
Median duration of treatment (months)
(range)
8.9 (0–25) 13.1a
Median dose intensity (mg) (range) 19.4 (7–24) NR
Dose reductions owing to AEs (%) 43.9 NR
Dose interruptions owing to AEs (%) 70.7 NR




Decreased appetite 43 25.3
Weight loss 39 41.3
Fatigue 38 24.7
continued
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Lenvatinib: 24-mg dose (n= 82) Sorafenib after placebo (n= 150)
Hand–foot syndrome NR 56.7
Alopecia NR 56.7
Rash NR 29.3
Common grade ≥ 3 AEs (%)b
Hypertension 24 NR




Treatment-related fatal AEs (%) 4.9 NR
NR, not reported.
a Reported as 56.9 weeks, converted to months by dividing by 4.34812141.
b AEs are reported to be treatment related for SELECT and treatment emergent for DECISION.
Notes
Results are reported from the start of the open-label treatment.
Information drawn from Robinson et al.118 and Bayer HealthCare.7
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Appendix 8 Evidence from observational studies
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TABLE 58 Study characteristics of observational studies
Parameter
Observational study
Study 201 Study 208 Study 12636 UPCC-03305 Chen et al. Duntas et al. Kloos et al. Study 12791
Marotta
et al.
Intervention Lenvatinib Lenvatinib Sorafenib Sorafenib Sorafenib Sorafenib Sorafenib Sorafenib Sorafenib
Number of
patients






RR-DTC: 9 RR-DTC: 11 All: 56
RR-DTC: 52
RR-DTC: 31 RR-DTC: 17

































Country USA, Italy, UK,
Australia, Poland
and France









































a Data taken from lenvatinib EPAR.27
b Converted from weeks into months by dividing by 4.34812141.
c This was the median length of follow-up reported for an interim analysis presented by Brose et al.;75 final results have been presented at later dates98,137 and so the median follow-up is
















TABLE 59 Participant characteristics of observational studies
Parameter
Observational study




et al. Kloos et al. Study 12791
Marotta
et al.
Intervention Lenvatinib Lenvatinib Sorafenib Sorafenib Sorafenib Sorafenib Sorafenib Sorafenib Sorafenib






RR-DTC: 9 RR-DTC: 11 All: 56
RR-DTC: 52
RR-DTC: 31 RR-DTC: 17
Median age (years)
(range)
63 (34–77) NR All: 55 (21–78) Initial 30 patients:
63 (31–89)
NR NR PTC/no prior chemotherapy
(n = 19): 67 (33–90)
PTC/prior chemotherapy




% male 59 NR All: 55.9 All: 49.075 NR 36.4 All: 55.4
PTC (n = 41): 51.2
61.2 23.5
Race (%) White: 86 NR NR NR NR NR White
l All: 83.9
l PTC (n= 41): 87.8
NR NR
ECOG PS ≥ 2 (%) 6.9 NR All: 0 Initial 30 patients: 0 NR NR NR NR 35.3
PTC (%) 74.1 NR All: 23.5 All: 52.7 100 NR 73.2 41.9 35.3
FTC (%) 25.9a NR All: 14.7 32.7a 0 NR 19.6a 48.4 64.7
Lung metastases (%) 93 NR NR NR NR NR NR Lung only: 25.8 NR
Bone metastases (%) 45 NR NR NR NR NR NR Lung and bone
only: 25.8
23.5
Prior TKI 29.3 NR NR NR NR NR NR 0 11.8
ATC, anaplastic thyroid carcinoma; FTC, follicular carcinoma; MTC, medullary thyroid carcinoma; NR, not reported.








































































































































































TABLE 60 Efficacy findings from observational studies
Parameter
Observational study
Study 201 Study 208 Study 12636 UPCC-03305a Chen et al. Duntas et al. Kloos et al. Study 12791 Marotta et al.
Intervention Lenvatinib Lenvatinib Sorafenib Sorafenib Sorafenib Sorafenib Sorafenib Sorafenib Sorafenib
Number of
patients






RR-DTC: 9 RR-DTC: 11 All: 56
RR-DTC: 52





















12.6 (9.9 to 16.1) RR-DTC only:








NR All PTC (n= 41): 15
(10 to 27.5)
18 (7 to 29)
(n = 26)
12





NR NR NR NR NR NR All responses
achieved in the





12.7 (8.8 to NE)
(n= 29)





ATC, anaplastic thyroid carcinoma; MTC, medullary thyroid carcinoma; NE, not estimable; NR, not reported.
a Findings are from Keefe et al.98
b Data taken from lenvatinib EPAR.27
c Converted from weeks into months by dividing by 4.34812141.
d Data taken from sorafenib EPAR.26
Note

























All-grade AEs 100a NR NR
Hypertension 76 to 90a 21 to 42c 43a
Diarrhoea 55 to 67a 52 to 77c 75 to 80a
Decreased
appetite
52 to 78a 29b 20 to 82a
Weight loss 69b 29 to 58a 60 to 82a
Nausea 50b 10 to 27a 30 to 55a
Fatigue 60 to 73a 59b 63 to 66a
Headache 43b 15b 16b
Stomatitis/
mucositis
31 to 57a 27 to 48c 16 to 47a
Vomiting 38a 18b 18b
Proteinuria 61 to 64a NR NR
Hand–foot
syndrome
22 to 77a 71 to 79c 63 to 93a/63 to 91a,d
Dysphonia 43b NR NR
Rash 24b 55 to 88a 79 to 80a/79 to 85a,d
Alopecia 9b 52 to 74a 43 to 79a
Other types of
all-grade AEs
Other AEs experienced by
≥ 25% of patients in Study
20177 (Study 208135 only
reported AEs that were




l Dry mouth, 35
l Back pain, 33
l Pain in extremity, 33
l Dyspnoea, 31
l Musculoskeletal pain, 31
l Abdominal pain upper, 31
l Abdominal pain, 28
l Epistaxis, 28
Other AEs experienced by ≥ 25%
of patients in any one study:59,126
l Infection, 68
l Hypocalcaemia, 48









l Myocardial infarction, 10
Other treatment-related AEs
experienced by ≥ 25% of
patients in Kloos et al. 2009:101




l Pain abdomen or rectal, 68
l Heartburn, 39
l Muscle cramps, 36
l Flushing, 32
l Nail changes, 59
NR, not reported.
a Range of AE incidence reported by two studies.
b Incidence of AEs reported by one study.
c Range of AE incidence reported across three studies.
d Terry et al.137 later examined treatment-related hand–foot syndrome and rash for UPCC-03305 (12192)88 and data in the
table are reported as ranges using earlier and later data cut-off points, respectively.
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Study 201 Study 208 Study 12636 UPCC-03305a,b Chen et al. Duntas et al. Kloos et al.a Study 12791
Intervention Lenvatinib Lenvatinib Sorafenib Sorafenib Sorafenib Sorafenib Sorafenib Sorafenib






RR-DTC: 9 RR-DTC: 11 All: 56
RR-DTC: 52
RR-DTC: 31
All-grade AEs 58 (100) 51 (100) NR NR NR NR NR NR
Hypertension 44 (76) 46 (90) 7 (21) 13 (43) NR 3 (27) 24 (43) 13 (42)
Diarrhoea 39 (67) 28 (55) 26 (77) 24 (80) NR One of the
most frequent
AEsc
42 (75) 16 (52)
Decreased
appetite/anorexia
30 (52) 40 (78) 10 (29) 6 (20) NR NR 46 (82) NR
Weight loss 40 (69) NR 10 (29) 18 (60) NR NR 46 (82) 18 (58)
Nausea 29 (50) NR 9 (27) 9 (30) NR NR 31 (55) 3 (10)




Headache 25 (43) NR 5 (15) NR NR NR 9 (16) NR
Stomatitis/mucositis 18 (31) 29 (57) 9 (27) 14 (47) NR NR 9 (16) 15 (48)
Vomiting 22 (38) NR 6 (18) Included with nausea NR NR 10 (18) NR
Proteinuria 37 (64) 31 (61) NR NR NR NR NR NR
Hand–foot
syndrome
13 (22) 39 (77) 27 (79) 28 (93) NR One of the
most frequent
AEsc
35 (63) 22 (71)
Dysphonia 25 (43) NR NR NR NR NR NR NR
Rash 14 (24) NR Dermatology (other):
30 (88)
24 (80) NR NR 44 (79) 17 (55)























by ≥ 25% of patients:
l Cough, 26 (45)
l Arthralgia, 21 (36)
l Dry mouth, 20 (35)
l Back pain, 19 (33)
l Pain in extremity,
19 (33)












≥ 55% of patients
Other AEs
experienced by
≥ 25% of patients:




l Glossitis, 12 (35)
l Haemorrhage,
10 (29)




and rash. AE data for
all 55 patients not
RR-DTC only (n= 47):
l Hand–foot
syndrome, 50 (91)
l Rash, 49 (85)
NR NR Other AEs experienced
by ≥ 25% of patients:
l Pain abdomen or
rectal, 35 (63)
l Heartburn, 22 (39)
l Flatulence, 39 (70)




l Dry skin, 47
l Pruritis, 43
l Nail changes, 33
l Hypocalcaemia, 15 (48)
l Hypophosphataemia,
11 (35)
l Anaemia, 11 (35)
l Hypoparathyroidism,
10 (32)
l Thrombopenia, 9 (29)
l Hypothyroidism, 8 (26)
l Leukopenia, 7 (23)
l Myocardial infarction,
3 (10)
ATC, anaplastic thyroid carcinoma; MTC, medullary thyroid carcinoma; NR, not reported.
a Treatment-related.
b The majority of findings are from Terry et al.137








































































































































































TABLE 63 Grade ≥ 3, serious and fatal AEs reported in the prospective observational studies
Event









Grade ≥ 3 AEs 72a NR NR
Hypertension 10b 6 to 16a 4 to 13a
Diarrhoea 10b 3 to 7a 4 to 7a
Decreased appetite 2b 0b 3b
Weight loss 12b 0 to 10a 5 to 10a
Nausea 0b 0a 0a
Fatigue 9b 9a 3 to 16a
Headache 2b 3b 0b
Stomatitis/mucositis 2b 9 to 10a 0 to 2
Hand–foot syndrome 2b 23 to 44a 7 to 10a/7a,c
Proteinuria 10b NR NR
Asthenia NR NR NR
Dyspnoea 0b NR 0b
Dysphagia NR 0b NR
Rash 0b 6 to 16a 4 to 10a/4 to 18a,c
Other types of grade
≥ 3 AEs
Other grade ≥ 3 AEs
experienced by ≥ 5% of
patients in Study 201:
l Dehydration, 9
l Arthralgia, 5
l Grade ≥ 3 AEs not
reported in Study 208
Other grade ≥ 3 AEs
experienced by ≥ 5% of






l Drug hypersensitivity, 9
Other grade ≥ 3 treatment-related
AEs experienced by ≥ 5% of
patients in either study:
l Hand or foot pain, 12
l Arthralgia, 11
l Fatigue, 16
l Hand–foot syndrome, 7
l Musculoskeletal chest pain, 7
l Asymptomatic
hyponatraemia, 5
l Function tests, 7
l Pruritus, 3
l Sleep disturbance/anxiety, 3
SAEs 48b NR NR
Fatal AEs 5 to 8a 1b NR
Type of SAEs SAEs that occurred in




l Pulmonary embolism, 3
l Abdominal pain, 3
l Hypertension, 3
l Cardiac failure, 3
NR NR
NR, not reported.
a Range of AE incidence reported by two studies.
b Incidence of AEs reported by one study.
c Terry et al.137 later examined treatment–related hand–foot syndrome and rash for UPCC-03305 (12192)88 and data in the
table are reported as ranges using earlier and later data cut-off points, respectively.
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TABLE 64 Incidence of grade ≥ 3 AEs reported from observational studies
Parameter
Observational study, n (%)
Study 201 Study 208 Study 12636 UPCC-03305a Chen et al. Duntas et al. Kloos et al.a Study 12791
Intervention Lenvatinib Lenvatinib Sorafenib Sorafenib Sorafenib Sorafenib Sorafenib Sorafenib






RR-DTC: 9 RR-DTC: 11 All: 56
RR-DTC: 52
RR-DTC: 31
Grade ≥ 3 AEs 42 (72) RR-DTC: 12 (72) NR NR NR – see ‘other’ NR NR NR
Hypertension 6 (10) NR 2 (6) 4 (13) NR NR 2 (4) 5 (16)
Diarrhoea 6 (10) NR 1 (3) 2 (7) NR NR 2 (4) 2 (7)
Decreased appetite 1 (2) NR 0 1 (3) NR NR 0 NR
Weight loss 7 (12) NR 0 3 (10) NR NR 3 (5) 3 (10)
Nausea 0 NR 0 0 NR NR 0 0
Fatigue 5 (9) NR 3 (9) 1 (3) NR NR 9 (16) NR
Headache 1 (2) NR 1 (3) NR NR NR 0 NR
Stomatitis/mucositis 1 (2) NR 3 (9) 0 NR NR 1 (2) 3 (10)
Hand–foot
syndrome
1 (2) NR 14 (44) 3 (10) NR NR 4 (7) 7 (23)
Proteinuria 6 (10) NR NR NR NR NR NR NR
Asthenia NR NR NR NR NR NR NR NR
Dyspnoea 0 NR NR NR NR NR 0 NR
Dysphagia NR NR 0 NR NR NR NR NR
Rash 0 NR Dermatology
(other): 2 (6)









































































































































































TABLE 64 Incidence of grade ≥ 3 AEs reported from observational studies (continued )
Parameter
Observational study, n (%)
Study 201 Study 208 Study 12636 UPCC-03305a Chen et al. Duntas et al. Kloos et al.a Study 12791
Other types of
grade ≥ 3 AEs
Other grade ≥ 3






NR Other grade ≥ 3 AEs
reported:
l Infection, 3 (9)




l Constipation, 1 (3)
l Muscle cramps,
1 (3)
l Anaemia, 1 (3)
l Fever, 1 (3)
l Elevated liver function tests,
2 (7)
l Pruritus, 1 (3)
l Sleep disturbance/anxiety,
1 (3)
Terry et al. 2013137 later examined
hand–foot syndrome and rash.
AE data for all 55 patients not
RR-DTC only (n= 47) (treatment-
related):
l Hand–foot syndrome, 4 (7)







NR Grade ≥ 3 AEs
reported, in text
Most common (≥ 5%
frequency) grade 3
AEs included:


















l Small cell lung
cancer, 1 (3)

















TABLE 65 Incidence of SAEs and fatal AEs reported from observational studies
Parameter
Observational study, n (%)
Study 201 Study 208 Study 12636 UPCC-03305 Chen et al. Duntas et al. Kloos et al. Study 12791
Intervention Lenvatinib Lenvatinib Sorafenib Sorafenib Sorafenib Sorafenib Sorafenib Sorafenib
Number of
patients






RR-DTC: 9 RR-DTC: 11 All: 56
RR-DTC: 52
RR-DTC: 31
SAEs 28 (48) NR NR NR NR NR NR NR






l Lower abdominal pain (3)
l Hypertension (3)
l Cardiac failure (3)
NR NR NR NR NR NR NR








NR NR NR NR 1 (not considered
treatment related)
NR























































































































































































66a 42 to 100a 47 to 52b/47 to 55b,c
AE
discontinued
2 to 26b 23a 20a
Other AEs that led to lenvatinib withdrawal
and occurred in ≥ 3.5% patients in
Study 201:
l Proteinuria, 5
l Pulmonary embolism, 3
l Deep-vein thrombosis, 3
Two out of three patients with a
PR withdrew from the study after
5–7 months of treatment in one study
79% of patients required a dose
reduction by one dose level to 400 mg
daily and one-third of these patients
underwent a further reduction to the
lowest dose level of 400 mg on
alternate days in one study
NR, not reported; PR, partial response.
a Incidence of AEs reported by one study.
b Range of AE incidence reported by two studies.
c Terry et al.137 later examined treatment-related hand–foot syndrome and rash for UPCC-03305 (12192)88 and data in the
table are reported as ranges using earlier and later data cut-off points, respectively.
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TABLE 67 Dose modifications reported from observational studies
Parameter
Observational study, n (%)
Study 201 Study 208 Study 12636 UPCC-03305a Chen et al. Duntas et al. Kloos et al.a Study 12791
Intervention Lenvatinib Lenvatinib Sorafenib Sorafenib Sorafenib Sorafenib Sorafenib Sorafenib
Number of
patients











43 (74) NR 28 (82) NR NR NR NR NR
AE dose
reductions








15 (26) 1 NR 6 (20) NR NR NR 7 (23)
Other AEs that led to lenvatinib
withdrawal and occurred







79% of patients required a
dose reduction by one dose
level to 400 mg daily and
one-third of these patients
underwent a further reduction
to the lowest dose level of
400 mg on alternate days




2/3 with a PR
withdrew from the
study after 5 to
7 months of
treatment









































































































































































TABLE 68 Other AE information reported from observational studies
Parameter
Observational study, n (%)
Study 201 Study 208 Study 12636 UPCC-03305 Chen et al. Duntas et al. Kloos et al. Study 12791
Intervention Lenvatinib Lenvatinib Sorafenib Sorafenib Sorafenib Sorafenib Sorafenib Sorafenib
Number of
patients












changes in mean vital
signs from baseline to









with an increase in
blood pressure
Liver abnormalities were
common (32% of patients
experiencing a grade 1/2
transaminitis; 15% of
patients developed grade
3 amylasaemia) but no
patients developed acute
pancreatitis
Lipase levels were found
to be raised in 22% of
patients, half of which
were grade ≥ 3
12% of patients
developed an elevated






by increasing the T4 dose
There was a marked
and rapid change in the
serum thyroglobulin
level after start of
treatment, with a mean




Tg level was variably
decreased by up to 85%
Although dramatic
sustained decreases in
serum Tg levels were
observed in some
patients with PRs and
stable disease, neither
baseline Tg nor Tg
response consistently
correlated with degree





a PR had a median
decrease in their serum
Tg levels. Patients with
stable or progressive
disease showed an




Most of the increases in
blood pressure were
observed in the first
cycle. Downwards trends
in both systolic and
diastolic blood pressure







From Terry et al. 2013137
(n= 55):
The severity of skin toxicity
peaked by cycle 1 for rash
and cycle 2 for HFSR. The
severity improved dramatically
for rash by cycle 3 and for
HFSR by cycle 6. Our data
support the close supervision
of skin-related AEs in the first
six cycles of treatment with
sorafenib. However, the
sustained high prevalence of
rash and HFSR requires that
all patients receive ongoing
skin care for the duration of
therapy
The majority of AEs
were seen in the
























Observational study, n (%)
Study 201 Study 208 Study 12636 UPCC-03305 Chen et al. Duntas et al. Kloos et al. Study 12791
Other The authors316 concluded
that lenvatinib had an
acceptable safety profile
for patients with refractory
thyroid cancer and no























Our data support the
close supervision of skin-
related AEs in the first six
cycles of treatment with
sorafenib. However, the
sustained high prevalence
of rash and hand-foot
syndrome requires that all
patients receive ongoing















































































































































































































Appendix 9 Ongoing studies (summary)
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TABLE 69 Characteristics of the ongoing studies
Parameter
Study
E7080–G000–21 (Study 211) E7080–C086–308 (Study 308) MATiSSe NEXAVAR-TC-01 (Study 17391)
Description Postmarketing safety study of
lenvatinib (Study 211)
Lenvatinib for RR-DTC in China A pilot study evaluating the safety and
efficacy of sorafenib
Postmarketing safety study of sorafenib
Sponsor Eisai Ltd Eisai Ltd Royal Marsden NHS Foundation Trust Bayer HealthCare
Commencement
date
28 March 2016 7 February 2017 Ethics approval, 8 January 2007 27 June 2014
Expected end date 30 October 2020 April 2020 NR 30 June 2021
Participants 161 patients with RR-DTC 150 patients with RR-DTC 33 patients with RR-DTC or MTC 443 patients with RR-DTC
Outcomes l ORR at 6 months
l Percentage of treatment-emergent
grade ≥ 3 AEs (up to 6 months)
l PFS (up to 18 months)
l PFS after next line of treatment
(PFS2, up to 18 months after
initiating next line of treatment)
l Number of participants with
treatment-emergent AEs and SAEs
(up to 1 month)
l Time to treatment discontinuation
attributable to an AE (up to
1 month)
l Dose reductions and interruptions
(up to 1 month)
l AUC of lenvatinib (predose and
2-hour to 12-hour postdose)
l HRQoL (up to 18 months)
l PFS (up to 12 months)
l ORR (up to 36 months)
l OS (up to 36 months)
l Number of participants with
treatment-emergent AEs
(up to 36 months)
l Proportion of patients who have
achieved a response during 6 months
of treatment with sorafenib
l Proportion of patients achieving a
response during 9 and 12 months of
treatment with sorafenib
l Biomarkers toxicity outcomes at 1, 3,
6, 9 and 12 months
l PFS and OS
l Number of participants with adverse
drug reactions (up to 9 months)
l Number of participants with SAEs
(up to 9 months)
l Number of participants with serious
adverse drug reactions (up to
9 months)
l 2-year survival
l Time to treatment failure (up to
9 months)
















Appendix 10 Additional tables summarising key
features of the companies’ economic models
TABLE 70 Total monthly routine care costs
Parameter
Model costs (£)
Eisai Ltd Bayer HealthCare
Pre-progression
Response 280.61 –
Stable disease 297.98 –
Sorafenib and lenvatinib – Commercial in confidence
Placebo/BSC – Commercial in confidence
Progressive disease/post progression 1315.56 Commercial in confidence
Note
Information drawn from Eisai Ltd8 (table 25) and Bayer HealthCare7 (table 28).
TABLE 71 Adverse event frequencies/rates and costs
Parameter
Model
Eisai Ltd (lenvatinib) Bayer HealthCare (sorafenib)
Frequency of




Rate of grade 3 and 4 AEs
(per 28 days) (%)
Cost per patient
per 28 days (£)
Lenvatinib Sorafenib Lenvatinib Sorafenib Placebo/BSC Grade 3 Grade 4
Hypertension 3.5 0.79 850.67 3.55 0.76 0.43 158 65.06
Weight
decrease
0.40 0.19 639.83 0.67 0.58 0.19 345 –
Diarrhoea 0.40 0.28 571.30 0.55 0.55 0.13 223 102
Decreased
appetite
0.40 0.00 639.83 – – – – –
Hypocalcaemia 0.40 0.69 615.83 0.18 0.72 0.30 9 9
Hypokalaemia 0.00 0.00 615.83 – – – – –
Asthenia 0.00 0.00 658.83 – – – – –
Fatigue 0.00 0.00 658.83 0.64 0.48 0.18 61 74
Hand–foot
syndrome
0.00 1.40 450.35 0.23 1.64 – 155 –
Proteinuria 0.40 0.19 778.67 – – – – –
Note
Information drawn from Eisai Ltd8 (tables 27 and 28) and Bayer HealthCare7 (tables 23 and 30).
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Appendix 11 The NICE reference case checklist
(summary)
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Decision problem The scope developed by NICE ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓
Comparator(s) As listed in the scope developed by NICE ✓/✗ ✓ ✓ ✓ ✓/✗ ✓ ✓/✗ ✓/✗
Perspective costs NHS and PSS ✗ ✗ ✗ ✗ ✗ ✗ ✗ ✗
Perspective benefits All direct health effects, whether for
patients or carers
✓/✗ ✓/✗ ✓ ✓ ✓ ✓ ✓ ✓
Form of economic evaluation Cost–utility analysis with fully
incremental analysis
✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓
Time horizon Long enough to reflect all important
differences in costs or outcomes
✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓
Synthesis of evidence on
outcomes
Based on systematic review ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓
Outcome measure Health effects should be expressed in
QALYs (EQ-5D preferred)
✓ NR ✓ ✓ ✓ ✓ ✓ ✓
Health states for QALY Reported directly by patients and/or
carers
✓ NR ✓ ✗ ✓ ✗ ✗ ✗
Benefit valuation Time trade-off or standard gamble ✓ NR ✗ ✓ ✓ ✓ ✓ ✓
Source of preference data for
valuation of changes in HRQoL
Representative sample of the UK
population
NR NR ✓ ✗ NR ✗ NR ✗
Discount rate The same annual rate for both costs and
effects (currently 3.5%)
NR ✗ ✓ ✓ NR NR NR NR
















Appendix 12 The Drummond checklist (summary)
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Was a well-defined question posed in answerable form? ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓
Was a comprehensive description of the competing alternatives
given?
✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓
Was the effectiveness of the programme or services established? ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓
Were all the important and relevant costs and consequences for
each alternative identified?
✓ Unclear ✓ ✓ ✓ ✓ Unclear ✓
Were costs and consequences measured accurately in
appropriate physical units?
Unclear Unclear ✓ ✓ Unclear ✓ Unclear ✓
Were the cost and consequences valued credibly? Unclear Unclear ✓ ✓/✗ Unclear ✓ Unclear ✓/✗
Were costs and consequences adjusted for differential timing? Unclear ✓ ✓ ✓ Unclear Unclear Unclear Unclear
Was an incremental analysis of costs and consequences of
alternatives performed?
✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓
Was allowance made for uncertainty in the estimates of costs
and consequences?
✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓
Did the presentation and discussion of study results include all
issues of concern to users?
✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓
















Appendix 13 The NICE reference case checklists
in full
TABLE 74 The NICE reference case checklist completed by the AG: Erdal et al. 2015
Attribute Reference case
Does the economic evaluation match the
reference case? (Erdal et al. 2015163)
Decision problem The scope developed by NICE Yes
Comparator(s) As listed in the scope developed by NICE Partial – sorafenib is compared with BSC but
not to lenvatinib
Perspective: costs NHS and PSS Turkish payer’s perspective taken
Perspective: benefits All direct health effects, whether for
patients or, when relevant, carers
Partial – patient related direct health effects
were considered
Form of economic evaluation Cost–utility analysis with fully
incremental analysis
Yes
Time horizon Long enough to reflect all important
differences in costs or outcomes
between the technologies being
compared
Yes – lifetime horizon
Synthesis of evidence on
outcomes
Based on systematic review Data have been primarily taken from
DECISION
Outcome measure Health effects should be expressed in
QALYs. The EQ-5D is the preferred
measure of HRQoL in adults
Yes – health effects were expressed in QALYs
and based on EQ-5D data collected in
DECISION
Health states for QALY Reported directly by patients and/or
carers
Yes – reported directly by patients in
DECISION
Benefit valuation Time trade-off or standard gamble Yes
Source of preference data for
valuation of changes in
HRQoL
Representative sample of the UK
population
Does not state in abstract which valuation set
is used for the EQ-5D estimates of utility
Discount rate The same annual rate for both costs and
effects (currently 3.5%)
Not stated
Equity An additional QALY has the same weight
regardless of the other characteristics of
the individuals receiving the health benefit
Yes – all QALYs estimated by the economic
model have the same weight
Sensitivity analysis The scope developed by NICE Sensitivity analysis was conducted, but no
details of the methods used were reported
PSS, Personal Social Services.
DOI: 10.3310/hta24020 HEALTH TECHNOLOGY ASSESSMENT 2020 VOL. 24 NO. 2
© Queen’s Printer and Controller of HMSO 2020. This work was produced by Fleeman et al. under the terms of a commissioning contract issued by the Secretary of State for
Health and Social Care. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional
journals provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should
be addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
167
TABLE 75 The NICE reference case checklist completed by the AG: Huang et al. 2016
Attribute Reference case
Does the economic evaluation match the
reference case? (Huang et al. 2016158,159)
Decision problem The scope developed by NICE Yes
Comparator(s) As listed in the scope developed by NICE Yes – lenvatinib vs. sorafenib and both drugs
vs. placebo. The placebo evidence is derived
from the Phase III trials; the AG assumes
placebo and BSC are equivalent comparators
Perspective: costs NHS and PSS US perspective. The authors states that direct
medical costs were used, but some costs
were sourced from Medicare Fee Schedule,
which reflects tariffs rather than direct costs
Perspective: benefits All direct health effects, whether for
patients or, when relevant, carers
Partial – patient-related direct health effects
were considered, although source and values
were not reported in the abstract
Form of economic evaluation Cost–utility analysis with fully
incremental analysis
Yes
Time horizon Long enough to reflect all important
differences in costs or outcomes
between the technologies being
compared
Yes – lifetime horizon
Synthesis of evidence on
outcomes
Based on systematic review Data have been primarily derived from
DECISION and SELECT
Outcome measure Health effects should be expressed in
QALYs. The EQ-5D is the preferred
measure of HRQoL in adults
Authors state the utility values were taken
from published sources, but it is unclear
which measurement tools were used as the
published sources were not referenced
Health states for QALY Reported directly by patients and/or
carers
Unclear
Benefit valuation Time trade-off or standard gamble Unclear
Source of preference data for
valuation of changes in HRQoL
Representative sample of the UK
population
Unclear but unlikely to be representative of
UK population as the study is set in the USA
Discount rate The same annual rate for both costs and
effects (currently 3.5%)
Yes – 3% used
Equity An additional QALY has the same weight
regardless of the other characteristics
of the individuals receiving the health
benefit
Yes – all QALYs estimated by the economic
model have the same weight
Sensitivity analysis The scope developed by NICE Sensitivity analysis was conducted, but no
details of the methods used were reported
PSS, Personal Social Services.
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TABLE 76 The NICE reference case checklist completed by the AG: Tremblay et al. 2016
Attribute Reference case
Does the economic evaluation match the
reference case? (Tremblay et al. 2016160)
Decision problem The scope developed by NICE Yes
Comparator(s) As listed in the scope developed by NICE Yes – lenvatinib vs. sorafenib
Perspective: costs NHS and PSS US perspective
Perspective: benefits All direct health effects, whether for




Cost–utility analysis with fully incremental
analysis
Yes
Time horizon Long enough to reflect all important
differences in costs or outcomes between
the technologies being compared
Yes – 5-year and 10-year results reported
Synthesis of evidence on
outcomes
Based on systematic review Data have been primarily derived from
DECISION and SELECT
Outcome measure Health effects should be expressed in
QALYs. The EQ-5D is the preferred measure
of HRQoL in adults
QALYs – not EQ-5D
Health states for QALY Reported directly by patients and/or carers UK general population
Benefit valuation Time trade-off or standard gamble Neither
Source of preference data
for valuation of changes in
HRQoL
Representative sample of the UK population Yes
Discount rate The same annual rate for both costs and
effects (currently 3.5%)
Yes – 5% (details provided by lead author)
Equity An additional QALY has the same weight
regardless of the other characteristics of
the individuals receiving the health benefit
Yes – all QALYs estimated by the economic
model have the same weight
Sensitivity analysis The scope developed by NICE Sensitivity analysis was conducted, but no
details of the methods used were reported
PSS, Personal Social Services.
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TABLE 77 The NICE reference case checklist completed by the AG: Wilson 2017
Attribute Reference case
Does the economic evaluation match the
reference case? (Wilson 2017161)
Decision problem The scope developed by NICE Yes
Comparator(s) As listed in the scope developed by NICE Yes
Perspective: costs NHS and PSS US health-care perspective
Perspective: benefits All direct health effects, whether for




Cost–utility analysis with fully incremental
analysis
Yes
Time horizon Long enough to reflect all important
differences in costs or outcomes between
the technologies being compared
Yes – lifetime
Synthesis of evidence on
outcomes
Based on systematic review Data have been primarily derived from
SELECT and DECISION
Outcome measure Health effects should be expressed in
QALYs. The EQ-5D is the preferred measure
of HRQoL in adults
Yes – health effects were expressed in QALYs
Health states for QALY Reported directly by patients and/or carers No – utility is estimated from a vignette study
generated from a sample of the general UK
population in which participants were asked
to value health-state scenarios they were
presented with
Benefit valuation Time trade-off or standard gamble Yes
Source of preference data
for valuation of changes in
HRQoL
Representative sample of the UK population No
Discount rate The same annual rate for both costs and
effects (currently 3.5%)
Yes – 3%
Equity An additional QALY has the same weight
regardless of the other characteristics of
the individuals receiving the health benefit
Yes – all QALYs estimated by the economic
model have the same weight
Sensitivity analysis The scope developed by NICE Yes
PSS, Personal Social Services.
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TABLE 78 The NICE reference case checklist completed by the AG: SMC 2015
Attribute Reference case
Does the economic evaluation match
the reference case? (SMC 201548)
Decision problem The scope developed by NICE Yes
Comparator(s) As listed in the scope developed by NICE Partial – sorafenib is compared with BSC
but not with lenvatinib
Perspective: costs NHS and PSS NHS Scotland
Perspective: benefits All direct health effects, whether for patients




Cost–utility analysis with fully incremental
analysis
Yes
Time horizon Long enough to reflect all important
differences in costs or outcomes between the
technologies being compared
Yes – time horizon up to 10 years
Synthesis of evidence on
outcomes
Based on systematic review Data have been primarily taken from
DECISION
Outcome measure Health effects should be expressed in QALYs.
The EQ-5D is the preferred measure of HRQoL
in adults
Yes – health effects were expressed in
QALYs and taken from EQ-5D data
collected in DECISION
Health states for QALY Reported directly by patients and/or carers Yes – reported directly by patients in
DECISION
Benefit valuation Time-trade off or standard gamble Yes
Source of preference data
for valuation of changes
in HRQoL
Representative sample of the UK population Does not state which valuation set is used
for the EQ-5D estimates of utility
Discount rate The same annual rate for both costs and
effects (currently 3.5%)
Not stated
Equity An additional QALY has the same weight
regardless of the other characteristics of
the individuals receiving the health benefit
Yes – all QALYs estimated by the economic
model have the same weight
Sensitivity analysis The scope developed by NICE One-way parameter sensitivity analysis
conducted, but no mention of PSA
PSS, Personal Social Services.
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TABLE 79 The NICE reference case checklist completed by the AG: SMC 2016
Attribute Reference case
Does the de novo economic evaluation
match the reference case? (SMC 201638)
Decision problem The scope developed by NICE Yes
Comparator(s) As listed in the scope developed by NICE Yes
Perspective: costs NHS and PSS NHS Scotland
Perspective: benefits All direct health effects, whether for




Cost–utility analysis with fully incremental
analysis
Yes
Time horizon Long enough to reflect all important
differences in costs or outcomes between
the technologies being compared
Yes – time horizon up to lifetime
Synthesis of evidence on
outcomes
Based on systematic review Data have been primarily derived from
DECISION and SELECT
Outcome measure Health effects should be expressed in
QALYs. The EQ-5D is the preferred measure
of HRQoL in adults
Yes – health effects were expressed in
QALYs
Health states for QALY Reported directly by patients and/or carers No – utility is estimated from a vignette
study generated from a sample of the
general UK population in which participants
were asked to value health-state scenarios
they were presented with
Benefit valuation Time trade-off or standard gamble Yes
Source of preference data
for valuation of changes in
HRQoL
Representative sample of the UK population Not applicable
Discount rate The same annual rate for both costs and
effects (currently 3.5%)
Not stated
Equity An additional QALY has the same weight
regardless of the other characteristics of
the individuals receiving the health benefit
Yes – all QALYs estimated by the economic
model have the same weight
Sensitivity analysis The scope developed by NICE One-way parameter sensitivity analysis was
conducted, but there was no mention of
PSA in the publication
PSS, Personal Social Services.
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TABLE 80 The NICE reference case checklist completed by the AG: CADTH 2015
Attribute Reference case
Does the economic evaluation match
the reference case? (CADTH 20155)
Decision problem The scope developed by NICE Yes
Comparator(s) As listed in the scope developed by NICE Partial – sorafenib is compared with BSC
but not with lenvatinib
Perspective: costs NHS and PSS Canadian health-care perspective
Perspective: benefits All direct health effects, whether for




Cost–utility analysis with fully incremental
analysis
Yes
Time horizon Long enough to reflect all important
differences in costs or outcomes between
the technologies being compared
Yes – up to 10 years
Synthesis of evidence on
outcomes
Based on systematic review Data have been primarily derived from
DECISION
Outcome measure Health effects should be expressed in
QALYs. The EQ-5D is the preferred measure
of HRQoL in adults
Yes – health effects were expressed in
QALYs and based on the EQ-5D data
collected in DECISION
Health states for QALY Reported directly by patients and/or carers Yes – reported directly by patients in
DECISION
Benefit valuation Time trade-off or standard gamble Yes
Source of preference data
for valuation of changes in
HRQoL
Representative sample of the UK population Does not state in the abstract which
valuation set is used for the EQ-5D
estimates of utility
Discount rate The same annual rate for both costs and
effects (currently 3.5%)
Not stated
Equity An additional QALY has the same weight
regardless of the other characteristics of
the individuals receiving the health benefit
Yes – all QALYs estimated by the economic
model have the same weight
Sensitivity analysis The scope developed by NICE One-way parameter sensitivity analysis was
conducted, but there is no mention of PSA
in the publication
PSS, Personal Social Services.
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TABLE 81 The NICE reference case checklist completed by the AG: CADTH 2016
Attribute Reference case
Does the de novo economic evaluation
match the reference case? (CADTH 2016162)
Decision problem The scope developed by NICE Yes
Comparator(s) As listed in the scope developed by NICE Partial – lenvatinib is compared with BSC but
not with sorafenib
Perspective: costs NHS and PSS Canadian health-care perspective
Perspective: benefits All direct health effects, whether for patients




Cost–utility analysis with fully incremental
analysis
Yes
Time horizon Long enough to reflect all important
differences in costs or outcomes between the
technologies being compared
Yes – up to 10 years
Synthesis of evidence on
outcomes
Based on systematic review Data have been primarily derived from SELECT
Outcome measure Health effects should be expressed in QALYs.
The EQ-5D is the preferred measure of
HRQoL in adults
Yes – health effects were expressed in QALYs
Health states for QALY Reported directly by patients and/or carers No – utility is estimated from a vignette study
generated from a sample of the general UK
population in which participants were asked
to value health-state scenarios they were
presented with
Benefit valuation Time trade-off or standard gamble Yes
Source of preference
data for valuation of
changes in HRQoL
Representative sample of the UK population No
Discount rate The same annual rate for both costs and
effects (currently 3.5%)
Not stated
Equity An additional QALY has the same weight
regardless of the other characteristics of
the individuals receiving the health benefit
Yes – all QALYs estimated by the economic
model have the same weight
Sensitivity analysis The scope developed by NICE One-way parameter sensitivity analysis was
conducted, but there is no mention of PSA in
the publication
PSS, Personal Social Services.
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Appendix 14 Drummond checklists in full
TABLE 82 Critical appraisal checklist for the economic analysis completed by the AG: Erdal et al. 2015
Erdal et al. 2015:163 question Critical appraisal AG comment
Was a well-defined question posed in
answerable form?
Yes
Was a comprehensive description of the
competing alternatives given?
Yes
Was the effectiveness of the programme or
services established?
Yes Outcomes from DECISION
Were all the important and relevant costs
and consequences for each alternative
identified?
Yes Resource use estimates generated from an
expert panel
Were costs and consequences measured
accurately in appropriate physical units?
Unclear Sources of cost evidence described, but no
details of what was measured were reported
Were the cost and consequences valued
credibly?
Unclear Not reported
Were costs and consequences adjusted for
differential timing?
Unclear Not reported
Was an incremental analysis of costs and
consequences of alternatives performed?
Yes ICERs were calculated accurately
Was allowance made for uncertainty in the
estimates of costs and consequences?
Yes One-way and probabilistic sensitivity analysis
were undertaken, but details of the methods
and parameters varied were not reported
Did the presentation and discussion of study
results include all issues of concern to users?
Yes
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TABLE 83 Critical appraisal checklist for the economic analysis completed by the AG: Huang et al. 2016
Huang et al. 2016:158,159 question Critical appraisal AG comment
Was a well-defined question posed in
answerable form?
Yes
Was a comprehensive description of the
competing alternatives given?
Yes
Was the effectiveness of the programme or
services established?
Yes Outcomes from DECISION and SELECT
Were all the important and relevant costs and
consequences for each alternative identified?
Unclear Based on the Phase III trials, but does not report
resource use or costs used within the model
Were costs and consequences measured
accurately in appropriate physical units?
Unclear Sources of cost evidence described, but no
details of what was measured were reported
Were the cost and consequences valued credibly? Unclear Details of resource use estimates were not reported
Were costs and consequences adjusted for
differential timing?
Yes 3% discount rate used
Was an incremental analysis of costs and
consequences of alternatives performed?
Yes ICERs were reported
Was allowance made for uncertainty in the
estimates of costs and consequences?
Yes One-way and probabilistic sensitivity analyses
were undertaken, but details of the methods and
parameters that were varied were not reported
Did the presentation and discussion of study
results include all issues of concern to users?
Yes
TABLE 84 Critical appraisal checklist for the economic analysis completed by the AG: Tremblay et al. 2016
Tremblay et al. 2016:160 question Critical appraisal AG comment
Was a well-defined question posed in
answerable form?
Yes
Was a comprehensive description of the
competing alternatives given?
Yes
Was the effectiveness of the programme or
services established?
Yes Outcomes from DECISION and SELECT
Were all the important and relevant costs and
consequences for each alternative identified?
Partially unclear Based on data from the Phase III trials, time
trade-off utility values that were taken from
the Kerr et al.167 abstract (details provided via
correspondence by lead author of paper). Details
of resource use and costs were presented in the
abstract. Details of discount rates were provided
via correspondence with lead author (5%)
[Dr Gabriel Tremblay, Purple Squirel Economics
(previously at Eisai), June 2017]
Were costs and consequences measured
accurately in appropriate physical units?
Yes
Were the cost and consequences valued
credibly?
Yes
Were costs and consequences adjusted for
differential timing?
Yes % discount rate used for both costs and
outcomes obtained through correspondence
with lead author
Was an incremental analysis of costs and
consequences of alternatives performed?
Yes ICERs were reported
Was allowance made for uncertainty in the
estimates of costs and consequences?
Yes PSA was mentioned in the conclusion, but no
results or methods were reported
Did the presentation and discussion of study
results include all issues of concern to users?
Yes
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TABLE 85 Critical appraisal checklist for the economic analysis completed by the AG: Wilson 2017
Wilson 2017:161 question Critical appraisal AG comment
Was a well-defined question posed in
answerable form?
Yes
Was a comprehensive description of the
competing alternatives given?
Yes
Was the effectiveness of the programme or
services established?
Yes Outcomes from data collected in DECISION and
SELECT
Were all the important and relevant costs and
consequences for each alternative identified?
Yes
Were costs and consequences measured
accurately in appropriate physical units?
Yes
Were the cost and consequences valued
credibly?
Partially Utility estimates were from a published study
rather than directly from the trial population
Were costs and consequences adjusted for
differential timing?
Yes
Was an incremental analysis of costs and
consequences of alternatives performed?
Yes Incremental cost, QALYs, LYs and ICERs were
reported
Was allowance made for uncertainty in the
estimates of costs and consequences?
Yes Parameter and probabilistic sensitivity analyses
were conducted
Did the presentation and discussion of study
results include all issues of concern to users?
Yes
LY, life-year.
TABLE 86 Critical appraisal checklist for the economic analysis completed by the AG: SMC 2015
SMC 2015:48 question Critical appraisal AG comment
Was a well-defined question posed in
answerable form?
Yes
Was a comprehensive description of the
competing alternatives given?
Yes
Was the effectiveness of the programme or
services established?
Yes Outcomes from DECISION
Were all the important and relevant costs and
consequences for each alternative identified?
Yes
Were costs and consequences measured
accurately in appropriate physical units?
Unclear
Were the cost and consequences valued
credibly?
Unclear
Were costs and consequences adjusted for
differential timing?
Unclear
Was an incremental analysis of costs and
consequences of alternatives performed?
Yes ICERs were reported
Was allowance made for uncertainty in the
estimates of costs and consequences?
Yes Results of multiple-parameter sensitivity analysis
were reported
Did the presentation and discussion of study
results include all issues of concern to users?
Yes
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TABLE 87 Critical appraisal checklist for the economic analysis completed by the AG: SMC 2016
SMC 2016:38 question Critical appraisal AG comment
Was a well-defined question posed in
answerable form?
Yes
Was a comprehensive description of the
competing alternatives given?
Yes
Was the effectiveness of the programme or
services established?
Yes Outcomes from DECISION and SELECT
Were all the important and relevant costs and
consequences for each alternative identified?
Yes
Were costs and consequences measured
accurately in appropriate physical units?
Yes
Were the cost and consequences valued
credibly?
Yes
Were costs and consequences adjusted for
differential timing?
Unclear
Was an incremental analysis of costs and
consequences of alternatives performed?
Yes ICERs were reported
Was allowance made for uncertainty in the
estimates of costs and consequences?
Yes Scenario and sensitivity analysis was completed
Did the presentation and discussion of study
results include all issues of concern to users?
Yes
TABLE 88 Critical appraisal checklist for the economic analysis completed by the AG: CADTH 2015
CADTH 2015:5 question Critical appraisal AG comment
Was a well-defined question posed in
answerable form?
Yes
Was a comprehensive description of the
competing alternatives given?
Yes
Was the effectiveness of the programme or
services established?
Yes Not detailed in the report but effectiveness data
were derived from DECISION
Were all the important and relevant costs and
consequences for each alternative identified?
Unclear Not reported
Were costs and consequences measured
accurately in appropriate physical units?
Unclear
Were the cost and consequences valued
credibly?
Unclear
Were costs and consequences adjusted for
differential timing?
Unclear
Was an incremental analysis of costs and
consequences of alternatives performed?
Yes ICERs were reported
Was allowance made for uncertainty in the
estimates of costs and consequences?
Yes Results of several sensitivity analyses were
presented
Did the presentation and discussion of study
results include all issues of concern to users?
Yes
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TABLE 89 Critical appraisal checklist for the economic analysis completed by the AG: CADTH 2016
CADTH 2016:162 question Critical appraisal ERG comment
Was a well-defined question posed in
answerable form?
Yes
Was a comprehensive description of the
competing alternatives given?
Yes
Was the effectiveness of the programme or
services established?
Yes Outcomes from data collected in DECISION and
SELECT
Were all the important and relevant costs and
consequences for each alternative identified?
Yes
Were costs and consequences measured
accurately in appropriate physical units?
Yes
Were the cost and consequences valued
credibly?
Partially From a published study168 rather than directly
from the trial population
Were costs and consequences adjusted for
differential timing?
Unclear
Was an incremental analysis of costs and
consequences of alternatives performed?
Yes Incremental cost, QALYs, LYs and ICERs were
reported
Was allowance made for uncertainty in the
estimates of costs and consequences?
Yes Parameter sensitivity analysis was conducted
Did the presentation and discussion of study
results include all issues of concern to users?
Yes
ERG, Evidence Review Group; LY, life-year.
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